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Abstract
An adverse intrauterine environment high in circulating nutrients in pregnancies complicated
by maternal obesity and diabetes mellitus has been well linked with the development of
metabolic health disorders in the exposed offspring. Impairments in placental development,
mitochondrial respiration, and nutrient processing are thought to specifically underlie the inutero programming of these metabolic diseases. In these “at-risk” pregnancies a maternal diet
high in fat as well as poor glycemic control have been highlighted to be important regulators
of placental metabolic functions (including the transport, storage, and oxidation of dietary
nutrients), and consequently regulators of offspring metabolic health outcomes. However, the
independent impacts of dietary saturated and monounsaturated fatty acid (FA) and glucose
exposures on important placental metabolic functions, and their underlying regulation,
remains poorly understood. Thus, the purpose of this thesis was to investigate placental
metabolic function following independent exposure to increased levels of the dietary FA
species palmitate and oleate, and hyperglycemia using an in vitro cell culture system. The
impacts of nutrient overabundance on BeWo trophoblasts (an in vitro model of both
progenitor cytotrophoblasts and differentiated syncytiotrophoblasts) were specifically
examined using functional readouts of cellular metabolism and mitochondrial respiration,
measurements of nutrient storage, in conjunction with multi-omic analyses integrating
transcriptomics, metabolomics, and lipidomics. Through the work in this thesis, we
demonstrated that saturated FA (palmitate) and glucose exposure was associated with
alterations in placental metabolic function indicative of an early phenotype of mitochondrial
dysfunction. Further, glucose and oleate exposures were demonstrated to increase nutrient
stores in placental trophoblasts. Finally, BeWo trophoblast cells displayed differential
transcriptomic, metabolomic, and lipidomic profiles following exposure to dietary FA
species and hyperglycemia. These works further demonstrated that increased nutrient supply
directly modulates important placental nutrient processing functions. More importantly, these
investigations provided greater insight into the underlying mechanisms that regulate the
responses of placental trophoblast cells following exposure to dietary nutrient
overabundance. Overall, these data suggest that the clinical management of obese and
diabetic pregnancies should continue to emphasize reducing placental exposures to excessive
ii

saturated FA and glucose levels to preserve physiological placental nutrient handling, and
ultimately limit risks to the developing fetus.

Summary for Lay Audience
The placenta is the central organ responsible for transferring nutrients and oxygen from
mother to developing fetus over the 40-weeks of pregnancy. Normal placental functions
ensure healthy fetal growth. In situations of excessive nutrient supply (pregnancies
complicated by maternal obesity and diabetes) placental functions change leading to
impacted fetal growth. This abnormal placental function has been shown to set the stage for
later life metabolic diseases (obesity and type 1 diabetes) in the unborn baby. Recently, a
poor maternal diet high in saturated fats in obese pregnancies and inadequate maternal
control of blood glucose levels in diabetic pregnancies have been found to be important
factors that promote changes in placental function. The objective of this thesis was to
examine the independent impacts of different fat and glucose exposures on trophoblast
(placental) cells and further characterize how these nutrients directly affect placental
function. This thesis utilized a well characterized placental model (BeWo cells) to
specifically determine how nutrient storage, and the breakdown of nutrients to produce
cellular energy (ATP) are impacted in the placenta following exposure to excess dietary fats
and glucose. Additionally transcriptomic profiles (examines the expression of all cellular
genes), metabolomic profiles (quantifies all metabolites), and lipidomic profiles (quantifies
the abundance of all fat types) were examined in nutrient-exposed placental cells to better
understand how underlying placental cell functions are modified following these nutrient
exposures. In this thesis, trophoblast cells exposed to elevated levels of saturated fats and
glucose were found to have markers that suggested their mitochondria (important producers
of ATP) were transitioning towards a state of failure. Additionally, placental cells exposed to
excess levels of monounsaturated fats and glucose were found to have increased nutrient
stores (triglycerides and glycogen). These nutrient-mediated alterations in placental cell
functions may ultimately impact nutrient transfer from mother to baby and could be
specifically involved in increasing the child’s risk of developing metabolic diseases. Overall,
this thesis further demonstrated that dietary fats and glucose are important regulators of
iii

placental metabolism and suggests that reducing placental fat and glucose exposures could
help protect the unborn baby from later life disease.
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1.1 The Developmental Origins of Health and Disease
Throughout the gestational period maternal nutrient handling must adapt to the
increasing needs of the growing fetal-placental unit to ensure developmental processes
continue in a healthy and physiological manner. For example, maternal insulin sensitivity
diminishes, and fasting serum lipid levels rise late in gestation to preserve necessary
macronutrients to support placental development, and fetal growth [1–3]. However, there
is a fine balance within these physiological metabolic alterations that, when disrupted by
environmental influences, can shift the course of in utero programming to promote the
early life development of non-communicable metabolic disorders in the offspring.
The study of the impacts of maternal gestational environment on fetal growth and
development is encompassed within the field of research known as The Developmental
Origins of Health and Disease (DOHaD) [4,5]. This field of study evolved from the
observations of Anders Forsdahl and David Barker in the 1970s and 80s. Forsdahl
originally described an increased risk of death by coronary heart disease in those who
were relatively impoverished during childhood, but later experienced prosperity [6].
Barker expanded these observations to include in utero gestational influences and
reported that low birthweight babies were at a greater risk for developing metabolic
complications such as obesity, type 2 diabetes (insulin resistance) and metabolic
syndrome in adulthood [4,5]. This field of study has since expanded to include the
observed increased risk of later life non-communicable diseases associated with
metabolic syndrome in offspring exposed to adverse intrauterine environments such as
those that occur with maternal nicotine use [7,8], perinatal hypoxia [9,10], and
environmental and chemical toxicants [11]. Of particular interest in this thesis, are the
adverse intrauterine environments caused by excessive nutrient abundance in pregnancies
complicated by maternal gestational obesity, and diabetes mellitus (DM) [12–14].

1.2 Impacts of maternal obesity and diet during pregnancy
1.2.1

Maternal obesity and offspring metabolic health
The World Health Organization (WHO) categorizes healthy bodyweight in both

adults and children via body-mass index (BMI, kg/m2), whereby a BMI>25 is
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overweight and a BMI>30 is obese [15]. The effects of an increased maternal body mass
and associated adiposity during the gestational period on offspring later life health has
been extensively documented in humans via population studies and meta-analyses [16–
21]. In line with the DOHaD concept, obesity-exposed offspring have been found to be at
a greater risk for later-life metabolic health issues due in part to an increased prevalence
of having a birthweight that is not appropriate for their gestational age (AGA) [16,19].
While maternal gestational obesity has largely been associated with infants being born
Large for their Gestational Age (LGA), there has also been a link between maternal
obesity and greater risk of the offspring being born Small for their Gestational Age
(SGA) [16,17,20]. Independent from maternal factors, LGA and SGA offspring are at an
increased risk for developing non-communicable “adult-associated” metabolic disorders
as early as four years of age [18,19]. However, there are concerning reports that children
born to obese women are more likely to develop metabolic disorders regardless of their
birthweight, suggesting that maternal body composition during pregnancy influences
offspring metabolic health beyond simply altering birthweight [20]. Indeed, recent studies
have suggested that maternal factors including pre-pregnancy BMI may better predict the
development of offspring health complications than birthweight alone [20,21].
The negative influence that maternal adiposity has on offspring metabolic health
has additionally been reported in numerous animal models that have attempted to
elucidate the mechanisms that lead to early-life metabolic diseases in these offspring
[22,23]. While maternal diet-induced obesity has been well associated with poor fetal
metabolic outcomes in these models, it is important to note that variations are present in
the dietary fat contents and periods of exposure used in these studies (Table 1-1). Rodent
models in particular have been heavily utilized as pre-clinical models in studies
examining the development of metabolic disorders. In these studies, pathological in utero
programming has been suggested to facilitate the increased risk of metabolic disease in
offspring born to high-fat diet (HFD) induced obese dams [24,25]. Specifically, high-fat
exposed rodent offspring have been found to exhibit abnormal lipid profiles including
hepatic steatosis that ultimately leads to Non-Alcoholic Fatty Liver Disease (NAFLD)
and fibrosis at early life stages [26]. Altered glucose homeostasis is also prevalent in
these obesity-exposed rodent offspring and is manifested as insulin resistance and an
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eventual development of type 2 diabetes mellitus during adolescence [27,28]. Overall, the
altered glucose and liver lipid metabolism observed in these offspring has been thought to
be a precursor to the ultimate development of metabolic syndrome in gestational obesityexposed adolescents [29,30].
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Table 1-1 Summary of diet fat or feeding treatments utilized in animal models of maternal diet-induced gestational obesity and
gestational high-fat exposure with and without diet reversal
Animal Model

Dietary Fat
(% Caloric Intake)

Pre-gestational
Obesity

Pre-conception Diet
Exposure

Gestational Diet
Exposure

Maternal Diet
Reversal

Offspring
Weaning

Reference

C57/B6 mice

60% High fat diet
(HFD)
25% fat control diet
45% HFD
10% fat control diet

HFD-induced obesity

HFD maintained
through pregnancy
and lactation
HFD through
pregnancy

Yes – 2-cell stage
embryo transfer

Weaned onto
control diet

Sasson [45]

No

HFD-induced obesity

No

High trans-fat diet
(6% partially
hydrogenated
vegetable oil + 1%
soybean oil)

No pre-pregnancy
obesity

N/A

HFD through
pregnancy
HFD maintained
through pregnancy
and weaning
High trans-fat diet
through pregnancy
and weaning only

Randomly
assigned HFD
or control diet
Fetal
collections
Pups weaned
onto standard
chow
Weaned onto
control diet

Elahi [26]

32% HFD
11% fat control diet
16% HFD
control diet 3% fat

10–12-week HFD
exposure before
pregnancy
Diet commenced at 4
weeks; breeding at 10
weeks
8-week pre-conception
HFD-exposure
6-week diet exposure
pre-conception

HFD-induced obesity

HFD commenced
Postnatal day (PND) 24;
breeding PND 120
3-week overfeeding prior
to conception

HFD throughout
pregnancy

No

Weaned onto
control diet

Srinivasan [24]

Overfeeding
discontinued
during pregnancy

Yes – dams
switched to control
feeding through
pregnancy and
lactation

Randomly
weaned onto
control (17%
fat) or HFD
(45% fat)

Borengasser [46]

C57/B6 mice

C57/BL6 mice
C57/B6 mice

C57/B6 mice

Sprague-Dawley
Rats

7% soybean oil
control diet
60% HFD
24% fat control diet

Sprague-Dawley
Rats

140% overfeeding
model

HFD-induced obesity

Diet-induced obesity

Overfeeding-induced
obesity

No

No

Jones [23]
Samuelsson [28]

de Velasco [61]
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Table 1-1 Summary of diet fat or feeding treatments utilized in animal models of maternal diet-induced gestational obesity and
gestational high-fat exposure with and without diet reversal (continued)
Animal Model
Sprague-Dawley
Rats

Wistar Rats

Dietary Fat
(% Caloric Intake)
140% overfeeding
model

Pre-gestational
Obesity
Overfeeding-induced
obesity

Pre-conception Diet
Exposure
3-week overfeeding
prior to conception

Gestational Diet
Exposure
Overfeeding
discontinued
during pregnancy

45% HFD
18% fat control diet

HFD-induced obesity
with pre-gestational
HFD exposure

Pre-conception HFD commenced PND 22;
breeding at PND 120

HFD through
pregnancy

Wistar Rats

38% HFD-diets
15% fat control diet

No pre-pregnancy
obesity

Wistar Rats

20% lard supplement
in HFD
5% fat control diet

HFD-induced
obesity

Sheep

155% overfeeding
model

No pre-gestational
obesity

Sheep

150% overfeeding
model

Overfeeding-induced
obesity

Sheep

150% overfeeding
model

Overfeeding-induced
obesity

Pregnancy and lactation
HFD - commenced at
breeding and maintained
through lactation)
N/A

HFD during
pregnancy only;
cross-fostered to
lean dams during
lactation
HFD exposure from PND HFD maintained
21 to breeding at PND
through
120
pregnancy and
lactation
Overfeeding
Overfeeding from
commenced gestational
gestational day 115
day 115
to gestation (~day
150)
60-day overfeeding
Overfeeding
exposure before mating
through gestation,
control diet during
lactation
60-day overfeeding
Overfeeding until
exposure before mating
fetal collection

Maternal Diet
Reversal
Yes – dams
switched to control
feeding through
pregnancy and
lactation
No

Offspring
Weaning
Randomly
weaned onto
control (17%
fat) or HFD
(45% fat)
Randomly
assigned HFD
or control diet

Reference

No

Weaned onto
control diet;
HFD exposure
at 8 weeks

Dong [60]

Yes – diet
intervention back
to control diet at
PND 90
No

Not specified

Zambrano [44]

Control diet
during
lactation and
weaning
control diet

Philip [32]

Fetal
collection

Zhu [102]

No

No

Borengasser [47]

Howie [27]

Long [31]
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Table 1-1 Summary of diet fat or feeding treatments utilized in animal models of maternal diet-induced gestational obesity and
gestational high-fat exposure with and without diet reversal (continued)
Animal Model

Dietary Fat
(% Caloric Intake)
150% overfeeding
model

Pre-gestational
Obesity
Overfeeding-induced
obesity

Pre-conception Diet
Exposure
60-day overfeeding
exposure before mating

Gestational Diet
Exposure
Overfeeding
continued through
pregnancy (with no
intervention)

Japanese
Macaque

36% HFD
14% fat control diet

HFD-induced obesity

4–7-year HFD exposure
pre-conception

Japanese
Macaque

32% HFD
14% fat control diet

HFD-induced obesity

2–4-year pre-gestational
HFD induced obesity

HFD maintained
through to fetal
collections at
gestational day 130
HFD, or dietreversal through
pregnancy

Japanese
Macaque

32% HFD
14% fat control diet

HFD-induced obesity

4–7-year pre-gestational
HFD exposure

HFD, or diet
reversal through
pregnancy

Japanese
Macaque

32% HFD
14% fat control diet

HFD-induced obesity

2–9-year pre-conception
HFD exposure

HFD, or diet
reversal through
pregnancy

Sheep

Maternal Diet
Reversal
Yes - 150%
overfeeding until
gestational day 28
(with obesity
intervention)
Yes – diet reversal
3 months prior to
breeding

Offspring
Weaning
Fetal
collection

Reference

Fetal
collection

Salati [105]

Yes – preconception diet
reversal on
subsequent
pregnancy
Yes – switched
back to control diet
in 5th breeding
season
Yes – switched
back to control diet
in 9th breeding
season

Weaned onto
mothers
gestational
diet

McCurdy [34]

Weaned onto
in utero or
reverse diet

Pound [35]

Fetal
collections

Wesolowski [43]

Tuersunjiang [33]
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Larger mammal species, including sheep, have also been used to study maternal
overfeeding and obesity and its subsequent effects on offspring health and disease. As
observed in human meta-analyses and experiments using rodent models, sheep offspring
exhibit metabolic dysfunction both neonatally and into adulthood—including increased
prevalence of obesity and aberrant lipid and glucose metabolism—in response to
maternal obesity during gestation [31–33]. The non-human primate (NHP) model has
also been well utilized to identify the underlying mechanisms that pre-dispose obesityexposed offspring to later life metabolic disease. Specifically, these studies have
demonstrated that third trimester fetal hepatic lipid and glucose metabolism is
dysregulated in offspring exposed to maternal obesity during gestation [34,35].
Together, these human meta-analyses and animal models demonstrate that
maternal obesity during the gestational period primes the exposed offspring for
dysregulated lipid and glucose metabolism that ultimately results in metabolic disease
development early in life. Furthermore, it is important to note that the negative impacts of
maternal obesity on offspring in utero growth have been highlighted to occur in a sexdependent manner, however different models have yielded conflicting data. For example,
in humans maternal BMI has been demonstrated to correlate with bodyfat at birth in
female infants, but not in males [36,37]. This increased risk of macrosomia at birth, may
predispose females to greater risk of DOHaD related non-communicable diseases. Rodent
models in contrast, have largely highlighted increased adiposity in adulthood is more
prevalent in male offspring exposed to maternal obesity in utero than in female offspring.
The increased risk of later life obesity in male offspring may be attributed to a greater
rate of postnatal weight gain, increased food intake, increased circulating triglycerides
levels, and increased susceptibility to visceral fat accumulation compared to their female
counterparts [38–40]. These sex-dependent effects (and potential species-related
differences in sex-dependent effects) need to be better elucidated to fully understand the
impacts of in utero environment on later-life health.
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1.2.2

Is maternal BMI an accurate predictor of offspring metabolic
health?
The reports from these human and animal studies that link maternal obesity to

offspring metabolic disease are of increasing importance to healthcare systems as the
prevalence of obesity worldwide has reached unprecedented rates over the last several
decades [41]. The WHO estimates that about 40% of men and women over the age of 18
were overweight or obese in 2016, and that proportion continues to rise [41]. More
specific to pregnancy outcomes and in line with data from most industrialized nations,
Health Canada reported in 2012-13 that 24% of Canadian women between 20-39 years of
age (those of child-bearing age) were obese, and 44% had a waist circumference that was
predictive of high risk for the development of health complications [42]. These reports
suggest that the prevalence of early-onset metabolic syndrome in offspring will only
continue to increase alongside the rising rates of maternal obesity.
Animal models utilizing dietary interventions in obese pregnancies, however,
have highlighted that body composition metrics may not be the most accurate predictors
of offspring future metabolic health and that maternal gestational diet is also an important
influence on offspring health (Table 1-1). For example, in sheep models of gestational
overfeeding-induced obesity, a maternal dietary intervention early in gestation resulted in
lower circulating plasma triglyceride (TG) levels (improved lipid metabolic function) as
well as decreased plasma insulin levels (improved glucose metabolism) in fetuses from
obese pregnancies at both mid and late gestation [33]. Additionally, NHP data suggests
that there are vast differences in the metabolic profiles of fetuses from obese mothers that
consume different diets during gestation [34,35,43]. McCurdy et al. (2009) identified that
a diet reversal to a control diet in obese pregnant Japanese macaques was sufficient to
improve liver steatosis in third trimester fetuses, suggestive of a decreased risk of
postnatal NAFLD. Subsequent studies described reductions in maternal and fetal
dyslipidemia and oxidative stress in diet-reversed obese pregnancies leading to benefits
in fetal liver development during the third trimester [43]. Additionally, improved third
trimester pancreatic islet vascularization has been reported in response to diet reversal in
NHP models, which suggests that these offspring would be less susceptible to later-life
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development of type-2 diabetes mellitus [35]. These NHP studies highlight that maternal
gestational obesity alone may not be the best predictor of offspring metabolic health and
suggest that gestational diet is important in determining metabolic health risk in the
obesity-exposed offspring.
Rodent models of obese pregnancy have also demonstrated the benefits of
gestational diet reversals (Table 1-1). For example, male offspring of obese rats given a
dietary intervention during the gestational period have improved metabolic outcomes
including improved insulin sensitivity both neonatally and into adulthood [44]. However,
additional rodent studies have suggested that a diet-reversal during pregnancy may not be
sufficient to reverse the effects of maternal pre-pregnancy obesity, as has observed in
sheep and NHP models. For example, mouse embryos transferred at the 2-cell stage from
high-fat fed dams to control fed dams displayed poor in utero growth and neonatal catchup growth, as well as an altered expression of imprinted genes that have been associated
with obesity development [45]. These findings suggest that oocytes may be primed for
adverse development as a direct result of poor maternal diet pre-conception [45].
Furthermore, other rodent models have reported poor liver and skeletal muscle
mitochondrial health at post-natal day 35 in offspring exposed to maternal pre-pregnancy
obesity [46,47]. Specifically, hepatic tissue of rat offspring born to obese dams displayed
a marked decrease in the protein expression of markers of mitochondrial health and
biogenesis despite both control and obese dams being fed a control diet during the
gestational period [47].
The presence of the conflicting data between rodent and larger mammal (sheep
and NHP) models may simply arise from physiological differences between these
species. For example, the longer gestational period of sheep and NHP, and the fact that
these species, like humans, have largely prenatal developmental processes potentially
underlies the impacts of a gestational diet reversal intervention on fetal growth and
development [48,49]. Further studies must be conducted to fully understand whether
dietary changes during human pregnancy are sufficient to reverse insults from a poor
maternal diet as in the NHP and sheep models and some rodent models or if human
oocytes are ‘primed’ for metabolic disease with pre-gestational obesity exposure. Overall,
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these diet reversal studies have suggested that maternal diet prior to conception and
during pregnancy has a profound impact of the metabolic health of the offspring.

1.2.3

Maternal dietary fat consumption and offspring metabolic
health
Human population data has demonstrated that circulating maternal free fatty acid

(FA) levels are predictive of offspring metabolic health risks independent from measures
of maternal body composition, highlighting the importance of dietary lipids during
gestation [50]. Additionally, in animal-based studies, dietary fat components are altered
in obese pregnancy dietary interventions further signifying dietary fats themselves are
important in promoting the development of metabolic disorders in obesity-exposed
offspring.
In general, different FA species have varying impacts on metabolic health based
on the length of the FA chain (short, medium, long, or very-long chain FA) as well as on
the degree of saturation of the FA [51,52]. For example, a diet rich in cismonounsaturated FA species (MUFAs) and polyunsaturated fats (PUFAs)) has been
associated with increased level of High-Density Lipoprotein (HDL), the “good
cholesterol”, and thus a healthier lipid metabolic profile [52,53]. Consumption of omega3 PUFA species is also associated with reduced hepatocyte production of TG-rich verylow density lipoprotein (VLDL) particles, resulting in decreased delivery of FA species
to peripheral tissues [54–56]. Overall, omega-3 PUFAs have been linked to
improvements in metabolic health and function and may be an important factor in
preventing insulin resistance and type 2 diabetes in obese populations [57,58]. In
contrast, a high consumption of trans-unsaturated FA species has been found to lower
serum levels of HDL and promote a less healthy metabolic profile [53]. Additionally, a
high consumption of saturated FA species has been associated with poor metabolic
profiles including increased serum levels of TGs (stored in VLDL particles), free
cholesterol, low-density lipoprotein (LDL; the “bad cholesterol”) and an increased risk of
metabolic syndrome [52,59].
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More importantly, consumption of certain FA species during pregnancy may
promote the development of metabolic disorders in the offspring. For example, studies in
rodent models have highlighted maternal diets comprised of different saturated FA chain
lengths have varying impacts on offspring later-life metabolic health [60]. Specifically,
gestational diets that were overabundant in medium chain length FA species from
coconut oil (55% of FA species C14:0 or shorter) resulted in decreased offspring obesity
development compared to offspring exposed to a maternal overconsumption of longerchain FA species from soybean oil (all FA C16:0 or longer) [60]. Additional rodent
models have demonstrated that maternal diets rich in trans-unsaturated FA species
adversely affect offspring liver mitochondrial oxidative function, as well as increase
circulating levels of TGs, highlighting an overall dysregulation of hepatic lipid handling
[61]. These studies further highlight that maternal dietary fat consumption is important an
independent factor in offspring risk for metabolic disease development.
To determine the impact of maternal dietary fat content upon fetal health
outcomes in human populations, it is important to fully understand the diet consumption
patterns of pregnant women. More importantly, it is necessary to understand how these
maternal diets deviate from the recommendations of government health agencies and
clinical guidelines to provide insight into possible dietary interventions that can reduce
offspring metabolic health complications. Canada’s food guide for example, recommends
that pregnant women only consume a small amount (1-3 tbsp) of saturated fat each day.
In addition to limiting saturated fat intake, it is also recommended that these less healthy
FA species are replaced with more polyunsaturated omega-3 and omega-6 FAs (PUFAs).
Specifically for pregnant women, Health Canada guidelines suggest consumption of at
least 200 mg of Docosahexaenoic acid (DHA) (an omega-3 PUFA) as this FA is
necessary for proper fetal brain development [62]. However, despite these guidelines,
blood lipid analysis has suggested that a majority of pregnant women consume diets that
greatly deviate from food guide recommendations [63]. It is estimated that on average
one-third of total caloric intake in pregnant women is from lipid sources [63–65]. While
this total fat intake falls within current Food Guide recommendations, many women do
not consume healthy amounts of PUFAs and saturated fats [63–65]. Specifically, these
women have been found to consume diets that are calorie-dense but low in nutrients,
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overabundant in long-chain saturated FA, and lacking in important unsaturated FA
species such as DHA [65–67].
Overall, an increased maternal consumption of long-chain saturated FAs and
limited intake of omega-3 PUFAs during pregnancy may be an important in utero insult
that predisposes the offspring to metabolic complications early in life and may
specifically underlie poor outcomes in obese pregnancies.

1.3 Maternal diabetes mellitus and pregnancy outcomes
1.3.1

Maternal diabetes mellitus and offspring metabolic health.
Similar to maternal obesity and also in line with the DOHaD hypothesis, maternal

DM during pregnancy has been associated with poor metabolic health outcomes in the
exposed offspring. For example, offspring of mothers with gestationally-developed DM
(GDM) have an increased risk of being born LGA, and developing non-communicable
cardiometabolic diseases such as obesity, type 2 diabetes, and metabolic syndrome [68–
71]. It is important to note that there is significant overlap between obese and GDM
pregnancies, as obesity is an independent risk factor of GDM development [72,73].
Thus, offspring metabolic disease in GDM pregnancies may be partially mediated by
maternal obesity. However, recent studies have highlighted that GDM, and obesity are
independent regulators fetal growth and development despite the overlaps in these comorbidities [74,75]. Interestingly, maternal dietary patterns have also been linked to the
pathophysiology of GDM, and a maternal adherence to a healthy lifestyle diet lowers the
risk of maternal GDM development [76–78]. These data further highlight that maternal
diet during pregnancy is an important factor in not only determining fetal metabolic
health outcomes, but maternal metabolic health outcomes as well.
In addition to GDM, maternal pre-pregnancy type 2 DM has been linked with
poor pregnancy outcomes, and offspring metabolic disease [79]. However, as maternal
GDM and type 2 DM are often concurrent with maternal obesity, the direct impacts of
maternal DM on offspring outcomes may be confounded in these pregnancies. Thus,
examining the impacts of pre-existing type 1 DM, may better highlight the independent
negative impacts of DM during pregnancy on fetal development. For example, children
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born to type 1 diabetic mothers have an increased risk of developing obesity, and
metabolic syndrome compared to peers born to healthy mothers, and these diseases are
manifested as early as 7 years of age [80–83]. Additionally, offspring of type 1 diabetic
mothers are often born LGA which, as described previously, may directly underlie their
increased risk of metabolic disease development [84,85]. Like in cases of maternal
obesity, the negative impacts of pre-pregnancy DM on offspring health have been
highlighted in studies utilizing animal models. For example, studies using rodent models
exposed to streptozotocin (STZ, a pancreatic β-cell toxin) to induce pre-pregnancy
diabetes have demonstrated increased adiposity, and impaired glucose metabolism in
diabetic-exposed offspring both neonatally and into adulthood [86–88]. Additional
readouts in STZ-induced diabetes in larger mammals such as sheep have likewise
highlighted impaired glucose metabolism in the exposed offspring [89].
The impacts of maternal diabetes during pregnancy, much like those of maternal
gestational obesity, have been highlighted to occur in a sex-dependent manner. In
humans, maternal diabetes and gestational hyperglycemia has been associated with
macrosomia, increased rates of congenital abnormalities, and increased rates of
respiratory disorders in males but not females [36,90]. Follow-up cohort investigations
have further revealed that males, but not females, exposed born from a pregnancy
complicated by GDM had an increased risk of being overweight by 5 years of age [91].
The increase in macrosomia at birth and adiposity in childhood in males, may increase
their risk of developing non-communicable metabolic diseases later in life. Interestingly,
mothers carrying male fetuses have been found to have an increased risk of developing
GDM, compared to mothers carrying female fetuses, highlighting that some pregnancy
complications are impacted by fetal sex [92]. Overall, these studies have further
highlighted that fetal sex is a crucial consideration in the DOHaD field of study and
understanding specifically how male and female fetuses adapt to environmental stress,
especially the stresses in conditions of nutrient overabundance is of increasing
importance.
While the impacts of maternal obesity on offspring metabolic health may likely be
mediated by a poor maternal diet overabundant in saturated FA species, the impacts of
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maternal diabetes on fetal development are likely due to maternal hyperglycemia. In fact,
children born to diabetic women who maintained appropriate glycemic control
throughout gestation have been found to have reduced birthweight and improved neonatal
outcomes compared to children born to diabetic mothers with poor glycemic control
[93,94]. Thus, maintaining appropriate glycemic control and preventing maternal
hyperglycemia in diabetic pregnancies may be essential in limiting impacts to offspring
metabolic health.
Overall, investigations into the impacts of obesity and maternal DM on
offspring metabolic health have revealed that nutrient overabundance (i.e. dietary fats in
obesity, and glucose in DM) is an important factor in the in utero programming of
offspring metabolic health.

1.4 The Developmental Origins of Health and Disease and
the placenta
The placenta is a transient organ composed of a heterogeneous population
of cells that facilitates hormone production, fetal immunity and all gaseous, nutrient and
waste transport between maternal and fetal circulation. It consists of two distinct but
important populations of placental trophoblast cells (extravillous trophoblasts (EVTs) and
villous trophoblasts) that arise from the outer trophectoderm layer of the pre-implantation
blastocyst, as well as the fetal extraembryonic mesoderm and fetal placental blood
vessels. EVTs are responsible for invading into the uterine decidual tissue to establish the
maternofetal blood connection (by remodeling uterine spiral arteries) as well as act to
anchor chorionic villi to the uterine wall (Figure 1-1a). In contrast, the villous
trophoblast cells of the chorionic villi act as a transport layer and comprise the physical
barrier between maternal blood supply (facilitated by maternal spiral arteries emptying
into the intervillous space) and fetal circulation (Figure 1-1a). The villous trophoblast
layer is comprised of two unique cell populations: underlying progenitor cytotrophoblast
(CT) cells and fused multi-nucleated (differentiated) syncytiotrophoblast (SCT) cells [95]
(Figure 1-1b). The SCT cells of the villous trophoblast layer arise following the
differentiation and fusion of progenitor CT cells.
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Figure 1-1 Structure of the human placenta.
Illustration showing (A) a sagittal cross-section of the mature human placenta, and (B) a
magnified view of the placenta chorionic villus highlighting the location of
cytotrophoblasts and syncytiotrophoblast cells. Created with biorender.com.

17

Maintenance of normal physiological function of the placenta is vital for proper
fetal development, and impairments in placental growth, development, and function in
obese and diabetic pregnancies are thought to underlie the in utero programming of
offspring metabolic disease [96–99]. For example, placentae from obese pregnancies
have morphological abnormalities including immature chorionic villi structures, and an
increased placental-to-fetus weight ratio (a marker of placental insufficiency or a poorly
functioning placenta) [100,101]. Additionally, maternal gestational obesity is often
associated with increased inflammation in placental tissues highlighted by increased proinflammatory cytokine abundance (e.g. TNFα, IL-6) and macrophage accumulation that
can be detected as early as mid-gestation [102–104]. NHP models of gestational obesity
have likewise demonstrated reduced placental and uterine blood perfusion and increased
placental inflammation with maternal obesity [105,106]. However, these impairments in
obese NHP placentae were improved with a diet-reversal from a high-fat diet to a healthy
control diet [105], overall suggesting that a poor maternal diet in obese pregnancies
facilitates the development of offspring metabolic health complications by impairing the
function of the placenta.
Morphological abnormalities have likewise been described in pregnancies
complicated with pre-existing DM or GDM. Specifically, DM during pregnancy has been
associated with increased intervillous space volume, increased placental vascularization
as well as an increased placental-to-fetal weight ratio [107–110]. Interestingly, metformin
(an insulin sensitizing drug) treatment has been linked with improved placental
development in some GDM pregnancies [111], which highlights that impaired maternal
glucose metabolism and hyperglycemia may underlie placental abnormalities in diabetic
pregnancies. Overall, these data highlight that maternal nutrient environment is a key
regulator of placental development.
Notably, placental abnormalities from obese and diabetic pregnancies have also
been demonstrated to be influenced by fetal sex. For example, in obese pregnancies,
female but not male placentae were found to have increased rates of chorionic villitis, an
inflammatory placental lesion [112]. In contrast, male placentae have been found to have
impaired anti-oxidant capacity in response to maternal obesity, which has been thought to
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promote the development of pregnancy complications and adverse outcomes [113]. These
studies may highlight that the molecular mechanisms that underlie aberrant in utero
programming in response to maternal adiposity is dependent on the sex of the fetus.
In diabetic pregnancies, female placentae display altered microRNA signatures
(associated with endoplasmic reticulum protein processing; proteoglycan synthesis; and
Hippo signaling) suggestive of an increased responsiveness to the nutrient excessive
environment of GDM [114]. This sex-specific difference especially in diabetic
pregnancies may highlight an underlying mechanism in the female placenta that may act
in an adaptive manner to protect the female fetus from an adverse hyperglycemic in utero
environment. More importantly, these sex-specific differences in placental function may
help explain the reduced rates of pregnancy complications and macrosomia in female
fetuses in diabetic pregnancies [36,90]. Future investigations are needed to highlight how
fetal sex impacts placental development, and function in order to better understand how
the placenta regulates in utero programming of non-communicable metabolic disease.

1.4.1

Placental metabolic impairments in adverse maternal
environments
In addition to facilitating morphological and structural alterations in the placenta,

maternal obesity and diabetes also negatively impacts metabolic and nutrient processing
functions in the CT and SCT cells of the placental villous trophoblast layer [115–118].
As CT and SCT cells are directly responsible for materno-fetal nutrient transport,
alterations to the metabolic functions in these cells may impact nutrient transport to the
fetus and directly underlie the in utero programming of metabolic disease. Specifically,
impairments in placental handling of glucose and dietary fats highlighted by alterations in
the transport, storage and oxidation of these nutrients has been documented in obese and
diabetic pregnancies. Understanding how maternal obesity, maternal dietary fat
consumption, maternal DM, and maternal hyperglycemia individually modulate these
important placental nutrient processing functions and elucidating what these changes
mean for the developing fetus, will provide a better understanding of the placental
mechanisms that facilitate early-onset metabolic diseases in the exposed offspring.

19

As the placenta is discarded at the end of pregnancy, the endpoint impacts of
maternal obesity and DM on placental nutrient processing functions can be explored by
analyzing term placental lysates. Moreover, examining term placentae may also allow
researchers to determine how maternal dietary interventions in obesity and appropriate
glycemic control in diabetes influence placental metabolic functions. For example, CT
cells have been cultured from term human placentae following planned, non-labouring
Caesarean-section births and utilized to examine placental metabolic function in obese
pregnancies with and without a dietary intervention [119,120]. Additionally, the isolated
effects of individual nutrients (fats and glucose) on placental metabolic processes can be
examined using immortalized villous trophoblast cell lines (including BeWo, JAR and
JEG-3 cells) that are available for commercial purchase. The BeWo choriocarcinoma cell
line in particular, has been demonstrated as a viable model of placental barrier function
and has been extensively utilized to examine the isolated effects that individual PUFA
species have on placental lipid processing [121,122]. Overall, the use of placental cell
lines such as the BeWo trophoblast cell line can allow for insight into how different
dietary FA species and hyperglycemia independently impact placental metabolism and
nutrient handling.

1.4.2

Mechanisms of fatty acid and glucose transport in the
placenta
The human placenta has an extensive ability to uptake lipid species and shuttle

them and their metabolic byproducts into fetal circulation. Proteomic analysis of term
primary human trophoblast (PHTs) has revealed that the placenta expresses lipid
transport proteins on both the apical microvillous (maternal-facing) and basolateral (fetalfacing) membranes [123]. Specifically, Fatty Acid Transport Proteins 1, 2 and 4 (FATP1,
FATP2, FATP4); Fatty Acid Binding Proteins 1 and 3 (FABP1, FABP3) as well as Fatty
Acid Translocase (FAT/CD36) are expressed in the human placenta [123–126]. In
addition, isolated PHTs have demonstrated activity of Lipoprotein Lipase (LPL)
indicating that lipid species packaged as TGs in lipoproteins (VLDL particles) can be
processed by the placenta [127,128]. Lipase enzymes such as LPL are responsible for
cleaving TG species in VLDL particles to release free FAs so that they can then be
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imported into the placenta by facilitative transport via the FATPs, FABPs and FAT/CD36
[129].
The FATPs as well as FAT/CD36 are localized on both the basolateral and apical
placental membranes and are involved in transporting a wide range of FA species across
the placenta [123,130]. The presence of these transporters on both apical and basal
placental membranes suggests a bidirectional transfer of non-esterified fatty acids
(NEFAs) can occur to respond to the changing nutrient demands of both mother and
developing fetus [123,130]. In contrast, FABP transporters that demonstrate preferential
binding for PUFA species are largely localized to the maternal-facing apical membranes
of the placenta [58,64]. This may suggest that PUFA species are transported
unidirectionally across the placenta into the fetal circulation in order to support and
prioritize proper fetal brain development [123,131]. Similar to PHTs, the BeWo cell line
has been demonstrated to uptake and transport dietary NEFA species [132]. Specifically,
this cell line has been shown to express the lipid transporters: FATP1, FATP4,
FAT/CD36 as well as FABP1 and FABP3 [132,133]. Although caution must be taken
with interpretation of data from immortalized cell lines, since BeWo cells express the
same lipid transport proteins as PHTs they may represent a viable model for studying
placental barrier function and lipid transport,
In addition to facilitating the transfer of lipid species to the developing fetus, the
placenta also has a high capacity to transport glucose from mother to fetus. In total, the
placenta has been shown to express multiple glucose transporter (GLUT) isoforms
including: GLUT1, GLUT3, GLUT4, GLUT8, GLUT9, GLUT10, and GLUT12 [134–
138]. The GLUT1 isoform is the highest expressed GLUT isoform in placenta,
highlighting its specific importance in facilitating trans-placental glucose transport
[136,137]. Additional work has demonstrated GLUT1 is largely localized to the
maternal-facing apical membrane of SCT cells which suggests that GLUT1 expression on
the fetal-facing placental basal membrane is a rate-limiting factor in transplacental
glucose transport [135,136]. Further, GLUT1 expression increases from the first trimester
and remain elevated throughout the duration of gestation, highlighting that materno-fetal
glucose transfer increases as pregnancy progresses to support fetal growth and
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development [136]. The BeWo trophoblast cell line also expresses GLUT1, GLUT3 and
GLUT8 isoforms [139–141]. Further studies have demonstrated an asymmetric
distribution of GLUT1 expression between apical and basal membrane in BeWo
trophoblasts, as well as that induction of syncytialization with 8-Br-cAMP in BeWo
trophoblasts increases GLUT1 expression [140,142]. These studies suggest that the
BeWo trophoblast cell line may additionally represent a viable model for studying
placental glucose transport and metabolism. Thus, BeWo trophoblasts may be useful in
elucidating placental responses to independent dietary fat overabundance and
hyperglycemia.

1.4.2.1

Maternal obesity and placental nutrient transport

Maternal obesity during pregnancy has been associated with an altered expression
and activity of lipid transporters in the placenta. Specifically, an increase in the activity of
LPL and mRNA expression of FAT/CD36 in conjunction with diminished mRNA levels
of FATP1, FATP4 and FABP3 as well as reduced protein expression of FABP3 have
been observed with increased maternal adiposity [127,128]. These alterations in placental
nutrient transporter expression have ultimately been associated with reduced placental
uptake of important omega-6 PUFA species such as linoleic acid [127], which could
overall impact important fetal growth processes including brain development. Overall,
the observed increases in the activity and expression of placental LPL and FAT/CD36
may facilitate increased lipid transport into fetal circulation and could potentially explain
the increased prevalence of LGA offspring in obese pregnancies. In contrast, the specific
reduction in the expression of FATP and FABP transporters may reflect that the placenta
is attempting to modulate transplacental lipid transport under conditions of lipid overload
to prevent fetal lipid toxicity. The notion that the placenta is able to modulate maternofetal lipid transfer in response to nutritional state is supported by recent NHP experiments
that identified increased protein expression of FATP and FABP transporters under
conditions of maternal nutrient restriction [143].
The relative influences that individual dietary FAs have on obesity-mediated
altered placenta lipid transport can help predict how maternal diet interventions may
impact fetal metabolic disease. While almost one-third of the total lipid consumption of
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pregnant women is saturated fats, current research into the effects of individual NEFA
supplementation on placental lipid transport has largely emphasized the effects of dietary
PUFAs. Cell culture experiments conducted with the BeWo cell line have found that a 24
hour exposure to 100 μM concentrations of individual unsaturated NEFAs (Oleate, DHA,
and Arachidonic Acid (AA)) has no influence on placental FATP expression [132].
Similarly, there were no significant alterations in FATP expression in PHTs from women
who took DHA supplements during the third trimester [144]. PUFAs may in contrast,
have an ability to alter the expression of FABP transporters within the placenta and
specifically AA has been found to increase the expression of FABP3 in BeWo cells
following 24 hours in culture [133]. Increased expression of FABP3 in AA-treated BeWo
cells may be reflective of the preferential transport of PUFA species by placental FABPs
[58,64]. Future research must increasingly focus on the effects of saturated dietary fats to
elucidate if a maternal saturated fat overconsumption independent of body composition
leads to increased materno-fetal lipid transport via LPL and FAT/CD36 mediated
transport. Furthermore, understanding the molecular mechanisms that potentially regulate
this increased materno-fetal lipid transport could lead to the development of
pharmacological inhibitors to better modulate in utero growth.
Overall, maternal obesity has largely not been associated with alterations in the
expression or protein abundance of GLUT1 transport proteins [145–147], although some
studies have shown reductions in placental GLUT1 expression in the obese placenta
[148]. Overall, these data suggest that increased maternal adiposity has limited impacts
on trans-placental glucose transport. However, current research has not investigated the
direct impacts of dietary FA species on placental expression of GLUT transport proteins,
and these interactions need to be elucidated.

1.4.2.2

The impacts of maternal diabetes mellitus on placental
nutrient transport

In contrast to obese pregnancies, diabetic pregnancies have been associated with
relatively limited alterations in the expression of placental FATP and FABP transporters.
Specifically, studies have found no alterations in the protein abundance or mRNA levels
of LPL, FAT/CD36, FATP2, and FATP4 in Type 1 diabetic and GDM pregnancies [149–
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152]. However, increased placental LPL activity has been highlighted in Type 1 diabetic
pregnancies, despite no alterations in LPL protein abundance, potentially indicating that
post-translational modifications regulate LPL activity [151]. Additionally, the expression
of endothelial lipase (EL) and hormone-sensitive lipase (HSL) is elevated in placentas
from Type 1 diabetic and GDM pregnancies [150,153]. Interestingly, the increased
expression of EL and HSL is more profound in women with poor glycemic control,
suggesting that maternal hyperglycemia directly modulates placental expression of these
enzymes [150]. The increased activity of LPL and increased expression of EL and HSL
in uncontrolled diabetic pregnancies may, like in obese pregnancies, facilitate increased
placental lipid uptake by increasing free FA concentrations at the placental barrier, and
may in turn underlie the increased risk of offspring being born LGA [84,85]. Placental
term explants from uncomplicated healthy pregnancies cultured under hyperglycemia for
18 hours, however, were not found to have altered expression of EL, LPL, FAT/CD36,
FATP2 or FATP4 [149]. The limited impacts of hyperglycemia on placental EL
expression in culture may simply be due to the limited duration of high glucose exposure
[149]. Currently, there is limited insight into how independent hyperglycemia impacts
lipid transport mechanisms in placental cell line models such as BeWo trophoblasts.
Maternal DM during pregnancy has also been linked with alterations in placental
glucose transport mechanisms. Specifically, pre-gestational diabetes and GDM have been
associated with increased basal membrane (but not apical membrane) GLUT1 expression
leading to approximately a 40-60% increase in glucose transport across the fetal-facing
membrane [154,155]. Interestingly, these differences in GLUT1 expression between
diabetic and control pregnancies were evident despite the diabetic groups displaying
normal glycated-hemoglobin (HbA1c) levels indicative of appropriate glycemic control
at term [154]. It is important to note however, that some studies have presented
conflicting data and have described no alterations to placental GLUT1 expression in
response to maternal GDM [156], indicating that the mechanisms underlying GDMmediated alterations to placental glucose transport remain poorly understood. Overall, as
correlations have been found between basal-membrane GLUT1 density and offspring
birthweight [147], increased placental expression of GLUT1 may underlie the
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development of fetal macrosomia, and in turn the development of later life metabolic
health complications in offspring exposed to DM [84,85].
Studies utilizing PHT culture systems, have highlighted that exposure to
independent hyperglycemia (20-25 mM for 48 hours) is associated with reduced placental
glucose transport, and reduced GLUT1 mRNA and protein abundance compared to
euglycemic cultured controls [157]. Further work from this research group additionally
highlighted that a 48 hour hyperglycemia exposure was associated with increased
internalization of GLUT1 transporters that may facilitate their previously observed
reductions in glucose transport [158]. Overall, these data highlighted that hyperglycemia
is an important regulator of placental glucose transport. However, the differences
between the impacts of hyperglycemia in vitro (reduced GLUT1 expression and
increased GLUT1 internalization) and the impacts of diabetes in vivo (increased basal
membrane GLUT1 expression) still need to be investigated and understood.

1.4.3

Placental nutrient storage
The villous trophoblast cells of the placenta not only have the capability to uptake

and transfer NEFAs from maternal circulation to the fetus, but also to store them as lipid
droplets for future metabolic needs [159–161]. Analysis of the activity of FA transport
proteins on placental membranes has indicated that placental lipid up take is greater on
maternal facing membranes than on fetal-facing membranes, highlighting that placental
lipid storage and/or metabolism is an important aspect of placental lipid processing [161].
In fact, both CT and SCT cells accumulate lipid droplets, and the lipid droplet abundance
and volume has been reported to be similar in these cells at term [162]. Interestingly
however, studies examining PHTs treated with fluorescently-labelled FA substrates have
found that only CT cells, and not SCT cells, exhibit FA esterification activity leading to
increased lipid droplet abundance [162–164]. Reduced lipid droplet synthesis in SCT
cells was associated with decreased expression of lipid metabolism genes including
Glycerol-3-Phosphate Acyltransferase 3 (GPAT3), an enzyme involved in TG formation
[162]. These data may highlight that transcriptional regulation directly underlies the
differences in lipid droplet synthesis between differentiated SCT cells and progenitor CT
cells. Additionally, placental villous trophoblast cells have been found to express Fatty
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Acid Synthase (FASN), highlighting that de novo lipogenesis may also contribute to
placental lipid droplet formation. However, the activity of enzymes involved in FA
synthesis have been found to be low in term placentae [165,166], suggesting that these
pathways may be of little importance in placental lipid handling.
Similar to placental lipid transporters, placental GLUT transporters are more
prevalent on maternal-facing apical placental membranes than on fetal-facing basal
membranes [135,136], suggesting that nutrient storage may also be an important aspect of
placental glucose processing. In fact, placental trophoblasts store large quantities of
glycogen [167–169], further highlighting that nutrient storage is an important component
of overall placental nutrient handling. Interestingly, CT cells are the predominant area for
glycogen storage in the placenta [167,168]. Since these cells are also the predominant
area for new lipid storage in the placenta, these cells may be especially important in
placental nutrient processing, as has recently been proposed [163].
Overall, placental nutrient stores are thought to be a mechanism by which the
placenta modulates materno-fetal nutrient transport in order to control fetal growth
trajectories [169–171]. Thus, any alterations in placental villous trophoblast nutrient
storage mechanisms in response to adverse maternal nutrient environments (such as those
in obese and diabetic pregnancies) may lead to aberrant trans-placental nutrient transport
and facilitate the in utero programming of fetal metabolic disease. As with nutrient
transport, the impacts of maternal obesity, and DM as well as the independent impacts of
dietary FA and hyperglycemia can be examined through the use of term placental lysates,
in conjunction with cultured PHTs, term placental explants, and placental cell line
systems.

1.4.3.1

The impacts of obesity, and maternal diet on placental
nutrient storage

Maternal gestational obesity has been well demonstrated to alter placental lipid
storage resulting in a pathological accumulation of lipid droplets (steatosis) at term
[116,165,172,173]. Analysis of the composition of these lipid droplets has demonstrated
that saturated FAs and MUFAs are the predominate lipid species that are stored in the
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obese placenta and may indicate increased supply of saturated FA and MUFA species to
the placental in obese pregnancies [174]. Further underlying this increased TG
accumulation in obese pregnancies is altered placental metabolic processing of FA
species via desaturation [175]. FA desaturation refers to the enzymatic introduction of a
new double bond in the carbon backbone of FA species, increasing the units of
unsaturation in the FA. In the placenta, an important mediator of FA desaturation is the
enzyme stearoyl-CoA desaturase-1 (SCD1) which introduces a new double bond into
palmitate or stearate producing the MUFA species palmitoleate and oleate, respectively
[176]. Previously, maternal obesity has been demonstrated to increase placental mRNA
expression of SCD1, that may highlight an increased formation of MUFA species in the
obese placentae [116]. As MUFA species have been found to be preferentially localized
to lipid droplets in the placenta [177], increased SCD1 expression in obese placentae may
underlie previously observed increases in TG accumulation. It is important to note
however, that conflicting reports have highlighted reduced SCD1 activity in obese
placentae, overall resulting in decreased placental palmitoleate synthesis [178]. The
mechanisms by which maternal obesity, and maternal dietary fat consumption impact
placental SCD1 expression and activity, and how these changes related to placental lipid
accumulation requires further investigation. The human placenta has also been found to
express isoforms of Fatty Acid Desaturase 1 (FADS1) and Fatty Acid Desaturase 2
(FADS2) which introduce double bonds into a variety of PUFA species [179,180],
although the activity of these enzymes is low in placental tissues [181,182].
Studies examining the impacts of independent dietary FAs on PHTs and BeWo
trophoblast cells have highlighted that oleate (a dietary MUFA) is highly lipogenic in
trophoblasts leading to increased TG abundance [132,183]. Interestingly, co-culture of
PHT cells with both oleate and palmitate (a dietary saturated FA) was associated with
reduced TG formation versus oleate-alone exposure [183]. Overall, these data highlight
that dietary FA species regulate placental lipid storage both independently and in
combination and may reflect that altered fat supply to the placenta facilitates the
development of steatosis in obese pregnancies. In fact, dietary intervention studies in
obese pregnancies, have highlighted that altering maternal dietary fat intake can modulate
placental lipid accumulation. Specifically, maternal dietary supplementation with omega-
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3 PUFAs decreases placental lipid accumulation at term in obese pregnancies [165].
Further, human population data indicates that obese women from pacific regions such as
Hawaii who naturally consume greater levels of omega-3 rich fatty foods such as fish
have less severe placental steatosis than obese women from landlocked areas such as
Ohio who generally consume diets less plentiful in omega-3 fats [116,184]. However, as
previously stated, lipid esterification is an important regulator of transplacental lipid
transport. Thus, an improvement in placental steatosis with omega-3 PUFA supplements
without correcting an underlying maternal overconsumption of saturated fats may be
harmful to the fetus through increasing transplacental saturated FA transport. In fact,
there may be an increased risk of offspring being born LGA in pregnancies that are
supplemented with omega-3 PUFA, which itself may promote the development of later
life metabolic disease [185,186]. Overall, a simple dietary supplementation may not be
sufficient to improve adverse fetal outcomes, and a more rigorous dietary intervention
that also addresses maternal saturated fat and MUFA consumption may be required.
While the impacts of maternal obesity on placental lipid storage have been
thoroughly explored, the impacts of obesity on glycogen storage in the human placenta
have not been well documented [187]. However, in rodent models maternal high-fat
feeding induced obesity has been associated with increased placental glycogen
accumulation [188], which may further highlight aberrant placental nutrient storage in
obese pregnancies. Overall, the direct influence of maternal obesity and dietary fat
consumption on placental glycogen synthesis, and how this may relate to materno-fetal
glucose transport remains not well defined.

1.4.3.2

Maternal diabetes mellitus and placental nutrient storage

Maternal pre-gestational Type 1 DM, and maternal GDM have also been
highlighted increase TG and lipid droplet accumulation in the placenta at term
[118,150,189–191]. Interestingly, placental expression of SCD1 is elevated in GDM
pregnancies, further highlighting the potential role of FA desaturation in facilitating
placental lipid accumulation [189]. However, it is important to note that additional
examinations of placental steatosis in diabetic pregnancies have highlighted that
increased placental TG abundance only occurs in women with GDM and a BMI>30, but
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not in women with pre-gestational Type 1 and Type 2 DM, or GDM and a BMI<30
[149]. The differences in placental lipid accumulation in these reports may be due to
differences in glycemic control between study populations.
Independent hyperglycemia has also been demonstrated to be an independent
regulator of placental lipid storage. Specifically, placental explants from healthy
uncomplicated pregnancies were found to have increased rates of FA esterification, and
increased TG accumulation when cultured under hyperglycemic conditions [149,191].
However, additional analyses have demonstrated that glucose overabundance does not
increase placental TG content to the extent that oleate exposure does, suggesting that
glucose is less lipogenic in placental trophoblasts than dietary MUFAs [192]. These data,
nonetheless, highlight that maternal hyperglycemia in diabetic pregnancies is an
important regulator of placental lipid storage and TG content.
Maternal pre-gestational DM and GDM are also well associated with increased
glycogen accumulation at term in both humans and in rodent models [190,193–196].
More importantly, data from both human and rat studies have highlighted that increased
placental glycogen accumulation is associated with poor maternal glycemic control,
suggesting that increased glucose supply to the placenta directly induces glucose storage
as glycogen [193,194]. This increased glycogen content in response to maternal
hyperglycemia may serve to modulate trans-placental glucose transport, potentially in an
effort to reduce fetal overgrowth, as has previously been hypothesized [170]. However,
the investigations into the direct impacts of elevated glucose levels on placental glycogen
storage using PHT and placental cell line culture systems are limited [197,198]. For
example, a study by Schmon et al. (1991) did not find differences in PHT glycogen
abundance after 4 days of high glucose exposure. The lack of glucose-mediated impacts
on glycogen content may arise as this study utilized differentiated SCT cells, which are
not a predominant site of placental glycogen storage [167,168]. In contrast, Pattillo et al.
(1971) has described increased glycogen accumulation in BeWo trophoblast cells
cultured under high glucose conditions. Overall, the mechanisms underlying glycogen
synthesis and storage in response to nutrient overload are poorly understood.
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1.4.4

Placental mitochondrial function and nutrient oxidation
Mitochondria are important organelles responsible for cellular energy production

and homeostasis in the placenta [199,200]. For example, the inner mitochondrial matrix
contains important metabolic enzymes involved in the citric acid cycle (or tricarboxylic
acid cycle (TCA cycle)) that are utilized to generate the co-factors NADH and FADH2
from acetyl-CoA [201] (Figure 1-2). The cellular acetyl-CoA utilized in the TCA cycle
in the placenta is the product of glucose and fatty acid metabolism, via glycolysis and βoxidation, respectively [201]. In brief, glycolysis is a metabolic process that occurs in the
cytosol, whereby one six-carbon glucose molecule is broken down and converted into 2
three-carbon pyruvate molecules [202]. The newly synthesized pyruvate can then be
processed anaerobically via Lactate Dehydrogenase (LDH) to form the metabolite lactate
[202]. Additionally, pyruvate can be processed inside the mitochondrial matrix via the
Pyruvate Dehydrogenase (PDH) complex to produce acetyl-CoA necessary for the TCA
cycle [203] (Figure 1-2). The process of FA β-oxidation is discussed in depth in Section
1.4.4.1. Additionally, the amino acid glutamine is an important oxidative fuel in placental
trophoblasts [204]. Once in the mitochondrial matrix glutamine is metabolized to
glutamate via the enzyme glutaminase, and subsequently to α-ketoglutarate via the
enzyme glutamate dehydrogenase [204] (Figure 1-2). The generated α-ketoglutarate then
directly feeds into the TCA cycle to generate NADH and FADH2.
Ultimately, the NADH and FADH2 generated by the TCA cycle act as electron
donors for the Electron Transport Chain (ETC) complexes on the inner mitochondrial
membrane [205]. The shuttling of electrons through the first 4 ETC complexes (ETC
complex I-IV) and ultimately to oxygen (the terminal electron acceptor) generates a
proton gradient across the inner mitochondrial membrane that is then utilized by the final
ETC complex (complex V or ATP synthase) to generate the cellular energy carrying
molecule adenosine triphosphate (ATP) [205] (Figure 1-2). This process is also known
as oxidative phosphorylation or mitochondrial respiration. ATP is subsequently utilized
in a variety of important cellular processes in the placenta, including the synthesis of
proteins, hormones, nucleic acids, and glycogen, as well as transplacental nutrient
transport [206–208].
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Figure 1-2 Schematic overview of mitochondrial nutrient oxidation.
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Interestingly, recent studies have highlighted that progenitor CT cells display
greater mitochondrial respiratory activity than differentiated SCT cells, further
highlighting the importance of CT cells in placental nutrient processing
[118,163,209,210]. More importantly, adverse maternal metabolic environments in obese
and diabetic pregnancies impair placental mitochondrial function. For example, maternal
gestational obesity has been linked with an overall reduction in mitochondrial ETC
activity (mitochondrial oxidative function) in term PHT cultures leading to reduced
placental ATP levels [115,211]. Notably, the expression of miR-210 (a marker of
mitochondrial dysfunction) is only elevated in the placentae of female fetuses from obese
pregnancies, potentially highlighting sex-dependent impacts of maternal environment on
placental mitochondrial function [212]. These sex-specific changes may underlie the
previously observed macrosomia only in female offspring of human obese pregnancies
[37]. Further targeted investigations of ETC complex activity in term placenta lysates has
also demonstrated specific impairments in complex I and complex II activity in the obese
placenta [117]. However, the direct impacts of maternal dietary fat consumption and
individual dietary FA species on placental mitochondrial respiratory activity and ETC
complex function are poorly understood.
PHTs cultured from GDM pregnancies also display similar impairments in
mitochondrial respiratory activity leading to reduced ATP production [118,210,213].
These impairments in mitochondrial activity in PHTs from GDM pregnancies were
shown to be restricted to CT cells, and not SCT cells, further demonstrating the
importance of these progenitor trophoblasts in regulating the overall metabolic function
of the placenta [118]. Further, women with GDM and a BMI>30 were found to have
morphological abnormalities in placental mitochondria that may specifically underlie
altered mitochondrial respiratory activity [214]. In addition to GDM, women with pregestational DM have also been found to have impaired ETC complex function at term
[117]. Specifically reduced activities of ETC complexes I, II, and II were observed in
term placental lysates from type 1 DM pregnancies and reduced activities of ETC
complexes II and II were observed in term placental lysates from type 2 DM pregnancies
[117]. Previously, independent hyperglycemia has been demonstrated to stimulate BeWo
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trophoblast mitochondrial dehydrogenase activity and decrease JAR and JEG-3 placental
trophoblast mitochondrial dehydrogenase activity following 24 hours of high glucose
exposure when analyzed by endpoint tetrazolium salt assay [215]. These data suggest that
hyperglycemia is an independent regulator of placental mitochondrial function. However,
targeted functional analysis of mitochondrial respiratory activity in PHTs cultured under
high glucose conditions revealed no hyperglycemia-mediated impairments to
mitochondrial function [118].
Overall, these data demonstrate that placental mitochondrial respiratory
impairments are highly prevalent in obese and diabetic pregnancies. These impairments
in placental mitochondrial respiration may have vast consequences on global placental
functions and may be of great importance in the placental programming of fetal
metabolic disease. However, underlying mechanisms regulating placental mitochondrial
respiration in response to dietary FAs and glucose need to be elucidated to better
understand the impacts of maternal obesity and DM on placental mitochondrial function.

1.4.4.1

Placental β-oxidation

In addition to impacting placental mitochondrial function via impacting oxidative
ATP production, maternal obesity and DM have been highlighted to impact placental
mitochondrial FA oxidation (β-oxidation). Alterations in this important mitochondrial
function in obese and diabetic pregnancies may not only impact placental ATP
production but also alter transplacental lipid transport, and subsequently impact fetal
growth and development.
As previously mentioned, β-oxidation is the process by which FA species are
catabolized into acetyl-CoA that is utilized to regenerate NADH and FADH2 (Figure 12). The first step of β-oxidation is the dehydrogenation of an acyl-CoA species and is
catalyzed by an acyl-CoA dehydrogenase enzyme. There are multiple isoforms of this
enzyme, each of which is responsible for initiating β-oxidation of acyl-CoA species of a
different length. Specifically, medium-chain acyl-CoA dehydrogenase (MCAD) has an
optimal activity with FA chains containing 8 carbon atoms; long-chain acyl-CoA
dehydrogenase (LCAD) has optimal activity with 12-carbon FAs; and very long-chain
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acyl-CoA dehydrogenase (VLCAD) is most active with 16-carbon FAs [216]. Next,
enolyl-CoA hydratase catalyzes the hydration of the newly formed Trans carbon double
bond. Subsequently, 3-hydroxyacyl-CoA dehydrogenase converts the newly formed
hydroxyl group to a keto functional group. Two isoforms of 3-hydroxyacyl-CoA
dehydrogenase, SCHAD and LCHAD, catalyze reactions derived from short-chain and
long-chain FAs respectively [216]. Finally, β-ketothiolase—which has the short and
long-chain isoforms, SKAT and LKAT—cleaves the carbon chain to generate a
shortened acyl-CoA molecule and a new molecule of acetyl-CoA [216]. Under normal
physiological conditions, complete β-oxidation occurs whereby all carbon atoms in the
FA backbone are converted into acetyl-CoA molecules that are oxidized for ATP
production [95,96]. However, under pathological conditions such as lipid overload,
mitochondrial β-oxidation may become incomplete resulting in accumulation of
shortened chain acyl-CoA molecules within the mitochondrial matrix that may then be
exported into circulation [217,218].
However, in order to undergo β-oxidation, the FA-derived acyl-CoA molecule
must be first transported into the mitochondrial matrix through a carrier-mediated
process. Acyl-CoA molecules are conjugated to l-carnitine, an amino acid-derived
molecule, in the cell cytosol through an enzymatic process via Carnitine
Palmitoyltransferase I (CPT1) at the outer mitochondrial membrane. The acylcarnitine
molecules are then shuttled into the intermembrane space where the protein transporter
translocase shuttles the molecule into the mitochondrial matrix. Finally, Carnitine
Palmitoyl Transferase II (CPT2) catalyzes the hydrolysis of the acyl-carnitine enabling
the free FA molecule to undergo β-oxidation. While the majority of circulating maternal
carnitine can be attributed to dietary sources, tissues including the placenta can
synthesize l-carnitine from precursor amino acids [219,220].
Immunohistochemical staining of isolated placental cells and western blot protein
analysis of term and early gestation human placental explants has revealed that villous
trophoblast cells express enzyme isoforms for all enzymatic steps in the mitochondrial βoxidation pathway. Both SCT and CT cells express the Acyl-CoA dehydrogenase
isoforms VLCAD, LCAD, and MCAD; enolyl-CoA hydratase; the 3-hydroxyacyl-CoA
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dehydrogenase enzyme isoforms SCHAD, and LCHAD; as well as the 3-ketoacyl-CoA
thiolase enzyme isoforms LKAT, and SKAT [221–223]. Notably, the expression levels of
these β-oxidation enzymes within placental explants are similar to that of skeletal
muscle—a tissue known to be highly dependent on β-oxidation for ATP production—
highlighting that FA oxidation is critical for placental function [221]. Additionally, the
ability of placental mitochondria to utilize lipid substrates for ATP production varies over
gestation [223]. Specifically, mid gestational placental explants display an elevated
expression of mitochondrial β-oxidation enzymes compared to term samples, suggesting
that the capacity of the placenta to utilize FA as a metabolic substrate may diminish as
pregnancy progresses [223].

1.4.4.2

Maternal obesity, and β-oxidation

Independently, maternal gestational obesity has been shown to impede the ability
of term placental mitochondria to oxidize FA species for ATP production [116,224].
Decreased intra-placental concentrations of acylcarnitine species (a marker of βoxidation) combined with an overall reduction in mitochondrial content within term
obese placentae suggests that this aberrant maternal environment can negatively impact
placental β-oxidation activity [116]. However, while β-oxidation primarily occurs within
the mitochondria, placental peroxisomes have also been found to express enzymes for FA
oxidation [120,225,226]. Specifically, the enzymes involved in peroxisomal β-oxidation
are acyl-CoA oxidases (ACOX), D-bifunctional protein (DBP) and 3-ketoacyl-CoA
thiolases [225,227]. In brief, peroxisomal β-oxidation shortens long-chain FA species
into acetyl-CoA and short-chain acyl-CoAs such as octanoyl-CoA which can then be
exported into the mitochondria in a CTP1 independent manner for further oxidation
[225,227]. More importantly, environmental cues such as fatty acid overabundance in
obesity are associated with increases in both the size and number of peroxisomes
[116,228]. Additionally, maternal obesity has been linked increased mRNA expression of
peroxisomal β-oxidation enzymes, suggesting that peroxisomal β-oxidation is a major
component of placental lipid handling in obese pregnancies [116]. Obese placentae were
further found to have greater rates of oxidation of radio-labelled palmitate following
treatment with etomoxir (a mitochondrial β-oxidation inhibitor) than non-obese placentae
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highlighting that increases in peroxisomal β-oxidation may act to modulate lipid
oxidation in obese pregnancies with poor mitochondrial function [116]. Overall, these
results suggest that the balance between mitochondrial and peroxisomal β-oxidation in
the placenta is disrupted by obesity.
Maternal diet has also been identified to impact placental lipid oxidative function
in some obese women. Specifically, obese Hawaiian women, who consume the Pacific
diet, have similar mRNA expression levels of mitochondrial and peroxisomal β-oxidation
enzymes as lean Hawaiian women [184]. This may suggest that the increased PUFA
content of the pacific diet could moderate the balance between mitochondrial and
peroxisomal lipid oxidation. In contrast however, dietary omega-3 PUFA
supplementation in obese pregnancies from landlocked areas (Ohio) was not linked to
alterations in mRNA expression of mitochondrial and peroxisomal β-oxidative enzymes
although these dietary supplements alleviated placental steatosis [165]. Additionally,
omega-3 PUFA supplements did not alter [3H]palmitate oxidation rates in cultured
villous trophoblast cells from otherwise healthy obese Ohioan women [165]. While
PUFA supplementation studies have highlighted some favourable outcomes, further
investigation of the impact upon mitochondrial and peroxisomal β-oxidation pathways is
warranted.
An illustration summarizing the impacts of maternal obesity and dietary
interventions on placental nutrient processing is available in Figure 1-3.
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Figure 1-3 Summary illustration of the alterations to placental villous trophoblast
nutrient processing and mitochondrial function under conditions of (A) maternal
obesity and (B) maternal obesity with maternal dietary intervention.
Maternal gestational obesity has been associated with increased transplacental lipid
transport (mediated by increased LPL activity and increased FAT/CD36 expression),
increased placental lipid esterification and lipid droplet formation as well as decreased
placental mitochondrial β-oxidation with concomitant increased peroxisomal β-oxidation.
Additionally, term placental villous trophoblasts from obese pregnancies have been found
to have impaired mitochondrial respiratory activity with specific underling impairments in
the activities of ETC complexes I and II. These changes are understood to be important in
utero insults that program the development of early-life metabolic disease in the offspring
from obesity-exposed pregnancies. An improved maternal diet in obese pregnancies, such
as with consumption of a ‘pacific diet’ or use of dietary PUFA supplements, has been
associated with reduced placental steatosis and improved placental β-oxidative function
(increased mitochondrial β-oxidation with simultaneous decreased peroxisomal βoxidation). These changes highlight that maternal dietary fat intake is an important
regulator of placental nutrient processing and suggests that a poor maternal diet underlies
the development aberrant placental metabolic function in obese pregnancies.
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1.4.4.3

Maternal diabetes mellitus and placental β-oxidation

Maternal DM during pregnancy, much like maternal obesity, is associated with
impaired placental β-oxidation processing. Specifically, cultured term placental explants
from both laboring vaginal deliveries and non-laboring cesarean section deliveries from
GDM pregnancies have been shown to have reduced [3H]palmitate oxidation compared
to explants form healthy control pregnancies [191,229]. Independent hyperglycemia
exposure was subsequently demonstrated to decrease [3H]palmitate oxidation rates, and
CPT1 activity in cultured explants from healthy control pregnancies, highlighting that
diabetic hyperglycemia may directly impairs placental β-oxidation [191]. Interestingly,
placental explants cultured with CPT1 agonists (resulting in increased β-oxidation) in
conjunction with hyperglycemia have reduced placental TG accumulation compared to
explants cultured with hyperglycemia alone [149]. These data suggest that decreased
placental β-oxidation is also implicated in the development of placental steatosis in
response to elevated glucose supply [149].
An illustration summarizing the impacts of maternal DM and independent glucose
exposure on placental nutrient processing is available in Figure 1-4.
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Figure 1-4 Summary illustration of the alterations to placental villous trophoblast
nutrient processing and mitochondrial function under conditions of (A) maternal
diabetes mellitus and (B) hyperglycemia in culture conditions.
Maternal diabetes mellitus has been associated with increased basal membrane GLUT1
protein abundance and increased glycogen content. Further, diabetic placentae exhibit
increased lipid esterification, and placental steatosis in conjunction with reduced βoxidation activity. Diabetic placenta mitochondrial have also been found to have impaired
mitochondrial respiratory activity highlighted by an underlying impairment in the functions
of ETC complexes I and II. These changes in placental nutrient oxidation and processing
are thought to mediate pathological transplacental nutrient transport, ultimately impacting
fetal growth and increasing the risk of offspring metabolic disease. High glucose exposure
in cultured ex vivo placental preparations and in vitro placental cell line systems has
subsequently highlighted that increased glucose levels independently regulates placental
nutrient storage (e.g., glycogen and triglycerides), nutrient transport, and nutrient
oxidation. Thus, maternal hyperglycemia in diabetic pregnancies may directly facilitate the
observed impairments in placental development and function.
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1.4.4.4

Acylcarnitines as biomarkers of placental β-oxidative
function

Overall, adverse intrauterine environments resulting from maternal obesity and
diabetes have been linked with impaired β-oxidative activity in the placenta.
Interestingly, placental β-oxidation biomarker signatures may have future utility in
clinical diagnostic tests to assess placental function in real time throughout gestation. One
potential method to quantify placental β-oxidative function in obese and diabetic
pregnancies may be through examining the acylcarnitine profiles of maternal blood
products. Previously, analysis of differences in acylcarnitine profiles has been utilized to
predict the presence of aberrant metabolic function in tissues including cardiac and
skeletal muscle [230–234]. As previously highlighted, obesity is associated with reduced
placental acylcarnitine abundance [116]. Thus, analyzing maternal blood acylcarnitine
profiles specifically in obese pregnancies may allow for the real-time identification of
aberrant placental mitochondrial β-oxidative function.
Acylcarnitine profiles have previously been examined as potential biomarkers for
the early-detection of other placental diseases such as pre-eclampsia [235,236].
Specifically, potential acylcarnitine biomarkers for the early detection of pre-eclampsia
were found in both maternal serum and plasma [235,236]. In addition, acylcarnitines
have also been examined as potential non-invasive biomarkers to examine placental
metabolic function under conditions of maternal obesity [116,237,238]. Notably
however, maternal acylcarnitine profiles differ based upon the blood faction that they are
isolated from. For example, increases in some short chain acylcarnitine species were
reported in maternal serum with increasing BMI [237], while no differences were found
in acylcarnitine profiles in maternal plasma [238]. As this field of investigation develops,
these blood fraction dependent differences in acylcarnitine profiles will need to be
considered in order accurately assess placental metabolic function.
Overall, acylcarnitine analysis represents an emerging field in placenta
physiology. Analysis of differences within these profiles in obese and diabetic women
may allow clinicians to diagnose placental mitochondrial dysfunctions early in the
gestational period, prior to onset of clinical disease. In turn, acylcarnitine biomarkers may
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allow clinicians to monitor the impacts of dietary interventions and stringent glycemic
control regimens on placental lipid handling during gestational period and subsequently
modulate the course of treatment, if needed, to limit the risks of offspring developing
disease in later life.

1.5 Omic analyses and the placenta
Recently, large datasets generated using omics based research approaches have
been utilized to elucidate the underlying mechanisms governing placental development
and function [239–241]. In a biological context omics generally refers to examining
something in its entirety [242]. For example, transcriptomics examines all expressed
ribonucleic acid (RNA) species, such as messenger RNA (mRNA), and highlights global
gene expression in a tissue or cell. Metabolomics, on the other hand, refers to the study of
small polar metabolite species that are the endpoint products of biological metabolic
processes. The metabolome of a given tissue or cell culture system is thought to be a
measure of the overall cell or tissue phenotype [243–245]. In addition, lipidome readouts
highlight global cellular polar and neutral lipid species profiles and is a relatively recent
development in omics research [246]. It is important to note that these readouts have
previously been utilized to identify markers associated with metabolic dysfunction in
other organs including cardiac [247,248] and hepatic [249,250] systems. In the
pregnancy field, these important hypothesis-generating tools have been utilized to help
elucidate how fetal sex impacts baseline placental metabolism in healthy pregnancies
[251,252]. These omics based approaches have also been utilized to provide detailed
insight into how an aberrant maternal environment disrupts normal physiological function
of the placenta [253]. While each of these omics based approaches has been demonstrated
to be useful on their own, recent studies have also highlighted that integrating or
combining these readouts can provide a more in depth understanding of the underlying
regulation of important biological functions [241,254,255].
In the context of maternal obesity and diabetes during pregnancy, omics based
analyses have allowed for a thorough understanding of underlying mechanisms that
underlie the development of impaired placental function. For example, transcriptomic
signatures have highlighted mechanisms involved in inflammation, lipid metabolic
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processing, and nutrient transport that are dysregulated in the obese and diabetic placenta
[256–260]. Excitingly, some of the markers (such as increased mRNA expression of
IGKV2D-28 and PTPRG) have been proposed to have utility as diagnostic biomarkers
that may enable clinicians to recognize early-onset GDM more easily [261]. Additionally,
lipidomic and metabolomic analyses have highlighted that maternal obesity and GDM are
associated with an altered placental lipid profile that may be implicated in altered transplacental lipid transport and subsequently altered fetal growth and development
[128,262–266]. Omics based analyses have also previously been used to elucidate
underlying mechanisms involved in placental responses to PUFA supplementation in
obese pregnancies [267]. For example, PUFA supplementation was found to increase
markers of proliferation in placental cells that, interestingly, were also directly correlated
with offspring birthweight [267]. These data may highlight that increased proliferation of
placental trophoblasts directly underlies the increased risk of offspring being born LGA
in obese pregnancies treated with dietary PUFA supplementation [185,186]. Overall,
omic based analyses have great potential to allow researchers to better understand the
regulation of placental function in response to overabundant nutrient supplies and may
highlight important placental pathways that may be targeted in future investigations that
aim to modulate or improve dysregulated placental metabolism.

1.6 Thesis overview, rationale, and objectives
Maternal diet is an important regulator not only of fetal metabolic health
outcomes, but also of the nutrient processing functions, and overall metabolism of the
placenta. Increasingly, women of reproductive ages consume a diet that may not be
optimal for successful pregnancy outcomes. These diets are characterized by high
processed sugar and saturated fat intake and are clinically associated with maternal
obesity and GDM development. Analysis of circulating NEFA levels in pregnant women
has highlighted that palmitate (hereafter PA), and oleate (hereafter OA) are the most
abundant circulating FA species in the third trimester, but more importantly, that the
circulating levels of these dietary FA species are elevated in both obese and GDM
pregnancies [268,269]. Since PA and OA are the most abundant FA species in the typical
“Westernized Diet”, these FA species themselves may be a link between poor maternal
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diet and aberrant placental function [63,65,270,271]. However, the independent and
combined impacts of dietary PA and OA in isolation on placental trophoblast metabolic
and mitochondrial function remains ill defined. This information is critical improve our
understanding of their potential contribution to placental dysfunction.
Likewise, maternal diabetes negatively regulates placental metabolic function,
however these negative outcomes may be facilitated by poor maternal glycemic control.
Additional, in vitro analyses using PHT and placental cell line systems have
demonstrated that hyperglycemia can also affect placental functions including nutrient
storage and transport, which in themselves may directly impact other aspects of placental
oxidative metabolism. However, the direct impacts of independent hyperglycemia on
important aspects of placental metabolic function including mitochondrial respiratory
activity and the regulation of nutrient storage remains poorly understood.
Thus, the collective aim of the work presented here was to further characterize the
direct and independent impacts of dietary FA overabundance and hyperglycemia on
BeWo trophoblast cell oxidative metabolism and nutrient storage. We specifically sought
to examine metabolic function, and nutrient storage using a combination of functional
readouts and endpoint analyses in both progenitor BeWo CT cells and differentiated
BeWo SCT cells. Furthermore, as CT cells have been highlighted to be the more
metabolically active villous trophoblast cell type, we additionally aimed to utilize a
multi-omics approach to further elucidate the underlying mechanisms governing
placental responses to nutrient overabundance in these progenitor cells. The governing
hypothesis of this thesis is increased nutrient abundance will impact placental metabolic
function specifically highlighted by altered nutrient storage, impaired mitochondrial
respiratory activity, as well as an altered transcriptomic, metabolomic, and lipidomic
profile representative of dysfunctional metabolism.

1.6.1

Chapter 2 – Objectives and hypothesis

1. Develop an in vitro cell culture protocol to examine prolonged PA and OA exposure
in BeWo CT and SCT trophoblast cells
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2. Quantify mitochondrial respiration and metabolic enzyme activities in PA and OA
exposed BeWo trophoblast cells using functional readouts
In Chapter 2, it was postulated that a prolonged exposure to the dietary NEFAs PA and
OA both independently and in combination would impair mitochondrial function in BeWo
CT and SCT cells.

Chapter 3 – Objectives and hypothesis

1.6.2

1. Characterize mitochondrial respiration and metabolic enzyme activity in BeWo CT
and SCT cells exposed to independent hyperglycemia using functional assays
2. Investigate the underlying mechanisms regulating nutrient storage in high glucose
exposed BeWo CT and SCT cells
3. Utilize a multi-omic approach combining transcriptomics, untargeted metabolomics,
and untargeted lipidomics to elucidate underlying mechanisms governing altered
metabolic processing in BeWo CT cells exposed to hyperglycemia.
In Chapter 3, it was postulated that hyperglycemic culture conditions would be
associated with increased nutrient storage and impaired mitochondrial respiratory
function in BeWo CT and SCT cells, in association with altered transcriptome,
metabolome, and lipidome signatures in BeWo CT cells indicative of altered metabolic
function.

1.6.3

Chapter 4 – Objectives and hypothesis

1. Examine FA and neutral lipid profiles in both progenitor BeWo CT cells and
differentiated BeWo SCT cells using targeted lipidomic analyses
2. Utilize transcriptomics, in conjunction with untargeted metabolomics and lipidomics
in BeWo CT cells to characterize the underlying mechanisms governing placental
responses to dietary FA overabundance
In Chapter 4, it was postulated that exposure to elevated levels of dietary NEFA
would alter BeWo trophoblast lipid profiles, highlighted by increased TG abundance,
and increased FA elongation and desaturation. It was additionally postulated that
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dietary-FA treated BeWo CT cells would display altered transcriptomic, metabolomic
and lipidomic profiles indicative of altered lipid processing.
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2.1

Introduction
The prevalence of obesity in women of reproductive age has been increasing

worldwide over the past several decades, and approximately 40 million pregnant women
globally are obese [1–3]. Additional reports have indicated that a majority of women of
reproductive age have a hip-to-waist ratio (WHR) indicative of a high risk for metabolic
disease development [4,5]. Increased body mass, obesity and elevated WHR prior to and
during pregnancy have not only been associated with negative health impacts for the
mother, but also with impaired metabolic health outcomes in the offspring [6–11]. For
example, children born to mothers who were overweight or obese throughout the
gestational period have an increased risk of developing metabolic complications such as
type 2 diabetes mellitus and obesity compared to children born to mothers with lean body
compositions [10]. Of greater concern, these children develop these “adult-associated”
metabolic diseases as early as four years of age, and the prevalence of pediatric metabolic
syndrome appears to be increasing [8,12,13].
The origin of early onset development of adult-associated diseases is the result of
aberrant in utero programming of fetal metabolism potentially induced by maternal
obesity-mediated alterations to placental mitochondrial function [14–16]. Specifically,
due to their close proximity to maternal blood, trophoblast cells within the placental
chorionic villi may be important in facilitating the adverse effects observed with
increased maternal adiposity [9,17]. In fact, the large multinuclear syncytiotrophoblast
(SCT) cells, and underlying progenitor cytotrophoblast (CT) cells that comprise the
chorionic villi in obese pregnancies have been found to display decreased mitochondrial
respiratory activity (oxidative phosphorylation) as well as reduced cellular ATP content
[17–19]. Obesity-associated impairments in placental mitochondrial function have also
been identified through analysis of enzymes within mitochondrial energy production
pathways. Specifically, the activity of citrate synthase (CS; a proxy measurement of total
cellular mitochondrial content) as well as the protein abundance and enzyme activity of
electron transport chain (ETC) complex I (NADH Dehydrogenase) and complex II
(Succinate Dehydrogenase) are decreased in villous trophoblast cells from term obese
placentae, [19,20]. Since progenitor CT and differentiated SCT cells form the materno-
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fetal interface and regulate nutrient and gaseous exchange between mother and
developing fetus, obesity-mediated mitochondrial dysfunction within these cell types may
alter transplacental nutrient transfer such that fetoplacental development becomes
pathological [21].
Recently however, analysis of dietary patterns in Westernized populations have
discussed a link between poor diet and metabolic health risks [22,23]. For example,
adherence to an unhealthy diet during gestation has been found to promote the
development of Gestational Diabetes Mellitus (GDM) [24–26], which in itself has been
found to promote poor metabolic health outcomes in the exposed offspring [27–30].
Studies analyzing gestational diet composition have demonstrated that many pregnant
women consume diets that are calorie-dense, but nutrient lacking and high in saturated
and monounsaturated fatty acids [31–34]. These reports are concerning as consumption
of a poor diet during gestation has been identified to facilitate the progression of placental
metabolic impairments that ultimately lead to the development metabolic disease in the
exposed offspring. For example, a pre-gestational diet-reversal from a high fat diet (HFD)
to healthy control diet in obese non-human primates has been associated with improved
placental vascular function as well as improvements in fetal metabolic health [35–38]. As
these diet reversal studies altered maternal fat intake to improve placental and fetal
metabolic health, dietary fatty acids (FA) themselves may be important in mediating
adverse outcomes in obese pregnancies.
Specific analysis of fasting blood lipid levels in pregnant populations revealed
that pregnancies complicated by maternal obesity and GDM display hyperlipidemia and
increased circulating levels of the saturated FA palmitate (C16:0, PA) and the
monounsaturated FA oleate (C18:1 cis 9, OA) [39–41]. As circulating PA and OA levels
have previously been found to be impacted by diet composition [42,43], these data
suggest that PA and OA are overabundant in the diets of women with pregnancies
complicated by obesity and GDM. It is important to note that increased PA levels have
been demonstrated to independently induce mitochondrial damage and impair
mitochondrial oxidative function leading to decreased ATP content in a number of cell
culture systems [44–46].
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Collectively these data could indicate that placental mitochondrial impairments
are the result of dietary FA overabundance, and that changes in maternal diet and fat
intake alone may have effects on placental function and ultimately offspring metabolic
health. However, the underlying independent effects of dietary saturated and
monounsaturated NEFAs in mediating these phenotypes remains uncertain. The objective
of this study was to examine the direct prolonged effects of PA and OA on placental CT
and SCT mitochondrial metabolism. It was postulated that a prolonged exposure to the
dietary NEFAs PA and OA both independently and in combination would impair
mitochondrial function in BeWo CT and SCT cells.

2.2 Materials and Methods:
2.2.1

Materials
All chemicals were purchased from Millipore Sigma (Oakville, Canada) unless

otherwise indicated.

2.2.2

Cell culture conditions
BeWo cells are a choriocarcinoma-derived immortalized cell line that are

representative system of villous trophoblast cells of the human placenta and have been
previously utilized to examine human villous trophoblast metabolic function [47,48].
Under basal conditions these cells are proliferative and CT-like, and when cultured with a
cAMP analogue (8-Br-cAMP) they differentiate into SCT-like cells that secrete human
chorionic gonadotropin (hCG) [49,50]. In the current study, BeWo cells were utilized as a
model to examine the independent effects of dietary NEFAs as these cells are isolated
from effects of maternal body composition and gestational diet.
BeWo cells (CCL-98) were purchased from the American Type Culture
Collection (ATCC; Cedarlane Labs, Burlington, Canada) and cultured in F12K media
(Gibco, ThermoFisher, Missasauga, Canada) supplemented with 1% PenicillinStreptomycin (Invitrogen, ThermoFisher, Mississauga, Canada) and 10% Fetal Bovine
Serum (Gibco). Cells were maintained at 37 ℃ in 5% CO2/95% atmospheric air and used
between passages 5-11 for all experiments. For each experiment, BeWo CT cells were
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plated at stated specific experimental densities and allowed to adhere to cell culture plates
overnight prior to NEFA treatment. For all NEFA treatments, fats were conjugated 2:1
(molar ratio) to FA free bovine serum albumin (BSA). NEFA medias were heated at 37℃
for at least 30 mins prior to media changes to ensure equilibrium state of FA-BSA
complexes [51]. Media supplemented with 0.3% BSA was used for control cultures in all
experiments (BSA-ctrl). For SCT differentiation, 250 µM 8-Br-cAMP was added to
experimental cell culture media at 24H and 48H. Media in all experimental conditions
were replenished every 24H. A schematic showing the experimental timeline is shown in
Figure 2-1.

Figure 2-1 Cell culture timeline for BeWo cell NEFA-treatments
BeWo cells were plated and allowed to adhere overnight prior to NEFA-treatment
initiation at T0H. At T24H 250 μM 8-Br-cAMP or a vehicle control was added to the cell
culture plates to allocate cells to either CT or SCT cell type. All metabolic activity assays
and cell collections were performed at T72H.
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2.2.3

Cell viability
Cell viability in response to increasing concentrations (0-200μM) of PA, OA, and

a 1:1 ratio of PA and OA (P/O) conjugated 2:1 (molar ratio) to BSA was assessed via the
CellTiter-Fluor live-cell protease activity assay (Promega Corporation, Madison, WI,
USA). BeWo cells were plated at 1x104 cells/well in 96-well opaque walled plates, and
viability was assessed at 72H for both CT and SCT cell types as per the manufacturer’s
instructions, using a SpectraMax M5 plate reader (Molecular Devices, San Jose, CA,
USA).

2.2.4

Immunofluorescent analysis of BeWo syncytialization
To assess the syncytialization of NEFA-treated BeWo cultures, percent fusion of

each treatment group was determined via zona occuldens-1 (ZO-1) immunofluorescent
cell imaging [52]. In brief, BeWo cells were plated at a density of 1.4x105 cells/well on
glass coverslips coated with laminin (2 µg/cm2) in 6-well cell culture plates and cultured
for 72H with 100 µM of PA, OA or P/O conjugated 2:1 (molar ratio) to BSA. At 72H
cells were washed once with Phosphate Buffered Saline (PBS) and fixed with 1:1
methanol:acetone for 30 mins at -20℃. Fixed cells were washed with PBS and
permeabilized with 0.3% Triton-X 100 in PBS for 5 mins. Coverslips were then washed
three times with PBS and blocked with 10% goat serum (abcam, Toronto, Canada) in
PBS (blocking buffer). Coverslips were then incubated with ZO-1 antibody (1:200
dilution in blocking buffer; catalog No. 33-9100, Invitrogen) for 1 hour at room
temperature. After washing with PBS three times coverslips were incubated with donkey
anti-mouse IgG secondary antibody, Alexa Fluor 594 (1:2000 dilution in blocking buffer;
Catalog No. R37115, Invitrogen) for 1 hour at room temperature. Coverslips were then
washed 3 more times in PBS and mounted on slides using Fluoroshield with DAPI.
Immunofluorescent images were then captured using the Zeiss Axioimager Z1
microscope (Carl Zeiss AG, Oberkochen, Germany) at the Biotron Integrated Microscopy
Facility, Biotron Research Centre, Western University, London, Ontario, Canada. Nuclei
and fused BeWo cells were then counted using ZEN software (Carl Zeiss AG), and
percent fusion calculated as the percentage of total counted cells lacking ZO-1
expression.
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2.2.5

Quantitative-PCR analysis of BeWo syncytialization
Relative mRNA transcript abundance of the genes encoding the beta subunit of

human chorionic gonadotropin beta (CGB), and Ovo Like Transcriptional Repressor 1
(OVOL1) were used as an indirect quantification of BeWo syncytialization following
NEFA-treatment. Cells were plated at a density of 2x105 cells/well 6-well plates and
treated with 100 µM NEFAs as described above. Total RNA was then extracted via
phenol-chloroform extraction using TRIzol reagent (Invitrogen) as per the manufacturer’s
specifications. Isolated RNA was then reverse transcribed using random decamer primers
and M-MLV reverse transcriptase (Invitrogen) and RT-qPCR was subsequently
performed using the CFX384 Real Time System (BioRad, Mississauga, Canada).
Target CGB primer sequences were obtained from Malhotra et al., (2015); primer
sequences for OVOL1 were obtained from Kusama et al., (2018); and primers for the
reference genes β-actin (ACTB) and Proteasome 20S subunit Beta 6 (PSMB6) were
designed using the NCBI/Primer-BLAST tool (Table 2-1). Amplification of target gene
expression was reported as fold change relative to control CT cells using the 2-∆∆Ct
method with the ∆Ct of each treatment condition being assessed as Ct(target) –
Geometric mean of Ct(ACTB) and Ct(PMSB6).

Table 2-1 Forward and reverse primer sequences used for quantitative Real-Time
PCR measurement of BeWo cell syncytialization.
Gene

Accession
No.

Annealing
Temperature (°C)

ACTB

NM_001101.4

60

PSMB6

NM_002798

60

CGB
OVOL1

Malhotra et al (2015)
[53]
Kusama et al (2018)
[54]

60
60

Primer Sequences
F – GTTGCTATCCAGGCTGTGCT
R – AGGTAGTCAGTCAGGTCCCG
F – CGGGAAGACCTGATGGCGGGA
R – TCCCGGAGCCTCCAATGGCAAA
F – CCCCTTGACCTGTGATGACC
R – TATTGTGGGAGGATCGGGGT
F – AGACATGGGCCACTTGACAG
R – AGGTGAACAGGTCTCCACTG

Efficiency
109.0%
107.1%
101.1%
99.5 %
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2.2.6

Quantification of apoptosis
The activation state of pro-apoptotic pathways in BeWo CT and SCT cells in

response to 100 µM NEFA treatments was assessed via caspase-3/7 activity at 72H. Cells
were plated at a density of 1x104 cells/well in opaque walled 96-well plates and treated
with 100 µM NEFAs as described above. Live cell caspase 3/7 activity was determined at
72H utilizing the Caspase-Glo 3/7 Assay (Promega Corporation) as per manufacturer’s
instructions. BeWo CT cells treated with 100 µM of each rotenone (ETC complex I
inhibitor) and antimycin A (ETC complex II inhibitor) were utilized as a positive control
for upregulation of pro-apoptotic pathways [55].

2.2.7

Optimization of Seahorse XF assay protocols
BeWo cells were plated at the determined optimal density of 7.5x103 cells/well in

Seahorse XF24 V7PS cell culture microplates (Agilent Technologies, Santa Clara, CA,
USA) coated with 9 µg/cm2 collagen I (Gibco). The optimal concentration of the ATP
synthase inhibitor oligomycin (1.5 µg/mL) was determined as per manufacturer’s
instructions. The mitochondrial uncoupler dinitrophenol (DNP; 50 µM) was utilized to
measure maximal mitochondrial respiratory activity. Attempts to follow the
manufacturer’s recommended uncoupler FCCP resulted in unstable and declining OCR
measurements. Previous reports have identified that progesterone, which is secreted by
BeWo cells, recouples FCCP uncoupled mitochondria, but not DNP uncoupled
mitochondria, and the optimization of DNP in our system produced the required stable
OCR increase to measure maximal respiratory rate [56,57]. The complex I inhibitor
rotenone (0.5 µM), complex II inhibitor antimycin A (0.5 µM), D-glucose (10 mM), and
2-deoxy-D-glucose (50 mM) were used as per manufacturer’s recommendation.

2.2.8

BeWo cell oxidative function
The optimized Mitochondrial (Mito) Stress Test was utilized to quantify the

oxidative function of NEFA-treated (100 µM) BeWo CTs and SCTs. At the 72H
timepoint the culture medium exchanged with Mito Stress Test assay media (Seahorse
XF base media (Agilent Technologies) supplemented with 10 mM D-glucose, 2 mM
sodium pyruvate, and 2 mM L-glutamine (Gibco, ThermoFisher, Mississauga, Canada),
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pH 7.4), and cells were incubated at 37℃ in 100% atmospheric air for 45 mins.
Following basal OCR readings subsequent injections of oligomycin; DNP; and rotenone
combined with antimycin A were utilized to measure parameters of mitochondrial
respiratory function. A representative Seahorse XF Mito Stress Test Tracing is available
in Figure 2-2.
Following the Mito Stress Test assay, cells were lysed via freeze-thaw method in
Seahorse assay media and total DNA was quantified using Hoechst dye fluorescence
[58,59]. Briefly, cell lysates were mixed with 2x Hoechst Dye assay mix (0.0324 mM
Hoechst 33342 Dye (Pierce, ThermoFisher Scientific, Mississauga, Canada), 2 M NaCl,
50 mM NaH2PO4, pH 7.4), fluorescence (360 nm excitation, 460 nm emission) was then
measured, and DNA content was determined via standard curve.

Figure 2-2 Representative Seahorse Mito Stress Test assay tracings.
Representative tracing of Oxygen Consumption Rate (OCR) throughout experimental
assay for NEFA-treated (A) BeWo CT cells and (B) BeWo SCT cells from the Mito Stress
Test. Data is represented as mean OCR of each group in technical duplicate from one
experiment and presented as percent CT untreated control.
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2.2.9

BeWo cell glycolytic function
The optimized Glycolysis Stress Test was utilized to quantity the glycolytic

function of NEFA-treated (100 µM) BeWo CTs and SCTs. At 72H culture media was
exchanged with Glycolysis Stress Test assay media (Seahorse XF base media
supplemented with 2 mM L-glutamine, pH 7.4), and cells were incubated at 37℃ in
100% atmospheric air for 45 mins. Following basal Extracellular Acidification Rate
(ECAR) readings, injections of D-glucose; oligomycin; and 2-Deoxy-D-glucuose were
utilized to measure parameters of glycolysis function. A representative Seahorse XF
Glycolysis Stress Test Tracing is available in Figure 2-3. ECAR readings were
normalized to total DNA content as described above.

Figure 2-3 Representative Seahorse Glycolysis Stress Test assay tracings
Representative tracing of Extracellular Acidification Rate (ECAR) throughout
experimental assay for NEFA-treated (A) BeWo CT cells and (B) BeWo SCT cells from
the Glycolysis Stress Test. Data is represented as mean ECAR of each group in technical
duplicate from one experiment and presented as percent CT untreated control.
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2.2.10

Immunoblot analysis

BeWo cells were plated at 1x106 in 100mm cell culture plates and cultured with
NEFAs (100 µM) as described. Total protein was collected with
radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors (leupeptin
and aprotinin (1 µg/mL each; Bioshop, Burlington, Canada); and phenylmethylsulfonyl
fluoride (PMSF, 1mM, Bioshop)) and phosphatase inhibitors (sodium orthovanadate (1
mM), New England Biolabs; and sodium fluoride (25 mM), Bioshop). The lysates were
sonicated with 5 bursts at 30% output (MISONIX: Ultrasonic liquid processor) and
centrifuged at 12,000g at 4°C for 15 mins. The supernatant was collected, and protein
concentration was quantified via Bicinchoninic Acid (BCA) assay (Pierce, ThermoFisher
Scientific).
Protein abundance was then determined via immunoblotting. Proteins were
separated by molecular weight on sodium dodecyl sulfate polyacrylamide gels (10-15%
acrylamide) and transferred to Immobilon polyvinylidene fluoride (PVDF) membrane
(EMD Millipore, Fisher Scientific). Transfer of proteins was confirmed with Ponceau-S
stain (0.1% Ponceau-S in 0.5% acetic acid), and ponceau band density was imaged with a
ChemiDoc Imager (BioRad) for total lane protein normalization. Respective primary
antibodies and horseradish peroxidase-labelled secondary antibodies were used to
visualize proteins of interest (Table 2-2). Protein bands were imaged with Clarity
western ECL substrate (BioRad) on a ChemiDoc. Protein band density was analyzed with
ImageLab software (BioRad) and protein abundance was normalized to total lane protein
[60]. Representative full-length uncropped blots highlighting the specificity of utilized
antibodies is available in Supplementary Figure 1 (doi.org/10.5683/SP3/XMPKOK).
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Table 2-2 Specifications of antibodies utilized in immunoblotting experiments, and the protein mass loaded for each protein
target
Protein Target
Human Mitoprofile
Lactate Dehydrogenase
Pyruvate Dehydrogenase
PDH-E1α (pSer232)
PDH Kinase 1
CPT1a
4-Hydroxynonenal
Nitrotyrosine
Anti-Rabbit Secondary
Anti-Mouse Secondary

Source
Mouse Monoclonal
Rabbit Polyclonal
Rabbit Polyclonal
Rabbit Polyclonal
Rabbit Monoclonal
Rabbit Polyclonal
Rabbit Polyclonal
Mouse Monoclonal
Goat
Horse

Dilution
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1500
1:10,000
1:10,000

Blocking solution
5% Milk
5% Milk
5% Milk
5% BSA
5% BSA
5% milk
5% milk
5% BSA
-

Protein Loaded
35 µg
20 µg
20 µg
10 µg
20 µg
10 µg
15 µg
15 µg
-

Heat (℃)
37
95
95
37
95
37
95
95
-

Company
ABCAM
Cell Signaling Technologies
Cell Signaling Technologies
EMD Millipore
Cell Signaling Technologies
Cell Signaling Technologies
ABCAM
Santa Cruz Biotechnology
Cell Signaling Technologies
Cell Signaling Technologies

Catalogue No.
ab110411
2012
3205
AP1063-50µG
3820
4691P
ab46545
sc-32757
7074
7076
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2.2.11

Metabolic enzyme activity assays

Full step-by-step experimental protocols for the enzyme activity assays utilized in
Chapter 2 are available in the Supplementary Materials (doi.org/10.5683/SP3/ZTN4ZR).

2.2.11.1 ETC complex I and II activity
ETC complex I and II was assessed as previously described and adapted for use
with cell culture lysates [61]. BeWo cells were plated at a density of 4x105 cells/well in
60mm plates and collected by scraping. Cells were lysed in ETC lysis buffer (250 mM
sucrose, 5 mM HEPES, 100 µg/mL saponin) containing protease and phosphatase
inhibitors (as described above), centrifuged at 5000 g for 5 mins at 4℃ and resuspended
in Phosphate buffer (25 mM K2HPO4). Enzyme assays were performed at 37°C using a
SpectraMax plate spectrophotometer (Molecular Devices) in a 96-well plate. Enzyme
activities were expressed relative to total protein concentration for each cell lysate
(determined by BCA assay).
Complex I activity was assessed as rate of NADH oxidation (measured at 340
nm) following the addition of cell lysate (approximately 15 µg total protein) to assay
buffer (25 mM KH2PO4, 2.5 mg/mL BSA, 0.13 mM NADH, 2 mM KCN, 2 µg/mL
antimycin A, 65 µM CoQ1). Complex I activity was calculated from the difference
between rates with and without rotenone (10 µM) to account for non-specific NADH
oxidation.
Complex II activity was assessed as rate of DCPIP oxidation (measured at 600
nm) following addition of CoQ1 (100 µM) to assay mix containing cell lysate
(approximately 10 µg total protein) in assay buffer (25 mM KH2PO4, 20 mM
monosodium succinate, 50 µM DCPIP, 2 mM KCN, 2 µg/mL antimycin A, 2 µg/mL
rotenone).

2.2.11.2 Lactate Dehydrogenase and Citrate Synthase activity
Lactate dehydrogenase (LDH) and CS activity were assessed as previously
described and adapted for use with cell culture lysates [62,63]. BeWo cells were plated at
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a density of 4x105 cells/well in 60 mm cell culture dishes collected by scraping at 72H.
Cells were subsequently lysed in glycerol lysis buffer (20 mM Na2HPO4, 0.5 mM EDTA,
0.1% Triton X-100, 0.2% BSA, 50% glycerol) containing protease and phosphatase
inhibitors (as described above) and stored at -80℃ until analyzed [64]. Assays were
performed at 37°C using a 96-well plate. Enzyme activity rates were normalized to total
protein content of cell lysates determined via BCA assay.
LDH activity was assessed as the rate of NADH oxidation (measured at 340 nm)
following addition of cell lysate (corresponding to approximately 1 µg total protein) to
assay buffer (0.2 mM NADH, 1mM sodium pyruvate).
CS activity was assessed as rate of Ellman’s reagent (DTNB) consumption
(measured at 412 nm), following addition of oxaloacetate (0.33 mM) to assay mix
containing cell lysate (approximately 30 µg total protein) in assay buffer (0.15 mM acetyl
CoA, 0.15 mM DTNB).

2.2.11.3 Analysis of total Pyruvate Dehydrogenase activity and
PDHE1-subunit activity
Total PDH activity was assessed at 72H using the PDH Activity Assay Kit
(Millipore Sigma). In brief, BeWo cells were plated at a density of 4*105 cells/well in
60mm cell culture plates and treated with NEFAs as previously described. At 72H cells
were lysed in 400 µL of the provided lysis buffer and 50 µL of cell lysate was mixed with
an equal volume of assay mix and PDH enzyme activity was assessed as per the provided
kit instructions.
The activity of the PDH-E1 enzyme subunit was assessed as previously described
and modified for use with the BeWo cell line [65]. BeWo cells were plated at a density of
4x105 cells/well in 60mm plates and treated with NEFAs as previously described. At
72H cells were collected by scraping and were lysed by sonication with 10 bursts at 15%
output (MISONIX: Ultrasonic liquid processor) in 50 mM K2HPO4 buffer containing
protease and phosphatase inhibitors. PDH-E1 enzyme activity was assessed at 37°C using
a SpectraMax plate spectrophotometer (Molecular Devices) in a 96-well plate, as the rate
of DCPIP oxidation (measured at 600 nm) following the addition of cell lysate
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(approximately 20 µg total protein) to assay buffer (50 mM KH2PO4, 1 mM MgCl2, 0.2
mM thymine pyrophosphate, 0.1 mM DCPIP, 2 mM sodium pyruvate). Enzyme activities
were expressed relative to total protein concentration for each cell lysate (determined by
BCA assay).

2.2.12

Statistical Analysis

A Randomized Block Design One-Way ANOVA and Dunnett’s Multiple
Comparisons Test of raw fluorescence values was utilized to compare cell viabilities of
BeWo cells treated with each NEFA to respective differentiation state BSA-alone control.
BeWo percent fusion data, as well as the Mito Stress Test parameters of Spare
Respiratory Capacity and Coupling Efficiency (expressed as expressed as percent basal
OCR) and the Glycolysis Stress Test parameter of Reserve Capacity (expressed as
percent ECAR) were log-transformed and statistically analyzed via Two-Way ANOVA
(2WA) and Bonferroni’s Multiple Comparisons. A Randomized Block Design 2WA and
Sidak’s Multiple Comparisons Test using raw data was utilized to analyze statistical
differences in the relative CGB mRNA transcript abundance; live-cell caspase 3/7
activity; protein abundance; metabolic enzyme activities; as well as all other Seahorse
Mito Stress Test and Glycolysis Stress Test parameters between the NEFA-treatment
groups for the BeWo CT and SCT cells [66]. Data were then expressed as percent of
untreated CT control (basal F12K media) for visualization in figures. All statistical
analyses were performed with GraphPad Prism 8 (GraphPad Software, San Diego, CA,
USA).

2.2.13

Supplementary materials

Supplementary materials including step-by-step enzyme activity assay protocols
(doi.org/10.5683/SP3/ZTN4ZR), and full-length representative immunoblot images
(doi.org/10.5683/SP3/XMPKOK) have been uploaded to a publicly available data
repository and can be accessed via the indicated Digital Object Identifier (DOI) webpage
addresses.
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2.3 Results
2.3.1

Characterization of BeWo CT and SCT cells treated with
NEFAs

Cell viability of BeWo CT and SCT cells following a prolonged (72H) NEFA treatment
was assessed to ensure that subsequent mitochondrial activity measurements were not
confounded by a potential stress activated cell death program. A 100 µM NEFA
treatment (PA, OA, and P/O) did not impact BeWo cell viability in either CT or SCT
cells relative to BSA-alone treated controls at T72H (Table 2-3, n=4/group).

Table 2-3 Cell viability of NEFA-treated BeWo CT and SCT cells
NEFA Treatment (µM)
BSA Control
PA

OA

P/O

50
100
200
50
100
200
50
100
200

CT Cell Viability
(% CT F12K)
72.35 ± 2.61
86.83 ± 3.56
77.34 ± 4.92
55.03 ± 10.31*
88.10 ± 4.93
72.97 ± 6.13
48.78 ± 10.19*
85.57 ± 4.39
76.37 ± 6.09
57.87 ± 10.59*

SCT Cell Viability
(% SCT F12K)
46.25 ± 4.17
87.08 ± 9.46 *
61.40 ± 12.14
45.32 ± 16.53
73.70 ± 9.62 *
59.02 ± 10.18
34.54 ± 11.59*
70.27 ± 10.72 *
57.92 ± 9.71
40.18 ± 14.48

Data are mean ± SEM. * denotes significantly different cell viability
relative to respective differentiation state BSA-control (n=4/group).

BeWo cells treated with 8-Br-cAMP displayed decreased ZO-1 protein expression
and increased cell fusion (mean 78% fusion) compared to CT cells (mean 15% fusion)
(Figure 2-4 A,B; 2WA: differentiation state p<0.001, n=3/group). Additionally, BeWo
cells treated with 8-Br-cAMP displayed elevated CGB (mean expression 86-fold higher)
and OVOL1 (mean expression 9-fold higher) mRNA abundance (23-85 fold higher
expression) consistent with the differentiation process (Figure 2-4 C,D; 2WA:
differentiation state p<0.01, n=5/group)
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The 100 µM NEFA treatments were additionally not associated with altered BeWo fusion
in either CT and SCT cells as measured with ZO-1 expression (Figure 2-4 A,B). Further,
these 100 µM treatments did not significantly alter the mRNA abundance of CGB or
OVOL1 (markers of syncytialization in BeWo cells) within the CT and SCT cells
(Figure 2-4 C,D).
Additionally, in each NEFA-treatment there was no significant difference in live-cell
caspase 3/7 activity compared to respective differentiation state BSA-control sample
(Figure 2-4 E; n=5/group).
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Figure 2-4 100 µM of PA, OA or P/O does not negatively impact BeWo cell
syncytialization or upregulate pro-apoptotic pathways at 72H.
(A) Representative ZO-1, DAPI and merged immunofluorescent images of BeWo CT and
SCT cells (scale bar = 50 µm); (B) Percent fusion of NEFA-treated BeWo CT and SCT
cells; data is expressed as percentage of nuclei lacking ZO-1 staining. Relative mRNA
abundance of (C) CGB and (D) OVOL1 in NEFA-treated BeWo CT and SCT cells; RTqPCR data is presented as the fold-change of target mRNA abundance compared to CT
BSA ctrl samples relative to the geometric mean of ACTB and PMSB6 mRNA abundance.
(E) Live-cell caspase activity of NEFA-treated BeWo CT and SCT cells; data is presented
as percent untreated CT control luminescence values (B n=3/group; C-E n=5/group;
different letters denote statistical significance p<0.05; B percent fusion data was log
transformed and analyzed via two-way ANOVA (2WA); C,D relative mRNA abundance
data was analyzed via randomized-block 2WA).
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2.3.2

The impact of prolonged NEFA exposure upon respiratory
activity of BeWo cells
BeWo CT cells treated with PA (100 µM) and P/O (containing 50 µM PA) for

72H exhibited a significant increase in basal mitochondrial activity compared to control
CT samples (Figure 2-5 A, 2WA: NEFA treatment p<0.01, n=5/group). Under DNPstimulated conditions CT cells exposed to PA and P/O exhibited a significant increase in
OCR compared to BSA-alone treated CT cells (Figure 2-5 B, 2WA: NEFA Treatment
p<0. 05, n=5/group). Conversely, BeWo SCT cells displayed diminished respiratory
activity and had significantly lower OCR under basal and DNP-stimulated conditions
compared to BeWo CT cells (Figure 2-5 A-B, 2WA differentiation state p<0.05). This
diminished respiratory activity observed in BeWo SCT cells was associated with a
significant reduction in spare respiratory capacity (Figure 2-5 D, 2WA differentiation
state p<0.001, n=5/group). No differences in BeWo cell proton leak or coupling
efficiency was observed with differentiation state or NEFA-treatment (Figure 2-5 C,E,
n=5/group)
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Figure 2-5 Mitochondrial respiratory activity of BeWo cells following prolonged
NEFA treatment.
Oxygen Consumption Rate (OCR) of experimental media was measured under basal
conditions and following subsequent injections of: Oligomycin (1.5 µg/mL); Dinitrophenol
(50 µM); and Rotenone and Antimycin A (0.5 µM each) to calculate the (A) Basal
Respiration, (B) Maximal Respiration, (C) Proton Leak, (D) Spare Respiratory Capacity,
and (E) Coupling Efficiency in NEFA-treated BeWo CT and SCT cells (n=5/group). (A,
B, C) Statistical analysis was performed on DNA-normalized OCR rates via Two-Way
Randomized Block ANOVA, Sidak’s multiple comparisons Test; (D, E) percent basal
OCR was log transformed and analyzed via Two-Way ANOVA. (A, B, C) Respiratory
activity data is expressed as OCR normalized to total DNA content and presented as
percent CT untreated control; (D, E) data is represented as percent basal OCR for each
condition. Different letters denote statistical significance (p<0.05, n = 5/group).
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2.3.3

Glycolytic function in BeWo cells is unaltered with NEFA
treatments
Basal glycolysis, maximum glycolysis, glycolytic reserve capacity, and non-

glycolytic acidification were not impacted after cells were differentiated to SCT cells and
were unaltered with NEFA treatment (Table 2-4, n=5/group).

Table 2-4 NEFA treatments did not affect the glycolytic activities of BeWo CT or
SCT cells
Differentiation
State
CT

SCT

Treatment
BSA Ctrl
PA
OA
P/O
BSA Ctrl
PA
OA
P/O

Basal
Glycolysis1
86.14 ± 10.71
89.99 ± 6.20
97.59 ± 11.09
89.26 ± 6.19
83.53 ± 7.97
81.91 ± 14.13
83.51 ± 11.90
75.55 ± 8.19

Max Glycolysis1
72.19 ± 8.22
81.61 ± 5.62
86.11 ± 11.81
85.82 ± 5.47
67.04 ± 6.54
66.57 ± 11.47
67.32 ± 8.49
65.30 ± 6.97

Reserve Glycolytic
Capacity2
120.80 ± 6.79
134.30 ± 6.77
129.50 ± 11.57
142.90 ± 6.68
115.50 ± 4.48
137.00 ± 27.10
118.40 ± 13.33
131.30 ± 7.73

Non-Glycolytic
Acidification1
84.25 10.01
91.31 8.53
87.72 11.08
91.90 7.33
117.70 9.16
104.90 13.76
105.00 9.36
98.36 8.68

Data are mean ± SEM (n=5/group). Data are presented as 1% untreated CT ECAR,
and 2% Basal Glycolysis
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2.3.4

NEFA impact upon electron transport chain complex protein
abundance and activity
BeWo CT cells treated with PA (100 µM) and P/O (containing 50 µM PA) for

72H exhibited a significant increase in basal mitochondrial activity compared to control
CT samples (Figure 2-5 A, 2WA: NEFA treatment p<0.01, n=5/group). Under DNPstimulated conditions CT cells exposed to PA and P/O exhibited a significant increase in
OCR compared to BSA-alone treated CT cells (Figure 2-5 B, 2WA: NEFA Treatment
p<0. 05, n=5/group). Conversely, BeWo SCT cells displayed diminished respiratory
activity and had significantly lower OCR under basal and DNP-stimulated conditions
compared to BeWo CT cells (Figure 2-5 A-B, 2WA differentiation state p<0.05). This
diminished respiratory activity observed in BeWo SCT cells was associated with a
significant reduction in spare respiratory capacity (Figure 2-5 D., 2WA differentiation
state p<0.001, n=5/group). No differences in BeWo cell proton leak or coupling
efficiency was observed with differentiation state or NEFA-treatment (Figure 2-5 C,E,
n=5/group).
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Figure 2-6 Prolonged NEFA treatment did not affect BeWo Electron Transport
Chain complex protein abundance.
Relative protein abundance of (A) complex I (NDUFB8 subunit) (B) complex II (SDHB
subunit) (C) complex III (UQCRC2 subunit) (D) complex IV (COX II subunit), and (E)
complex V (ATP5A subunit) of the Electron Transport Chain was determined at T72H via
immunoblotting. (F) Representative ponceau image used to quantify total lane protein.
Data is presented as percent untreated CT control for each experimental replicate
(n=5/group). Full-length representative western blot images are available in
Supplementary Figure 1 (doi.org/10.5683/SP3/XMPKOK).
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2.3.5

The impact of prolonged NEFA exposure on
metabolic enzyme activity
LDH activity was not significantly altered with differentiation state or NEFA-

treatment (Table 2-5, n=5/group). BeWo SCT cells exhibited a significantly increased
PDH-E1 subunit activity compared to CT cells (Table 2-5). However, BeWo SCT cells
displayed a significantly reduced rate of total PDH enzyme activity compared to CT cells
(Table 2-5; 2WA differentiation state p<0.01). Additionally, BeWo CT cells treated with
PA had a significantly reduced total PDH enzyme activity compared to BSA-alone
treated CT controls (Table 2-5; 2WA differentiation state p<0.05). There was no
differentiation state or NEFA dependent alteration in citrate synthase enzyme activity in
BeWo cells (Table 2-5).

100

Table 2-5 Maximal activity rates of mitochondrial enzymes in NEFA-treated BeWo CT and SCT cells.
Differentiation
State

Treatment

BSA Ctrl
PA
CT
OA
P/O
BSA Ctrl
PA
SCT
OA
P/O
*Differentiation state
difference

Citrate Synthase

ETC Complex I

116.20 ± 22.37
93.62 ± 15.00
85.31 ± 14.22
90.34 ± 5.44
60.68 ± 6.01
49.80 ± 4.60
39.80 ± 4.74
63.52 ± 4.14

120.7 ± 7.71
98.00 ± 10.03
100.00 ± 5.59
106.20 ± 10.32
191.50 ± 31.49 a
183.10 ± 25.80 a
129.2 ± 13.85 ab
103.60 ± 17.77 b

NS

*

ETC Complex II
Lactate Dehydrogenase
(% untreated CT U/mg protein)
113.8 ± 13.71
163.20 ± 45.50
98.99 ± 19.80
109.80 ± 14.41
94.46 ± 17.77
104.90 ± 19.23
93.67 ± 17.50
133.60 ± 31.71
61.76 ± 13.75
79.25 ± 18.77
62.05 ± 15.57
79.54 ± 16.18
51.88 ± 17.79
73.79 ± 17.63
58.96 ± 8.20
78.59 ± 13.26
*

NS

PDH-E1 subunit

Pyruvate Dehydrogenase

99.23 ± 6.37
101.72 ± 3.83
102.84 ± 16.80
118.96 ± 21.97
260.45 ± 41.81
246.35 ± 20.16
222.28 ± 19.02
233.78 ± 57.00

105.04 ± 6.93 a
86.78 ± 10.96 b
112.01 ± 10.41 a
99.56 ± 7.37 ab
84.66 ± 4.99
88.20 ± 9.06
80.33 ± 3.51
81.68 ± 8.10

*

*

Data are mean ± SEM. * denotes a differentiation state dependent difference in enzyme activity between BeWo CT and SCT
cells (n=5/group). Different letters denote significant differences between NEFA treatments within a differentiation state.
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2.3.6

Oxidative State in unaltered in NEFA-treated BeWo cells
There were no differences in the protein expression of 4-Hydroxynonenal (4-

HNE) and 3-Nitrotyrosine, markers of oxidative stress and nitrative stress respectively,
with prolonged NEFA treatment or differentiation in BeWo cells (Figure 2-7 A,B,
n=5/group).

Figure 2-7 Prolonged NEFA treatment does not alter oxidative state of BeWo cells.
Relative Protein abundance of (A) 4-Hydroxynonenal (4-HNE) and (B) 3-Nitrotyrosine
was determined in NEFA-treated BeWo CT and SCT cells at 72H via immunoblotting.
Data is presented as relative protein density normalized to total lane protein density and
expressed as percent CT untreated control protein abundance (n=5/group).
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2.3.7

The impact of prolonged NEFA exposure on metabolic
enzyme expression

There was a differentiation state dependent expression pattern in Pyruvate
Dehydrogenase (PDH) in both its unphosphorylated and phosphorylated (pPDH) form.
BeWo SCT cells displayed significantly reduced relative abundances of both PDH and
pPDH (Figure 2-8 A,B; 2WA differentiation state p<0.05, n=5/group), however the ratio
of pPDH:PDH (Figure 2-8 C, n=5/group) was not significantly altered between
differentiation states. No differentiation state or NEFA-treatment specific differences
were found in the relative protein abundances of either LDH or carnitine
palmitoyltransferase 1a (CPT1a) in BeWo cells (Figure 2-8 D,E, n=5/group).
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Figure 2-8 Prolonged NEFA treatments did not affect protein expression of enzymes
involved in mitochondrial uptake of pyruvate or long-chain fatty acid species.
Relative protein abundance of (A) Pyruvate Dehydrogenase (PDH), (B) PDH-E1α
(pSer232) (pPDH), (C) the pPDH/PDH ratio, (D) Pyruvate Dehydrogenase Kinase-1
(PDHK1) (E) Lactate Dehydrogenase (LDH), and (F) CPT1a was determined in NEFAtreated BeWo CT and SCT cells at 72H via immunoblotting. Data is presented as percent
CT untreated control (n=5/group). Uncropped representative western blot images are
available in Supplementary Figure 1 (doi.org/10.5683/SP3/XMPKOK).
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2.4 Discussion
The current study aimed to characterize the metabolic function and mitochondrial
respiratory activity in a model of the differentiating human villous trophoblast following
a prolonged (72 hour) NEFA challenge. To confirm that mitochondrial respiratory
activity and metabolic function was examined using a stable population of cells we
analyzed cell viability, CT-to-SCT differentiation potential and apoptotic state of the
treated cells. Our experiments demonstrated that NEFA treatments exceeding 200 µM
produced large variances in cell viability, which is consistent with previous observations
in primary human trophoblast culture systems [67]. A treatment of 100 µM of PA, OA
and P/O was found to not impact BeWo cell syncytialization or upregulate pro-apoptotic
pathways, yielding a stable cell culture system in which mitochondrial function could be
examined. Additionally, the 100 µM of PA and OA used in this current study also aligned
with published human third trimester fasting circulating lipid levels under conditions of
maternal obesity and GDM highlighting a physiological relevance of the utilized NEFA
treatment [39].

2.4.1

Differentiation and BeWo Metabolic Function
BeWo cells displayed a significant reduction in mitochondrial respiratory activity

(Mito Stress Test readouts) following 8-Br-cAMP induced differentiation to SCT cells.
These reductions in basal and maximal respiration rates were consistent with previous
reports in human primary trophoblast (PHT) cell culture systems, which demonstrated
that SCT cells are less metabolically active than progenitor CT cells [68]. More
strikingly, we observed these similarities despite the BeWo cells in our culture system
fusing at rates around 60%, further supporting that diminished mitochondrial oxidative
function is an important physiological marker of placental syncytialization.
This study provides novel insight into dynamic changes in the activity of
individual ETC complexes during CT differentiation in SCT. Specifically, we observed
significant differences in complex I and complex II activity between CT and SCT cell
types that were independent of alterations in mitochondrial biomass as assessed by CS
enzyme activity. The decreased complex II activity observed in BeWo SCT cells may
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allude to a biochemical mechanism that potentially explains the overall reduction in
respiratory activity observed in syncytialized BeWo cells.
Additionally, the BeWo SCT cells in our study may exhibit a diminished
oxidative metabolism of pyruvate substrates as evidenced by reduced protein expression
and enzyme activity of total Pyruvate Dehydrogenase (PDH). These data may indicate an
overall decrease in the conversion of glycolysis-derived pyruvate to acetyl-CoA in BeWo
SCTs and may further highlight the mechanism by which oxidative energy production is
suppressed in differentiated SCT cells. However, future studies are needed to elucidate if
similar mechanisms govern the reduction in mitochondrial function in the differentiated
SCT cell populations in both BeWo cells and isolated primary trophoblasts.

2.4.2

NEFAs and BeWo Metabolic Function
The current study demonstrated a novel NEFA-induced increase mitochondrial

respiratory activity in PA and P/O-treated BeWo CT cells under basal and DNPstimulated (maximal) conditions of the Mito Stress Test that was not associated with any
specific alterations in the individual enzyme activities of ETC complexes I and II.
Previously, an overall reduction in mitochondrial respiratory activity has been reported as
an indication of mitochondrial dysfunction in term placentae [19]. However, increases in
mitochondrial respiratory activity have also been described as a preliminary marker of
mitochondrial failure in disease states that are linked to an ultimate mitochondrial
dysfunction [69,70]. In particular, mitochondrial dysfunction induced in hepatocytes
under conditions of Non-alcoholic fatty liver disease (NAFLD) has been suggested to be
the result of an initial increase in mitochondrial respiratory activity stimulated by
increased saturated FA supply that in turn promotes increased Reactive Oxygen Species
(ROS) production, and ultimately, oxidative damage to mitochondria [69,71]. We
speculate that the increases in respiratory activity observed in the PA and P/O-treated
BeWo CT cultures may be indicative of an early timepoint of mitochondrial dysfunction
in the villous trophoblast, mirroring these other reports with an activation of
mitochondrial respiration prior to an ultimate failure.
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In many other culture systems PA exposures have been demonstrated to increase
ROS production leading to cellular oxidative stress [72–74]. As oxidative stress has
additionally been identified as a marker of metabolic dysfunction in the term obese
placenta, we speculate that the increased respiratory activity observed in PA and P/Otreated BeWo CT cells in this study could over time increase ROS production and lead to
oxidative stress [75,76]. However, at the 72H timepoint utilized in the current study there
were no indications of oxidative stress in any of the treatments, as evidenced by
immunoblots for total abundance of 3-nitrotyrosine and 4-HNE. Further studies are
needed to investigate if continued exposure of BeWo CT cells to the selected
physiologically relevant PA treatment will lead to ROS-induced mitochondrial oxidative
damage and ultimately impaired mitochondrial respiration.
It is important to note that OA has previously been shown to elicit anti-oxidant
capabilities and rescue mitochondrial function in muscle and pancreatic beta-cells treated
with high levels of saturated fats [45,77]. Thus, the co-culture of OA with PA (P/O) over
longer timepoints may prevent the accumulation of PA-stimulated ROS and could
preserve villous trophoblast mitochondrial function as has been observed in other
systems.
While this study has demonstrated the impacts of a prolonged PA exposure, and
differentiation state on placental cell metabolic function, the use of the immortalized
BeWo cell line may limit the conclusions that can be drawn as they may confer properties
not observed in primary culture or other ex vivo systems. Having said that, the use of a
cell line model of the villous trophoblast in the current study allowed for the analysis of
the effects of lipid exposure in isolation from factors of maternal body composition and
gestational diet. Specifically, the BeWo choriocarcinoma cell line enabled us to analyze
the metabolic function of SCTs differentiated under constant exposure to elevated
dietary-NEFAs, analogous to that of a differentiating trophoblast throughout gestation in
an obese or GDM pregnancy, but independent to non-dietary obesogenic and diabetic
environmental components [78–80]. However, future studies still need to examine if
prolonged NEFA challenge at physiologically relevant levels can lead to similar early
markers of mitochondrial dysfunction in primary-derived trophoblast cultures. However,
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the use of trophoblasts from early gestational periods may be required in these future
works to develop a primary culture model that, similar to this study, is independent from
the influence of material body composition and gestational diet.

2.4.3

Conclusion
The current study aimed to characterize the mitochondrial function and

respiratory activity in a model of the differentiating human villous trophoblast following
a prolonged (72 hour) NEFA challenge. Differentiated BeWo SCT cells displayed a
reduced basal and maximal mitochondrial respiratory activity, similar to that previously
observed in primary trophoblast culture. Additionally, this study highlighted that an
isolated and prolonged exposure to physiological levels of dietary-NEFAs, independent
from factors of maternal body composition, increases villous trophoblast cell
mitochondrial respiratory activity. The observed increases in basal and maximal
respiratory activity in response to PA and P/O treatments in this study may be indicative
of an early phenotype of placental mitochondrial impairment that may later trigger
oxidative damage to the mitochondria. Overall, this study highlights dietary fats
independently modulate villous trophoblast mitochondrial function, and further
demonstrates that maternal diet composition is an important regulator of the adverse
placental outcomes that underlie the development of metabolic disease in the offspring.
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Chapter 3

3

The impact of hyperglycemia upon BeWo trophoblast
cell metabolic function: A multi-OMICS and functional
metabolic analysis

This chapter is a version of a manuscript submitted for publication entitled “The impact of
hyperglycemia upon BeWo trophoblast cell metabolic function: A multi-OMICS and
functional metabolic analysis”
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3.1 Introduction
The rates of diabetes mellitus (DM) during pregnancy have increased
substantially over the past several decades [1]. It is currently estimated that up to 1 in 10
pregnancies worldwide are impacted by maternal DM [2,3], however these rates may be
even higher in certain at risk demographics such as in Indigenous populations [4]. These
increases are particularly concerning as maternal DM during pregnancy, regardless of
whether it is pre-existing (such as in type 1 DM or type 2 DM) or develops during
gestation (gestational DM (GDM)), is associated with a multitude of poor fetal health
outcomes [5–8]. Specifically, children exposed to DM during intrauterine development
have been found to be at a greater risk of developing non-communicable diseases such as
obesity, metabolic syndrome, and impaired insulin sensitivity early in their lives [5,9–
12]. Understanding the underlying mechanisms that link maternal DM during pregnancy
to the development of non-communicable diseases in offspring is critical to develop
appropriate prenatal clinical management practices that help reduce health risks to the
next generations.
As the placenta is responsible for nutrient, gas, and waste exchange between
mother and fetus, specific alterations in the function of this organ may underlie the
intrauterine programming of metabolic disorders in DM-exposed offspring.
Unsurprisingly, morphological, and functional abnormalities have been found to be
highly prevalent in placentae of diabetic pregnancies [13,14]. For example, diabetic
placentae are often heavier [15–17] and display increased glycogen and triglyceride
content [18–23], that is suggestive of altered nutrient storage and processing by the
placenta and subsequently altered nutrient delivery to the developing fetus. This increase
in nutrient storage in DM placentae has been thought to modulate trans-placental nutrient
transport and fetal growth trajectories [24,25]. Additionally, the progenitor
cytotrophoblasts (CT) and differentiated syncytiotrophoblasts (SCT) cells of the placenta
villous trophoblast layer (cells that form the materno-fetal exchange barrier and are a
primary site for placental energy (ATP) production) have impaired mitochondrial
function in response to maternal DM that may further impact placental nutrient handling
[26]. In particular, cultured primary CT and SCT cells from GDM pregnancies display
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reduced basal and maximal mitochondrial respiratory (oxidative) activity compared to
non-diabetic control trophoblasts [27,28]. Additionally, pre-existing DM has been found
to impact the activities of individual placental Electron Transport Chain (ETC)
complexes in whole placental lysates, highlighted by reduced complex I, II and III
activities in type 1 DM placentae, and reduced complex II and III activity in type 2 DM
placentae [29]. Overall, these studies suggest that impaired placental nutrient storage and
mitochondrial oxidative function may be implicated in the development of metabolic
diseases in DM-exposed offspring.
Previous work with placental cell lines and ex vivo placental explant preparations
have demonstrated that hyperglycemia (a hallmark symptom of both pre-existing and
gestationally-developed DM) is an important regulator of placental metabolic function.
For example, explants from uncomplicated pregnancies display altered metabolic
processing of lipids when cultured under hyperglycemic (HG) conditions (25 mM
glucose) for only 18 hours [22]. Further reports have highlighted transcriptomic and
metabolomic markers indicative of altered lipid metabolism, β-oxidation, and glycolysis
functions in BeWo CT cells cultured under HG-conditions (25 mM) for 48 hours [30].
Independent hyperglycemia (30 mM glucose for 72h) has also been linked to increased
Reactive Oxygen Species (ROS) generation in BeWo CTs [31], which directly promotes
mitochondrial oxidative damage [32,33].
These reports have suggested that hyperglycemia independently facilitates the
development of aberrant placental metabolic function in diabetic pregnancies. However,
the direct and independent impacts of hyperglycemia on placental mitochondrial
respiratory (oxidative) function are poorly understood. It is important to note that
elevated glucose levels (25 mM for 48h) have also been associated with altered
mitochondrial activity in BeWo CT cells when assessed by endpoint tetrazolium salt
(MTT) assay [34]. However, an interrogation of mitochondrial respiratory activity of
HG-exposed trophoblast cells using recently developed real-time functional readouts
(such as the Seahorse XF Analyzer), as has been performed with DM-exposed Primary
Human Trophoblasts (PHT), [27–29] is warranted. In addition, the direct impacts of
hyperglycemia on glycogen and lipid nutrient stores of placental trophoblasts and the

120

underlying mechanisms governing placental nutrient storage in HG-conditions are not
well defined. Thus, the first objective of the current study was to characterize the impacts
of independent hyperglycemia on placental mitochondrial respiratory activity and
nutrient storage by evaluating both progenitor BeWo CTs and differentiated BeWo SCTs
following a relatively prolonged 72-hour HG (25 mM) exposure.
Recently, the integration of transcriptomics, metabolomics, and lipidomics has
been identified as a useful method to elucidate cellular mechanisms that underlie
pathological placental development in pre-clinical models [30,35,36]. Thus, the second
objective of this study was to utilize a multi-omics research approach to thoroughly
characterize the underlying mechanisms leading to altered metabolic function specifically
in high-glucose exposed BeWo progenitor CT cells. Overall, it was postulated that HGculture conditions would be associated with increased nutrient storage and impaired
mitochondrial respiratory function in BeWo CT and SCT cells, in association with altered
transcriptome, metabolome, and lipidome signatures in BeWo CT cells indicative of
altered metabolic function.

3.2 Materials and methods
3.2.1

Materials
All materials were purchased from Millipore Sigma (Oakville, Canada) unless

otherwise specified.

3.2.2

Cell culture conditions
BeWo (CCL-98) trophoblast cells were purchased from the American Type

Culture Collection (ATCC; Cedarlane Labs, Burlington, Canada). Cells were cultured in
F12K media (Gibco, ThermoFisher Scientific, Mississauga, Canada) as recommended by
the ATCC, and supplemented with 10% Fetal Bovine Serum (Gibco) and 1% PenicillinStreptomycin (Invitrogen, ThermoFisher Scientific, Mississauga, Canada). All cells were
utilized between passages 5-15 and were maintained at 37℃ and 5% CO2/95%
atmospheric air.
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The F12K media contained 7 mM of glucose, a relatively physiological glucose
level, and was utilized for low-glucose (LG) controls. F12K media was supplemented to
25 mM glucose for hyperglycemic (HG) culture treatments as previously utilized with
BeWo trophoblasts [30,34]. BeWo trophoblasts cells were plated in LG F12K media at
the specifically stated experimental densities and allowed to adhere to cell culture plates
overnight before being treated with HG culture media. Cell media was replenished every
24 hours. At T24h and T48h subsets of BeWo trophoblasts were treated with 250 µM 8Br-cAMP to induce differentiation from cytotrophoblast-like (CT) cells to SCT cells. Cell
cultures were collected after 72 hours of high glucose exposure. A schematic of the HG
culture protocol is available in Figure 3-1.

Figure 3-1 Schematic of 72-hour hyperglycemic cell culture protocol.
BeWo trophoblasts were plated in F12K media and allowed to adhere to culture plates
overnight. At T0H cells were treated with low glucose (LG, 7 mM) or hyperglycemic (HG,
25 mM) supplemented F12K media. At T24H subsets of BeWo trophoblasts were treated
with 250 µM 8-Br-cAMP to induce CT-to-SCT differentiation. Cell media was replenished
every 24 hours and cells were collected at T72H for analysis of metabolic function.
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3.2.3

Cell viability
BeWo trophoblasts were plated at 7.5x103 cells/well in black walled 96-well cell

culture plates and cultured as described. At T72h cell viability of both CT and SCT
cultures was assessed via the CellTiter-Fluor cell viability assay (Promega Corporation,
Madison WI, USA) as per manufacturer’s instructions.

3.2.4

Immunofluorescent analysis of BeWo syncytialization
To determine the potential of HG culture conditions to impact the ability of BeWo

trophoblasts to differentiate into SCT cells, cell fusion of 8-Br-cAMP stimulated cells
(expressed as percent loss of the tight junction protein zona occludens-1 (ZO-1)) was
examined. In brief, BeWo cells were plated at 1.4x105 cells/well in 6-well plates
containing coverslips coated with laminin (2 µg/cm2) and grown under HG conditions as
described. Cellular expression of ZO-1 was then examined via immunofluorescent
microscopy as previously detailed in chapter 2 [37].

3.2.5

RT-qPCR analysis of BeWo syncytialization
The expression of the transcription factor Ovo Like Transcriptional Repressor 1

(OVOL1) as well as human chorionic gonadotropin subunit beta (CGB) was additionally
analyzed to ensure cell fusion in 8-Br-cAMP stimulated BeWo cells was associated with
increased expression of syncytialization-related genes. In brief, BeWo trophoblasts were
plated at 3.5x105 cells/plate in 60mm cell culture plates and cultured as described above.
At T72h cells were collected in TRIzol reagent (Invitrogen), and total RNA was extracted
as per the manufacturer’s protocol. RNA integrity was assessed via formaldehyde gel
electrophoresis, and RNA concentration was quantified by Nanodrop Spectrophotometer
2000 (NanoDrop Technologies, Inc., Wilmington, DE, USA). RNA (2 µg) was then
reverse transcribed with the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems; ThermoFisher Scientific). RT-qPCR was then performed via the CFX384
Real Time system (Bio-Rad, Mississauga, Canada). Relative gene expression of OVOL1
[38] and CGB [39] was then determined using the ∆∆Ct method with the geometric mean
of PSMB6 and ACTB utilized as a reference. Primer sequences and their efficiencies are
available in Table 3-1.
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Table 3-1 Forward and reverse primer sequences used for quantitative Real-Time
PCR analysis of BeWo cell syncytialization
Gene

Accession
No.

Annealing
Temperature (°C)

ACTB

NM_001101.4

60

PSMB6

NM_002798

60

CGB
OVOL1

Malhotra et al (2015)
[39]
Kusama et al (2018)
[38]

60
60

Primer Sequences
F – GTTGCTATCCAGGCTGTGCT
R - AGGTAGTCAGTCAGGTCCCG
F – CGGGAAGACCTGATGGCGGGA
R - TCCCGGAGCCTCCAATGGCAAA
F – CCCCTTGACCTGTGATGACC
R – TATTGTGGGAGGATCGGGGT
F – AGACATGGGCCACTTGACAG
R – AGGTGAACAGGTCTCCACTG

Efficiency
92.6%
108.4%
105.3%
101.1%
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3.2.6

Quantifying BeWo cell oxidative function
BeWo cells were plated at 7.5x103 cells/well in Seahorse XF24 V7PS plates and

cultured under LG and HG conditions as described above. At T72h mitochondrial activity
was assessed using the Seahorse XF Mito Stress Test, as previously optimized for BeWo
trophoblast cells [37]. In brief, oxygen consumption rate (OCR) of cell culture media was
quantified as a proxy measure of mitochondrial respiratory activity. Subsequent
injections of oligomycin (1.5 µg/mL), dinitrophenol (DNP, 50 µM) and Rotenone and
Antimycin A (0.5 µM each) were used to interrogate the basal respiration, maximal
respiration, proton leak, spare respiratory capacity, and coupling efficiency parameters of
mitochondrial respiratory activity. OCR measures were normalized to cellular DNA
content using Hoechst dye fluorescence as described in Chapter 2 [37].

3.2.7

Quantifying BeWo cell glycolytic function
BeWo cells were plated at 7.5x103 cells/well in Seahorse XF24 V7PS plates and

cultured under LG and HG conditions as described above. At T72h glycolytic activity
was assessed via the Seahorse XF Glycolysis Stress Test, as previously optimized for
BeWo trophoblasts [37]. In brief, Extracellular Acidification Rate (ECAR) of cell culture
media was assessed to quantify glycolytic activity in BeWo trophoblasts. Injections of
glucose (10 mM), oligomycin (1.5 µg/mL) and 2-deoxyglucose (50 mM) were utilized to
interrogate the basal glycolytic rate, maximal glycolytic rate, glycolytic reserve, and nonglycolytic acidification parameters of glycolytic function. ECAR data was normalized to
cellular DNA content using Hoechst dye fluorescence as previously described [37].
Representative tracings of the Seahorse XF Mito Stress Test and Glycolysis Stress
Test for LG and HG-cultured BeWo trophoblast cells are available in Figure 3-2.
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Figure 3-2 Representative tracings of the Seahorse XF Mito Stress Test and
Glycolysis Stress Test in LG and HG-cultured BeWo trophoblasts.
(A) Representative Seahorse XF Mito Stress Test assay tracings; data is presented as mean
Oxygen Consumption Rate (OCR) ± SEM of the technical replicates of each treatment
group from one experiment. (B) Representative Seahorse XF Glycolysis Stress Test assay
tracings; data is presented as mean Extracellular Acidification Rate (ECAR) ± SEM of the
technical replicates of each treatment group from one experiment.
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3.2.8

Immunoblot analysis
BeWo trophoblasts were plated at 9.5x105 cells/plate in 100 mm cell culture

dishes and cultured under LG and HG conditions as described. At T72h cells were
washed once in ice-cold PBS and subsequently lysed in radioimmunoprecipitation assay
(RIPA) buffer supplemented with protease and phosphatase inhibitors as described in
chapter 2 [37]. Protein concentrations were then adjusted to 2 µg/µL in Laemmli loading
buffer (62.5 mM Tris-Cl (pH 6.8); 2% SDS 10% glycerol; 0.002% bromophenol blue;
4% β-mercaptoethanol).
The relative abundance of target proteins was then determined via SDS-PAGE gel
electrophoresis. In brief, protein lysates were separated with on acrylamide gels (1015%), and separated proteins were transfer to polyvinylidene fluoride (PVDF)
membranes (EMD Millipore, Fisher Scientific). Total lane protein was then determined
via Ponceau stain (0.1% Ponceau-S in 5% acetic acid) and utilized to normalize
densitometry values. PVDF membranes were blocked in 5% dry-milk protein or 5%
Bovine Serum Albumin (BSA, BioShop Canada Inc., Burlington, Canada) and
membranes were incubated overnight at 4℃ with respective antibody solutions (Table 32). Membranes were then washed 3 times with Tris-buffered Saline with 0.1% Tween-20
(TBST) and incubated with respective secondary antibodies for 1 hour at room
temperature (Table 3-2). Membranes were washed 3 more times in TBST and imaged on
a ChemiDoc Imager (Bio-Rad) using Clarity western ECL substrate (Bio-Rad). Protein
band abundance and total lane protein (ponceau) were quantified with Image-Lab
Software (Bio-Rad). Representative uncropped images of immunoblot images
highlighting antibody specificity are available in Supplementary Figures 2 and 3
(doi.org/10.5683/SP3/XMPKOK).
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Table 3-2 Specifications of antibodies utilized in immunoblotting experiments, and the protein mass loaded for each protein
target
Protein Target
Human Mitoprofile
Glycogen Synthase
pSer641 Glycogen Synthase
GSK3-β
pSer9 GSK3-β
ACSL1
Fatty Acid Synthase
OPA1
DRP1
pSER616 DRP1
GLUT1
Anti-Rabbit Secondary
Anti-Mouse Secondary

Source
Mouse Monoclonal
Rabbit Polyclonal
Rabbit Polyclonal
Rabbit Monoclonal
Rabbit Monoclonal
Rabbit Polyclonal
Rabbit Monoclonal
Rabbit Monoclonal
Rabbit Monoclonal
Rabbit Monoclonal
Mouse Monoclonal
Goat
Horse

Dilution
1:1000
1:1000
1:1000
1:1000
1:1000
1:500
1:1000
1:1000
1:1000
1:1000
1:1000
1:10,000
1:10,000

Blocking solution
5% Milk
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
-

Protein Loaded
35 µg
25 µg
20 µg
25 µg
20 µg
12.5 µg
15 µg
15 µg
15 µg
12.5 µg
15 µg
-

Heat (℃)
37
95
95
95
95
95
95
95
95
95
20
-

Company
ABCAM
Cell Signaling Technologies
Cell Signaling Technologies
Cell Signaling Technologies
Cell Signaling Technologies
Cell Signaling Technologies
Cell Signaling Technologies
Cell Signaling Technologies
Cell Signaling Technologies
Cell Signaling Technologies
EMD Millipore
Cell Signaling Technologies
Cell Signaling Technologies

Catalogue No.
ab110411
3893
3891
9315
9323
4047
3180
67589
8570
4494
mabs132
7074
7076
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3.2.9

Enzyme activity assays

Full step-by-step experimental protocols for the enzyme activity assays utilized in
Chapter 3 are available in the Supplementary Materials (doi.org/10.5683/SP3/ZTN4ZR).

3.2.9.1

ETC complex I and II activity

BeWo trophoblasts were plated at 3.5x105 cells/plate in 60mm cell culture dishes
and cultured under LG and HG conditions as described. At T72h cells were washed once
with PBS and detached from cell culture plates by scraping. Cells were then pelleted
(400g, 5 mins), snap frozen in liquid nitrogen and stored at -80℃ until analyzed. Cell
pellets were subsequently lysed and complex I activity was assessed as the rate of
rotenone-sensitive NADH oxidation, and complex II activity was assessed as the rate of
DCPIP oxidation as previously detailed in Chapter 2 [37]. ETC complex activity assays
were normalized to cell lysate protein content via Bicinchoninic Acid (BCA) assay
(Pierce, ThermoFisher Scientific) as per manufacturer’s instructions.

3.2.9.2

Quantifying metabolic enzyme activities

BeWo trophoblasts were plated at 3.5x105 cells/plate in 60mm cell culture dishes
and cultured under LG and HG conditions as detailed above. To examine the enzyme
activities of Lactate Dehydrogenase (LDH) and Citrate Synthase (CS), cells were
collected by scraping and lysed in glycerol lysis buffer (20 mM Na2HPO4, 0.5 mM
EDTA, 0.1% Triton X-100, 0.2% BSA, 50% glycerol) containing protease and
phosphatase inhibitors as previously described [37,40]. LDH activity was assessed as the
rate of NADH oxidation, and CS activity was assessed as the rate of Ellman’s reagent
consumption as detailed in Chapter 2 [37]. The enzyme activity of LDH and CS were
normalized to cell lysate protein content via BCA assay.
Additional BeWo cultures were collected to analyze the activity of the E1 (ratelimiting) subunit of the Pyruvate Dehydrogenase (PDH) complex. PDH-E1 subunit was
assessed on freshly collected BeWo cells as the rate of DCPIP oxidation and normalized
to protein content via BCA assay as detailed in Chapter 2 [37].
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3.2.10

Analysis of nutrient storage

BeWo trophoblasts were plated at 3.5x105 cells/plate in 60mm cell culture dishes
and cultured under LG and HG conditions. At T72h cells were washed with PBS and
collected into fresh PBS (1.5 mL) by scraping. Cells were then pelleted (400g, 5 minutes)
and the PBS was aspirated.
To determine cellular glycogen content, the cell pellets were lysed in 200 µL ddH2O and
samples were boiled for 10 minutes to inactivate cell enzymes. Samples were stored at 20℃ until glycogen content was analyzed. Samples were diluted 5-fold and glycogen
content was analyzed via the Glycogen Assay Kit (ABCAM, ab65620) as per
manufacturer’s protocol. Glycogen content was then normalized to cell lysate protein
content via BCA assay.
To determine cellular triglyceride accumulation, the collected cell pellets were
snap frozen in liquid nitrogen and stored at -80℃ until analyzed. Cells were then lysed,
and cellular triglyceride content was analyzed via the Triglyceride Assay Kit (ABCAM,
ab178780) as per kit instructions. Triglyceride content was normalized to cell lysate
protein content measured by a BCA assay.

3.2.11

Transcriptomic analysis of gene expression changes

BeWo CT cells were plated at 3.5x105 cells/plate in 60 mm cell culture dishes and
grown under LG and HG culture conditions as described. At T72h cells with washed
once with PBS and collected in 900 µL TRIzol Reagent and stored at -80℃. Samples
were then shipped to the Genome Québec Innovation Centre for transcriptomic analysis
via Clariom S mRNA microarray. Automated RNA extraction was completed via
QIAcube Connect (Qiagen, Toronto, Canada). RNA content was then quantified via
NanoDrop Spectrophotometer 2000 (Nanodrop Technologies, Inc) and RNA integrity
was determined by Bioanalyzer 2100 (Agilent Technologies, Waldbronn, Germany). All
extracted RNA samples had an RNA Integrity Number (RIN) greater than 9.5. RNA was
then processed via the Affymetrix Whole Transcript 2 workflow and analyzed using a
Clariom S human mRNA microarray. In brief, sense-stranded cDNA was the synthesized
from 100 ng total RNA, and subsequently fragmented, and labelled with the GeneChip
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WT Terminal Labeling Kit (ThermoFisher Scientific) as per manufacturer’s instructions.
Labelled DNA was then hybridized to Clariom S human GeneChips (ThermoFisher
Scientific) and incubated at 45℃ in the GeneChip Hybridization oven 640 (Affymetrix,
ThermoFisher Scientific) for 17 hours at 60 rpm. GeneChips were washed using
GeneChip Hybridization Wash and Stain Kit (ThermoFisher Scientific) according to
manufacturer’s specifications. Microarray chips were scanned on a GeneChip scanner
3000 (ThermoFisher Scientific).
Microarray data was then analyzed via Transcriptome Analysis Console v4.0
(ThermoFisher Scientific), and raw data was normalized using the Robust Multiple-Array
Averaging (RMA) method. HG-treated samples were paired with respective LG-control
for each cell collection for analysis. Genes with a ≥ ±1.3 fold-change (FC) vs LG-control
and raw-p < 0.05 were determined to be differentially expressed. The list of differentially
expressed genes was then imported into WebGestalt for gene ontology (GO) analysis and
analysis of functional pathways using the Wikipathways database. Biological processes
and functional pathways were determined to be significantly enriched with and a False
Discovery Rate (FDR) p < 0.05.

3.2.12

RT-qPCR validation of differentially expressed genes
identified by mRNA microarray

RT-qPCR was utilized validate differentially expressed genes involved in
metabolic pathways that were highlighted by the mRNA microarray. The RNA utilized
for the microarray was returned by Genome Québec and 2 µg was reverse transcribed as
described above. The CT samples previously utilized to examine expression of
syncytialization-related genes were additionally utilized to validate the differentially
expressed genes identified in the microarray. RT-qPCR was then performed and analyzed
using the ∆∆Ct with the geometric mean of ACTB and PSMB6 used as a reference.
Primer sequences of validated targets and their efficiencies are available in Table 3-3.
Table 3-3 Forward and reverse primer sequences used for quantitative Real-Time
PCR mRNA microarray validation
Gene

Accession
No.

Annealing
Temperature (°C)

Forward Sequence
(5’-3’)

Efficiency
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ACTB

NM_001101.4

60

PSMB6

NM_002798

60

SLC27A2

NM_003645.4

60

HSD11B2

NM_000196.4

60

ACSL1

NM_001995.5

60

RPS6KA5

NM_001322232.2

60

HK2

NM_000189.5

60

3.2.13

F – GTTGCTATCCAGGCTGTGCT
R – AGGTAGTCAGTCAGGTCCCG
F – CGGGAAGACCTGATGGCGGGA
R – TCCCGGAGCCTCCAATGGCAAA
F – ACTTCTGGAACCACAGGTCTTC
R – TCATCTGCCTTCAATCCGCTT
F – GGCTGCTTCAAGACAGAGTCAG
R – GCTCGATGTAGTCCTTGCCG
F – AGTCAATCCTTGCCCAGATGA
R – ATCCGGTTCAGCAGTCTTGG
F – GTGCCTGCACCATTTAAGCC
R – AGCAACAAAGGAATAGCCCTGA
F – ACGCCAAAATCACGTCTCCG
R – AGAGATACTGGTCAACCTTCTGC

92.6%
108.4%
107.2%
100.9%
103.8%
95.0%
98.8%

Cell culture collections for metabolomic and lipidomic
profiling of BeWo CT cells

BeWo trophoblasts were plated at a density of 2x106 cells/plate in 150mm cell
culture plates and cultured under LG and HG-conditions as described. At T72h cell media
was aspirated and the cells were washed three times with cold PBS. Pre-cooled methanol
(-20℃) was then added to quench cellular metabolic processes. Cells were then scraped
and collected into microcentrifuge tubes, and the methanol was evaporated with a gentle
flow of nitrogen gas. Samples were then frozen at -80℃ and were subsequently
lyophilized to remove any residual moisture.
The samples were then sent to The Metabolomics Innovation Centre (Edmonton,
Canada) for subsequent metabolomics and lipidomics analysis via a High-Performance
Chemical Isotope Labelling (HP CIL) liquid chromatography mass spectrometry (LCMS) approach [41,42]. Samples were reconstituted in 50% methanol and freeze-thaw
cycles were utilized to lyse the cells. The lysed samples were then centrifuged at 16000 g
at 4 ℃ for 10 mins, and 300 µL of resultant supernatant was transferred to a fresh tube
for metabolomic profiling, while the remaining supernatant and cell pellets were utilized
for lipidomic profiling.

3.2.14

Untargeted metabolomic profiling

The collected supernatants for metabolomic analysis were dried down and redissolved in 41 µL of water. The total concentrations of metabolite were then determined
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via the NovaMT Sample Normalization kit (Edmonton, Alberta). Water was added to
adjust all the concentrations of samples to 2 mM. The samples were split into five
aliquots for respective labeling methods. Each of the individual samples was labeled by
12

C-DnsCl, base activated 12C-DnsCl, 12C-DmPA Br, and 12C-DnsHz, for amine-/phenol-,

hydroxyl-, carboxyl, and carbonyl- metabolomic profiling, respectively [43]. A pooled
sample was generated by mixing of each individual sample and labeled by 13C-reagent,
accordingly. After mixing the each of 12C-labeled individual sample with 13C- labeled
pool by equal volume, the mixtures were injected onto LC-MS for analysis. The LC-MS
system was the Agilent 1290 LC (Agilent Technologies) linked to the Bruker Impact II
QTOF Mass Spectrometer (Bruker Corporation, Billerica, US). LC-MS data was then
exported to .csv files with Bruker DataAnalysis 4.4 (Bruker Corporation), the exported
data were then uploaded to IsoMS pro v1.2.7 for data quality check and data processing.
Metabolite peak pairs were then identified using a three-tier approach, as
previously described [43]. In tier 1, peak pairs were identified by searching against a
labelled metabolite library (CIL library) based on accurate mass and retention time. In
tier 2, the remaining peak pairs were matched by searching against a linked identity
library (LI library), containing predicted retention time and accurate mass information. In
tier 3, the rest of peak pairs were matched by searching against MyCompoundID (MCID)
library, containing accurate mass information of metabolites and their predicted products
Metabolites with ≥ ± 1.5 FC and raw-p<0.05 vs LG CT were determined to be
differentially abundant in the HG-cultured BeWo CT cells. Subsequent pathway analysis
(Homo sapiens KEGG library) was performed using MetaboAnalyst v5.0 to elucidate the
biological impacts of the differentially abundant metabolites identified in tiers 1 and 2.
Pathways with an FDR p<0.05 were determined to be significantly enriched.

3.2.15

Untargeted lipidomic profiling

For lipidomic profiling, the remaining supernatant and cell pellets were processed
using a modified Folch liquid-liquid lipid extraction protocol, as previously detailed [44].
In brief, samples were vortexed with 5 µL Splash Lipidomix Mass Spec Standard and
methanol for 20s, and subsequently vortexed for an additionally 20s following additions
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of dichloromethane. Samples were then incubated at room temperature for 10 mins
before being centrifuged at 16,000g for 10 mins at 4℃. An aliquot of the resulting
organic layer was then dried using a SpeedVac. The resulting dried material was
resuspended in 15 µL of 10 mM ammonium formate in methanol:acetonitrile:water
(50:40:10 v/v/v), vortexed for 1 min then diluted with 135 µL 10 mM ammonium
formate in 95% isopropanol. A pooled mixture of all extracts was then prepared for
quality control (QC) samples that were injected into the mass spectrometer every 7 runs
to monitor instrument performance. Liquid Chromatography with tandem Mass
Spectrometry (LC-MS/MS) was then performed in both positive and negative ion modes
using a ThermoFisher Dionex UltiMate 3000 UHPLC machine (ThermoFisher Scientific)
with a Water BEH C18 Column (Manufacturer Information; 5 cm × 2.1 mm with 1.7 μm
particles) coupled with a Brunker Impact II QTOF Mass Spectrometer. Each sample was
analyzed in technical duplicate. Data from each of the positive and negative ion mode
runs were combined for each unique sample into a single feature-intensity table.
A three-tier approach was utilized to identify MS/MS lipid-species peaks. In tiers
1 and 2 positive MS/MS identification was performed by searching the MS Dial
LipidBlast database, the Human Metabolome database, and the MassBank of North
America LC-MS/MS, while lipid species in tier 3 were MS identified with the LipidMaps
database [44,45]. For tier 1 identifications cutoffs of: MS/MS match score ≥ 500;
precursor m/z error ≤ 5 mDa were utilized. For tier 2 identifications cutoffs of: MS/MS
match score ≥ 100; precursor m/z error ≤ 5 mDa were utilized. Finally, in tier 3, lipid
species were putatively identified by mass match with m/z error ≤ 5 mDa.
Identified features were combined and feature intensity normalized to the internal
mass spectrometry standards. Normalized feature intensities were then imported in
MetaboAnalyst v5.0 for statistical analysis. Lipid species were filtered if their relative
standard deviation (RSD; SD/mean) was greater than 30% in QC samples. Lipid species
in each NEFA treatment condition with ≥ ±1.5 FC and raw p-value < 0.05 versus BSA
control samples were considered to be differentially abundant.
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3.2.16

Statistical analysis for non-omic experiments

Data collected as a percentage (percent loss of ZO-1 staining data, spare
respiratory capacity, coupling efficiency, and glycolytic reserve) were log-transformed
and analyzed via Two-Way ANOVA (2WA) and Bonferroni’s Multiple Comparisons
post-hoc test. A Randomized Block Design 2WA and Sidak’s Multiple Comparisons Test
was utilized to analyze relative mRNA transcript abundances; relative protein
abundances; metabolic activity assay parameters; and nutrient storage data, using raw
experimental data from each experimental replicate blocked together, as previously
described [46]. These data were then expressed as percent of LG CT control for
visualization in figures. Statistical analysis was performed with GraphPad Prism 8
Software (GraphPad Software, San Diego, CA, USA). A paired T-test was utilized to
analyze gene FC data between HG and LG BeWo CT cells in the RT-qPCR validation of
the microarray.

3.2.17

Supplementary data and materials

Microarray data are available on the National Center for Biotechnology Information
(NCBI) Gene Expression Omnibus (GEO) database (GSE190025). Supplementary
materials including detailed enzyme activity assay protocols
(doi.org/10.5683/SP3/ZTN4ZR), and supplementary tables and figures
(doi.org/10.5683/SP3/XMPKOK) have been uploaded to a publicly available data
repository and can be accessed via the indicated Digital Object Identifier (DOI) webpage
addresses. Metabolomic and lipidomic peak-pair data are available in Supplementary
Tables 3 and 5, respectively.
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3.3 Results
3.3.1

Characterization of BeWo viability and differentiation under
high glucose culture conditions
HG culture conditions were associated with a mean 7% and 10% reduction in cell

viability in BeWo CT and SCT cells respectively (Figure 3-3; p<0.01; n=6/group). It is
important to note that these viability data were consistent with previously reported values
in BeWo trophoblasts and PHTs cultured under hyperglycemia (25 mM glucose) for 48h
[30,47], and highlights that a more prolonged 72H HG-culture protocol does not impact
the stability of cultured BeWo trophoblasts cells. Additionally, BeWo SCT cells
displayed lower viability relative to BeWo CT cells consistent with trophoblast cells
becoming less proliferative while undergoing syncytialization (Figure 3-3; p<0.001).
BeWo SCT cultures displayed a greater loss of ZO-1 protein expression (and thus
increased cell fusion) compared to BeWo CT cultures (Figure 3-4 A,B; p<0.0001,
n=4/group). However, HG-culture conditions had no impact on ZO-1 protein expression
in BeWo trophoblast cells (Figure 3-4 A,B).
BeWo SCT cultures additionally displayed increased relative transcript abundance
of the syncytialization-associated transcription factor OVOL1 (Figure 3-4 C; p<0.01,
n=5/group) as well as the syncytialization-associated hormone CGB (Figure 3-4 D;
p<0.01, n=5/group). HG culture conditions in BeWo SCT cells was additionally
associated with an increased transcript abundance of CGB compared to LG BeWo SCT
cells (Figure 3-4 D; p<0.05; 2WA: Interaction p<0.05).
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Figure 3-3 Viability of BeWo trophoblasts cultured under hyperglycemic (HG)
conditions for 72h.
BeWo trophoblasts were cultured for 72H under HG culture conditions as described, and
cell viability was assessed via the CellTiter-Flour cell viability assay. Data is presented as
percent of LG CT cell viability (n=6/group). Raw cell viability fluorescence data was
analyzed via Two-Way Randomized block design ANOVA (2WA). Different lower-case
letters denote differentiation state-dependent differences in viability, and different uppercase letter denote differences in viability within each differentiation state (p<0.05).
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Figure 3-4 Hyperglycemic (HG) culture conditions do not impact BeWo SCT cell
fusion but are associated with increased CGB transcript abundance at 72h.
(A) Representative DAPI (blue); Zona occludens-1 (ZO1; red) and merged
immunofluorescent images (scale bar = 50 µm) of BeWo CT and SCT cells. (B) Percent
fusion of HG-cultured BeWo trophoblasts. Percent fusion data was log-transformed and
analyzed via Two-Way Anova (2WA); data is expressed as the percentage of cells lacking
ZO-1 expression (n=4/group). BeWo cell syncytialization was additionally analyzed via
quantifying mRNA transcript abundance of the syncytialization markers (C) OVOL1 and
(D) CGB. Transcript abundance data was analyzed via Randomized Block 2WA and
Sidak’s multiple comparisons test; data is present as transcript fold-change versus LG CT
cultures (n=5/group). Different lower-case letters denote statistical differences between
differentiation states, and different upper-case letter denote differences between LG and
HG treatments within each respective differentiation state (p<0.05).
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3.3.2

BeWo mitochondrial respiratory and glycolytic activity
High glucose culture conditions did not impact any of the parameters of

mitochondrial respiratory function as assessed by the Seahorse XF Mito Stress Test
(Table 3-4; n=5/group). However, BeWo syncytialization was associated with reduced
Spare Respiratory Capacity (Table 3-4; p<0.0001) and reduced Coupling Efficiency
(Table 3-4; p<0.01) independent of culture glucose level.
The parameters of glycolytic function as measured with the Seahorse XF
Glycolysis Stress Test were not impacted by BeWo syncytialization, or by HG culture
conditions (Table 3-5; n=5/group).
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Table 3-4 Syncytialization but not HG culture conditions impacts BeWo trophoblast mitochondrial respiratory activity
Differentiation
State

Treatment

LG
HG
LG
SCT
HG
*Differentiation state difference
CT

Basal
Respiration1
199.70 ± 39.08
173.40 ± 24.69
173.00 ± 7.96
177.5 ± 19.07
NS

Maximal
Respiration1
249.10 ± 43.78
221.30 ± 36.78
154.40 ± 11.97
168.30 ± 18.27
NS

Spare Respiratory
Capacity2
129.00 ± 5.30
125.50 ± 6.79
89.02 ± 5.68
95.76 ± 5.83
*

Proton Leak1
55.48 ± 8.45
46.72 ± 3.76
78.20 ± 7.38
75.88 ± 12.12
NS

Coupling Efficiency2
70.38 ± 3.34
70.58 ± 4.59
55.04 ± 2.99
57.30 ± 3.80
*

Data are mean ± SEM (n=5/group). * denotes a differentiation state dependent difference in mitochondrial
respiratory activity between BeWo CT and SCT cells. 1Data are OCR/µg DNA; 2Data are % Basal OCR

Table 3-5 HG culture conditions do not impact BeWo trophoblast glycolytic activity
Differentiation
State

Treatment

LG
HG
LG
SCT
HG
*Differentiation state
difference
CT

Basal glycolytic
Rate1
75.71 ± 15.38
67.54 ± 7.30
69.21 ± 12.67
77.38 ± 6.78

Max Glycolytic
Rate1
101.4 ± 20.92
88.23 ± 11.82
84.45 ± 14.55
88.01 ± 8.17

Reserve Glycolytic
Capacity2
133.8 ± 1.14
129.5 ± 4.08
123.5 ± 3.70
113.6 ± 1.45

Non-Glycolytic
Acidification1
19.26 ± 4.43
18.38 ± 3.10
20.50 ± 3.39
23.30 ± 2.45

NS

NS

*

NS

Data are mean ± SEM (n=5/group). * denotes a differentiation state dependent difference in glycolytic activity
between BeWo CT and SCT cells. 1Data are ECAR/µg DNA; 2Data are % Basal Glycolysis
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3.3.3

The impact of high glucose and syncytialization upon
BeWo ETC complex protein abundance and activity
High glucose levels did not impact protein abundance of ETC complex subunits

in BeWo trophoblasts (Figure 3-5 A-E; n=4-5/group). Likewise, the HG-culture
conditions did not affect ETC complex I or II activity in BeWo trophoblasts (Table 3-6,
n=6/group).
However, BeWo syncytialization was associated with reduced ETC complex IV
Cytochrome c oxidase subunit II (COXII) relative protein abundance in both LG and HG
cultures (Figure 3-5 D; p<0.05). Additionally, BeWo SCT cells displayed reduced
activity of ETC complex II compared to CT cells independent of culture glucose level
(Table 3-6; p<0.001).

3.3.4

Metabolic enzyme activity and HG-cultured BeWo
trophoblasts
BeWo SCT cells displayed increased activity of the PDH-E1 subunit compared to

BeWo CT cells regardless of glucose level (Table 3-6; p<0.01, n=6/group). Additionally,
high glucose levels did not impact the activities of the PDH-E1 subunit, citrate synthase
or lactate dehydrogenase (LDH) in BeWo CT and SCT cells (Table 3-6, n=5-6/group).
Syncytialization additionally did not affect the enzyme activities of CS or LDH in BeWo
trophoblasts (Table 3-6).

142

Table 3-6 Syncytialization but not HG-culture media impacts BeWo metabolic enzyme activity and individual ETC complex
activity
Differentiation
State

Treatment

LG
HG
LG
SCT
HG
*Differentiation state
difference
CT

Citrate Synthase

ETC complex I

0.0126 ± 0.0034
0.0134 ± 0.0033
0.0080 ± 0.0020
0.0070 ± 0.0015

0.0354 ± 0.0040
0.0413 ± 0.0052
0.0722 ± 0.0208
0.0709 ± 0.0217

NS

NS

ETC complex II
(U/mg protein)
0.0470 ± 0.0036
0.0448 ± 0.0039
0.0321 ± 0.0035
0.0330 ± 0.0039
*

Lactate Dehydrogenase

PDH-E1 subunit

2.821 ± 0.277
3.095 ± 0.391
3.589 ± 0.312
3.504 ± 0.359

0.0046 ± 0.0006
0.0041 ± 0.0005
0.0090 ± 0.0012
0.0098 ± 0.0014

NS

*

Data are mean ± SEM (n=5-6/group). * denotes a differentiation state dependent difference in enzyme activity between BeWo CT and
SCT cells.
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Figure 3-5 Hyperglycemic (HG) culture conditions do not impact protein expression
of Electron Transport Chain (ETC) complexes in BeWo trophoblasts.
Relative protein abundance of (A) complex I (NDUFB8 subunit) (B) complex II (SDHB
subunit) (C) complex III (UQCRC2 subunit) (D) complex IV (COX II subunit), and (E)
complex V (ATP5A subunit) of the ETC in HG-cultured BeWo trophoblasts. Different
lower-case letters denote differentiation state-dependent differences in ETC complex
protein abundance (n=4-5/group; Two-Way Randomized Block ANOVA (2WA)). ETC
complex protein band density was normalized to total lane protein (ponceau) for statistical
analysis and the data is presented as percent of LG CT protein abundance for visualization.
Full-length representative western blot images are available in Supplementary Figure 2
(doi.org/10.5683/SP3/XMPKOK).
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3.3.5

HG-cultured BeWo trophoblast mitochondrial fission and
fusion dynamics
Regardless of glucose level BeWo SCT cells displayed increased relative protein

abundance of the mitochondrial fission marker DRP1 in conjunction with decreased
relative protein levels of the mitochondrial fusion marker OPA1 compared to progenitor
BeWo CT cells (Figure 3-6 A,C; p<0.05, n=5/group).
HG culture conditions additionally did not impact total protein abundance of
OPA1 and DRP1 in BeWo trophoblasts (Figure 3-6 A,C; p>0.05). However, there was a
trend towards increased pSER616 phosphorylation of DRP1 in HG-cultured BeWo
trophoblasts (Figure 3-6 B; p=0.0632, n=5/group) as well as reduced pSER616 DRP1
phosphorylation in syncytialized BeWo trophoblasts (Figure 3-6 B; p=0.0924).
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Figure 3-6 Syncytialization impacts mitochondrial dynamics in BeWo trophoblasts.
Relative protein abundance of (A) total DRP1 (B) pSER616 DRP1 (C) OPA1 in HG and
LG cultured BeWo trophoblasts. Different lower-case letters denote differentiation statedependent differences in relative protein abundance (n=5/group; Two-Way Randomized
Block ANOVA (2WA)). Protein band density was normalized to total lane protein
(ponceau) for statistical analysis and the data is presented as percent of LG CT abundance
for visualization. Uncropped representative western blot images are available in
Supplementary Figure 3 (doi.org/10.5683/SP3/XMPKOK).
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3.3.6

HG culture conditions impact glycogen storage in
BeWo trophoblasts
HG culture conditions in both BeWo CT and SCT cells increased cellular

glycogen content compared to respective differentiation state LG cultures (Figure 3-7 A;
p<0.0001; n=4/group). Furthermore, the glycogen content in BeWo CT cultures was
greater than that of the SCT cultures (Figure 3-7 A; p<0.0001). In addition, BeWo SCT
cells displayed increased GLUT1 protein abundance compared to BeWo CT cells
(Figure 3-7 B; p<0.05), however, no glucose-dependent impacts to GLUT1 protein
abundance were observed.
However, HG culture conditions reduced relative glycogen synthase protein
abundance in both BeWo CT and SCT cells (Figure 3-7C; p<0.05, n=5/group). HG
cultured BeWo CT and SCT cells subsequently displayed increased relative abundance of
phosphorylated (pSer641) glycogen synthase (Figure 3-7 D; p<0.01, n=5/group), and
differentiated BeWo SCT cells displayed increased phosphorylated (pSer641) glycogen
synthase levels relative to CT cultures (Figure 3-7 D; p<0.01, n=5/group).
Furthermore, differentiated BeWo SCT cells were found to have increased protein
levels of both Glycogen synthase kinase 3 beta (GSK3β) and phosphorylated (pSer9)
GSK3β relative to BeWo CT cultures (Figure 3-7 E-F; n=5/group). However, HG
culture conditions were not associated with alterations in the relative protein abundance
of GSK3β and phosphorylated (pSer9) GSK3β (Figure 3-7 E-F; p>0.05, n=5/group).
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Figure 3-7 Hyperglycemic (HG) culture conditions impact glycogen storage and
regulation in BeWo trophoblasts.
(A) Glycogen content and relative protein abundance of (B) GLUT1 (C) glycogen
synthase; (D) pSer641 glycogen synthase; (E) GSK3β; (F) pSer9 GSK3β in HG-treated
BeWo trophoblasts at T72H. Different lower-case letters denote differentiation statedependent differences in protein abundance, and different upper-case letters denote
glucose-level dependent differences within a differentiation state (Randomized-Block
Two-Way ANOVA (2WA), and Sidak’s multiple comparisons test, p<0.05). Glycogen
content data are presented as protein normalized glycogen abundance (µg glycogen per µg
protein; n=4/group). Protein band density was normalized to total lane protein (ponceau)
for statistical analysis and the data is presented as percent of LG CT abundance for
visualization (n=5/group). Uncropped representative western blot images are available in
Supplementary Figure 3 (doi.org/10.5683/SP3/XMPKOK).
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3.3.7

HG culture conditions increases TG abundance in
BeWo CT cells
HG culture conditions were associated with increased triglyceride accumulation

in BeWo CT cells, but not in BeWo SCT cells (Figure 3-8 A; p<0.01, n=4/group).
Furthermore, BeWo syncytialization and HG culture conditions did not impact the
relative abundance of ACSL1 protein, although there was a trend towards increased
expression in both differentiated BeWo SCT cells and in HG-treated BeWo trophoblasts
(Figure 3-8 B; 2WA: glucose level p = 0.0894; 2WA: differentiation state p = 0.0695,
n=5/group). Finally, syncytialization and HG culture conditions did not impact the
relative abundance of fatty acid synthase (FASN) in BeWo trophoblasts (Figure 3-8 C).
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Figure 3-8 Hyperglycemic (HG) culture conditions impact triglyceride content in
BeWo CT cells.
(A) Triglyceride content and relative protein abundance of (B) ACSL1, and (C) FASN in
HG-treated BeWo trophoblasts at T72H relative abundance. Different upper-case letters
denote differences between LG and HG treatments within each respective differentiation
state (Two-Way Randomized Block ANOVA; Sidak’s multiple comparisons test, p<0.05).
TG content data is presented as protein normalized TG abundance (pmol TG per µg
protein; n=4/group). Protein band density was normalized to total lane protein (ponceau)
for statistical analysis and the data is presented as percent of LG CT abundance for
visualization (n=5/group). Uncropped representative western blot images are available in
Supplementary Figure 3 (doi.org/10.5683/SP3/XMPKOK).
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Transcriptomic profiling of HG-cultured BeWo CT
cells

3.3.8

HG-cultured BeWo CT cells displayed 197 differentially expressed genes (75
upregulated, 122 down-regulated) compared to LG BeWo CT cells (≥ ±1.3 FC vs LG CT;
raw-p < 0.05, n=5/group). A summary of the differentially expressed genes between LG
and HG-cultured BeWo CT cells is available in Supplementary Table 1
(doi.org/10.5683/SP3/XMPKOK). A 3D principal component analysis (PCA) plot
(Figure 3-9 A), volcano plot (Figure 3-9 B) and 2D hierarchical clustering heatmap
(Figure 3-10) were constructed to visualize the degree of gene expression differences
between LG and HG cultured BeWo CT cells.
At the FC cut-offs selected, the differentially expressed genes were not associated
with significant enrichment in gene ontology (GO) biological processes (Figure 3-11 A).
Functional pathway analysis with WikiPathways revealed that the Overview of
Nanoparticle Effects Pathway was significantly enriched in the HG-cultured BeWo CT
cells (Figure 3-11 ; FDR < 0.05). The differentially expressed genes involved in this
pathway were: CCND3 (-1.41 FC), IL6 (-1.39 FC), PTGS1 (-1.31 FC), and PTK2 (-1.40
FC).
As there were no enriched metabolism-related pathways, individual differentially
expressed genes involved in cellular metabolic processes were individually identified and
selected for validation via RT-qPCR. Specifically, ACSL1, RPS6KA5, HSD11B2, HK2
and SLC27A2 were selected for validation (Figure 3-11 C, n=8/group). The altered
expression of ACSL1 (+1.36 FC in the microarray; +1.369 FC in the RT-qPCR
validation); RPS6KA5 (+1.32 FC in the microarray; +1.304 FC in the RT-qPCR
validation); and HSD11B2 (+1.35 FC in the microarray; +1.463 FC in the RT-qPCR
validation) in HG-cultured BeWo CT cells were validated via RT-qPCR. (Figure 3-11 C)
While not significant, the expression of HK2 was found slightly reduced in HG BeWo
CT cultures via RT-qPCR (-1.152 FC vs LG BeWo CT cells). The differential expression
of SLC27A2 in HG-cultured BeWo CT cells could not be validated via RT-qPCR (Figure
3-11 C).
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Figure 3-9 Principal Component Analysis (PCA) and volcano plot visualization of
differentially expressed genes between low-glucose (LG) and hyperglycemic (HG)
cultured BeWo CT cells.
(A) An unsupervised PCA plot was constructed to visualize the degree of separation in
transcriptomic profiles between LG (red dots) and HG (blue dots) cultured BeWo CT cells
(B) The volcano plot was generated to visualized differentially expressed genes in HGcultured BeWo CT cells (≥ ±1.3 fold-change, p<0.05, n=5/group). The x-axis indicated
fold-changes vs LG BeWo CTs, and the y-axis indicates the p-value (-log10). The green
dots represent statistically significant down-regulated genes, and the red dots represent
statistically significant upregulated genes in HG-cultured BeWo CT cells.
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Figure 3-10 Heat map visualization of differentially expressed genes in
hyperglycemic (HG) cultured BeWo CT cells.
Each column of the heat map represents an individual sample, with blue columns
representing HG-cultured BeWo CT cells and the red columns representing low-glucose
(LG) cultured BeWo CT cells. Each row represents an individual differentially expressed
gene. Gene expression intensity is color coded with orange representing low-expression
genes and black representing high-expression genes.
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Figure 3-11 Pathway analysis of differentially expressed genes and RT-qPCR
validation of microarray gene changes.
Webgestalt was utilized to examine significantly enriched pathways of the differentially
expressed genes identified in the Clariom S mRNA microarray. (A) Top 10 Geneontology
biological pathways and (B) top 10 Wikipathways functional pathways enriched in the
differentially expressed genes. Black bars represent significantly enriched pathways (FDR
p < 0.05) and grey bars represent pathways that were not significantly enriched in the gene
set (FDR p > 0.05). (C) RT-qPCR was utilized to validate differentially expressed genes
identified in the microarray. Data was analyzed via paired t-test (n=8/group), and data
expressed as fold-change vs LG BeWo CT (mean ± SEM). Down-regulated genes ratios
were inversed and expressed as a negative (e.g 0.5-fold is expressed as a minus-2 foldchange).

157

3.3.9

Impacts of HG culture conditions on the metabolome

of BeWo CT cells
On average 6541 ± 42 (mean ± SD) metabolite peak pairs were measured in each
sample. A summary of the metabolites identified in all tiers, and LG and HG-cultured
BeWo CT cell metabolite peak-pair data is available in Supplementary Table 2
(doi.org/10.5683/SP3/XMPKOK). Of these peak pairs, 179 were positively identified in
tier 1 and 602 peak pairs were identified with high confidence in tier 2. Of these
identified peak pairs, 7 from tier 1 and 116 from tier 2 were found to be differentially
abundant (≥ ±1.5 FC, raw-p<0.05, n=5/group) between HG and LG cultured BeWo CT
cells. A list of all differentially abundant metabolites between LG and HG-cultured
BeWo CT cells is available in Supplementary Table 3
(doi.org/10.5683/SP3/XMPKOK).
The degree of differences in metabolite profiles between HG and LG-cultured
BeWo CT cells was visualized by unsupervised principal component analysis (PCA) plot
as well as supervised partial least squares discriminant analysis (PLS-DA) scores plot
(Figure 3-12 A,B). Differentially abundant metabolites were subsequently visualized via
volcano plot and heat map (Figure 3-13 A,B).
Pathway analysis revealed that the glycolysis/gluconeogenesis (highlighted by
significantly increased lactate levels, and significantly decreased acetaldehyde levels);
pyruvate metabolism (highlighted by increased lactate (+2.72 FC) levels, and decreased
acetaldehyde (-1.20 FC) levels); drug metabolism – cytochrome P450 (highlighted by
increased 2-hydroxyiminostilbene (+2.52 FC) and 3-carbamoyl-2-phenylpropionic acid
(+5.42 FC) levels); ascorbate and aldarate metabolism (highlighted by increased Lgulonolactone (+2.46 FC) levels); riboflavin metabolism (highlighted by increased
riboflavin (+3.68 FC) levels); fatty acid biosynthesis (highlighted by increased malonate
(+3.74 FC) levels); as well as synthesis and degradation of ketone bodies (highlighted by
increased (R)-3-hydroxybutanoate (+1.60 FC) levels) pathways were significantly
enriched in HG-cultured BeWo CT cells (FDR-corrected p<0.05). A scatterplot of the
pathway nodes and summary of the differentially abundant metabolites within each
pathway is available in Figure 3-14.
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Figure 3-12 Visualization of the degree of separation between metabolite profiles in
HG and LG cultured BeWo CT cells.
(A) Unsupervised principal component analysis (PCA) and (B) supervised partial least
squares discriminant analysis (PLS-DA) plots were constructed to visualize the separation
in metabolite concentrations between LG (orange dots) and HG-cultured (blue dots) BeWo
CT cells.
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Figure 3-13 Visualization of differentially abundant metabolites in HG-cultured
BeWo CT cells.
(A) Volcano plot visualizing differentially abundant metabolites in HG-cultured BeWo CT
cells ((≥ ±1.5 fold-change, raw-p<0.05, n=5/group). The x-axis indicated log2(fold-change)
vs LG BeWo CTs, and the y-axis indicates the p-value (-log10). The red dots represent
significantly increased metabolites, and the blue dots represent significantly decreased
metabolites in HG-cultured BeWo CT cells. (B) heat map visualizing the top-100 (by pvalue) differentially abundant metabolites in HG-cultured BeWo CT cells. Each column
represents a different sample, and each row represents an individual differentially abundant
metabolite. Metabolite abundance was color coded with red representing increased
metabolite abundance and blue representing decreased metabolite abundance.
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Figure 3-14 Pathway analysis of metabolites identified in tiers 1 and 2.
Identified peak pairs from tiers 1 and 2 were imported into MetaboAnalyst v5.0 for analysis
of enriched KEGG pathways. A scatterplot was created to visualize identified pathways
with pathway impact (ratio of identified metabolites to total metabolites in the pathway)
on the x-axis and p-value (-log10) on the y-axis. Pathways with a false discovery rate
p<0.05 were determined to be significant and were labelled with uppercase letters. The (A)
Glycolysis/Gluconeogenesis, (B) Pyruvate Metabolism, (C) Drug Metabolism –
Cytochrome P450, (D) Ascorbate and Aldarate Metabolism, (E) Riboflavin Metabolism,
(F) Fatty Acid Biosynthesis, and (G) Synthesis and Degradation of Ketone Bodies
pathways were significantly enriched in HG-cultured BeWo CT cells.
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3.3.10

Impacts of HG culture conditions of the lipidome profiles of
BeWo CT cells.

On average 9406 ± 77 (mean ± SD) lipid species peak pairs were identified in the
LG and HG-treated BeWo CT cells. Of these features, 950 were positively identified in
Tier 1, and 161 were identified with high confidence in Tier 2. An additional 6808
features were putatively identified in Tier 3. A summary of the lipid class types identified
in the lipidome readouts, and their abbreviations is available in Supplementary Table 4
(doi.org/10.5683/SP3/XMPKOK). A summary of the identified lipid species in tiers 1, 2
and 3 and the peak-pair data for LG and HG-cultured BeWo CT cells is available in
Supplementary Table 5 (doi.org/10.5683/SP3/XMPKOK).
Overall, 131 lipid species were identified as significantly increased and 49 as
significantly decreased in HG-cultured BeWo CT cells (≥ ±1.5 FC vs LG; raw p-value <
0.05, n=5/group). An unsupervised Principal Component Analysis (PCA) 2D scores plot
as well as a supervised partial-least squares discriminant analysis (PLS-DA) 2D plot were
constructed to visual the degree of separation in lipidome profiles between LG and HGculture BeWo CT cells (Figure 3-15). Additionally, a volcano plot was constructed to
visualize the differentially abundant lipid species in the hyperglycemia exposed BeWo
CT cells (Figure 3-16). A summary of the differentially abundant lipid species in HGcultured BeWo CT cells is available in Supplementary Table 6
(doi.org/10.5683/SP3/XMPKOK).
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Figure 3-15 Multivariate visualization of the degree of separation in lipidome
profiles between LG and HG-cultured BeWo CT cells.
(A) Unsupervised principal component analysis (PCA), and (B) supervised partial least
squares-discriminant analysis (PLS-DA) plots were constructed to visualize the difference
in lipidome profiles between LG (green dots) and HG (red dots) cultured BeWo CT cells.
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Figure 3-16 Volcano plot visualization of differentially abundant lipid species in
HG-cultured BeWo CT cells.
A volcano plot was constructed to visualize the differentially abundant lipid species in HGcultured BeWo CT cells (≥ ±1.5 fold-change, raw-p<0.05, n=5/group). The x-axis
indicated log2(fold-change) vs LG BeWo CT, and the y-axis indicates the p-value (-log10).
The red dots represent significantly increased lipid species, and the blue dots represent
significantly decreased lipid species in HG-cultured BeWo CT cells.
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3.4 Discussion
The current study aimed to expand upon current published literature [22,30,31,34]
and explore the independent impacts of hyperglycemia on placental trophoblasts in more
depth by characterizing nutrient storage and mitochondrial respiratory activity in BeWo
trophoblasts following a relatively prolonged 72-hour HG-exposure (25 mM glucose).
While previous studies utilizing BeWo trophoblasts have specifically highlighted the
impacts of high glucose exposure on progenitor CT cells [30,31,34] the current study is
strengthened through the combined examination of both CT cells and differentiated SCT
cells as well as by the use of functional readouts of metabolic and mitochondrial activity.
The more chronic 72-hour culture protocol as utilized in this study allowed for exposure
of villous trophoblast cell populations to hyperglycemia prior to and during
differentiation, analogous to in vivo villous trophoblast layer development whereby
progenitor CT cells are exposed to dietary nutrients prior to and during syncytialization.
Subsequently, the current study utilized a multi-omics research approach and described
altered transcriptomic, metabolomic, and lipidomic signatures in HG-exposed BeWo CT
cells, that further described the glucose-mediated alterations to placental metabolic
function. Overall, the data presented in this study demonstrated that a 72-hour exposure
to hyperglycemia, while sufficient to modulate transcriptomic and metabolomic
signatures as well as increase triglyceride and glycogen nutrient stores in BeWo
trophoblast cells, is not associated with direct impairments in mitochondrial respiratory
activity.

3.4.1

Hyperglycemia and nutrient stores in BeWo trophoblasts
As previously highlighted, DM during pregnancy is associated with aberrant

nutrient storage in the villous trophoblast layer of the placenta [18–23]. Our results
demonstrated that HG-culture conditions directly facilitate increased glycogen content in
both BeWo CT and SCT cells, and additionally that CT cells have a greater glycogen
storage potential than SCT cells. It is important to note that these differentiation statedependent trends in glycogen content are consistent with previous reports from primary
human placental tissue which described that glycogen storage predominately occurs
within the CT cells of the placenta [24,48,49]. Increased glycogen abundance in diabetic
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placentae has been thought to be a mechanism by which the placenta limits materno-fetal
glucose transfer in times of nutrient overabundance to limit fetal overgrowth [24,25].
However, we speculate that the increased glycogen stores observed in the BeWo
trophoblast cells also functions to limit the pool of glucose available for glycolysis and
subsequent mitochondrial oxidation and in turn acts to protect trophoblast mitochondria
from glucose-mediated oxidative damage.
High-glucose exposure in both BeWo CT and SCT cells was also associated with
reduced relative protein abundance of glycogen synthase as well as with increased
inhibitory Ser641 phosphorylation [50] of glycogen synthase. As there were no glucosemediated differences in the protein abundance of GSK3β or the inhibitory Ser9
phosphorylation [51] of GSK3β, the increased inhibitory phosphorylation of glycogen
synthase in HG-cultured BeWo trophoblasts likely occurs via a GSK3β-independent
mechanism. These data could suggest that increased glycogen levels in placental
trophoblasts act via a negative feedback mechanism to prevent excessive glycogen
accumulation by altering glycogen synthase protein abundance and post-translational
modifications, as has previously been described [52]. Overall, these data suggested that
following 72-hours of hyperglycemia BeWo trophoblast cells have a diminished capacity
to store excess glucose as glycogen. Thus, we speculate that HG-cultured BeWo
trophoblast cells are at risk of developing glucose-toxicity if the exposure is continued
beyond our 72-hour timepoint.
In addition to increased glycogen stores, our study also demonstrated increased
triglyceride content in BeWo CT in response to excess glucose exposure. These data were
consistent with previous reports that have highlighted an increased accumulation of
triglyceride species in placental explants from healthy pregnancies under high glucose
conditions [22]. The current study further identified that there were no differentiation
state-dependent differences in triglyceride abundance in BeWo trophoblast cells, similar
to reports from freshly isolated villous trophoblast samples [53]. Readouts from primary
placenta samples have highlighted that lipid esterification processes occur primarily
within villous CT cells, and that lipid droplets present in primary SCT cells are likely
remnants from esterification process that occurred prior to syncytialization [53]. We
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speculate that a similar reduction in esterification activity also occurs in BeWo SCT cells
and may explain the absence of a HG-mediated difference in triglyceride content in our
BeWo SCT cells. Future studies utilizing functional readouts of lipid esterification
activity may be needed be better elucidate the mechanisms underlying differences in TG
abundance between BeWo CT cells and differentiated BeWo SCT cells.
Overall, these data suggest that hyperglycemia is an independent modulator of
nutrient storage in trophoblast cells and highlights that increased glucose availability may
be a direct mechanism underling aberrant placental nutrient storage in diabetic
pregnancies.

3.4.2

Hyperglycemia and metabolic function in BeWo trophoblasts
The current study demonstrated that cellular mitochondrial respiratory activity

(measured by the Seahorse XF Mito Stress Test) as well as that the activities of ETC
complex I and II are not impacted in BeWo trophoblasts cultured under hyperglycemia at
72H. Additional analysis of metabolic function via the Seahorse Glycolysis Stress Test
and activity assays for LDH and CS enzymes further indicated that isolated
hyperglycemia does not impact functional aspects of metabolism in BeWo trophoblasts.
Overall, our data suggests that hyperglycemia alone may not directly facilitate the
impairments in mitochondrial respiratory activity that have previously been observed in
DM-exposed primary placental samples [27–29].
Previous studies in other cell preparations, however, have demonstrated that the
impacts of HG-culture conditions on mitochondrial respiratory function are dependent on
the length of high-glucose exposure. For example, human kidney tubule (HK-2) cells
displayed reduced basal and maximal mitochondrial respiratory activity only when
cultured under HG-conditions (25 mM) for at least 4 days [54]. In contrast, mitochondrial
respiratory activity in kidney glomerular (HMC) cells was not impacted prior to 8 days of
high glucose exposure [54]. Likewise, mitochondrial activity of human umbilical cord
endothelial (EA.hy926) cells was not impaired after 3 days of high glucose (25 mM)
treatment, but was reduced after 6 days of HG-culture conditions, and this impairment in
mitochondrial function was sustained through 9 days of high glucose exposure [55].
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Overall, these studies suggest that there are time-course dependent factors that influence
whether hyperglycemia impacts cellular mitochondrial respiratory activity. Thus, the
conclusions of the current study may be limited due to the single timepoint utilized for all
analyses of metabolic function. It is possible that prolonging HG-culture conditions in
BeWo trophoblasts could ultimately lead to impaired mitochondrial function, as was
observed in EA.hy926 and HMC cells, and the impacts of a longer duration of high
glucose treatment in BeWo cells may need to be explored in future investigations.
In addition to impairing mitochondrial respiratory activity in trophoblast cells,
hyperglycemia negatively regulates mitochondrial function in some cell types through
altering mitochondrial fusion (regulated by OPA1) and fission (regulated by DRP1)
dynamics leading increased mitochondrial fractionation [56–59]. Increased mitochondrial
fission is associated with increased cellular oxidative stress, and impaired insulin
sensitivity, and ultimately mitochondrial respiratory dysfunction [60,61]. We observed a
trend towards increased (mean 19% increase) pSER616 phosphorylation of DRP1 (a posttranslational modification associated with increased mitochondrial translocation of DRP1
and subsequently increased mitochondrial fission) in HG-cultured BeWo trophoblasts
[62]. These post-translational modifications of DRP1, although non-significant, may
indicate that important underlying aspects of trophoblast mitochondrial function are
negatively regulated by hyperglycemia, even though global readouts of BeWo
mitochondrial respiratory activity were not impacted. We speculate that this could
indicate that the HG-cultured BeWo trophoblasts are at an early timepoint in a transition
towards mitochondrial dysfunction.

3.4.3

Transcriptomic analysis of HG-cultured BeWo CT cells
While functional readouts of BeWo trophoblast mitochondrial function were

sustained in response to hyperglycemia, we did observe impaired mitochondrial
respiratory activity in differentiated BeWo SCT cells. Syncytialization of BeWo
trophoblasts was associated with reduced mitochondrial spare respiratory capacity,
reduced coupling efficiency, concomitant with reduced activity of ETC complex II, and
reduced protein expression of ETC complex IV. Furthermore, BeWo SCT cells displayed
increased DRP1 protein abundance and decreased OPA1 protein abundance suggestive of
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increased mitochondrial fractionation. These data may indicate that alterations in
mitochondrial dynamics underlies the observed functional differences in mitochondrial
respiration between BeWo CT and SCT cells. Previous work by our research group has
likewise highlighted that BeWo CT cells are overall more metabolically active than
BeWo SCT cells [37], and similar trends have been reported in cultured PHT cells
[28,63]. As progenitor BeWo CT cells display greater metabolic activity and greater
alterations to nutrient stores in response to hyperglycemia than in differentiated SCT
cells, we speculated that alterations in omic profiles in response to high glucose culture
conditions would be more prevalent in these progenitor cells. Thus, this current study
sought to examine global gene expression as well as global metabolite and lipid species
abundance solely in HG-cultured BeWo CT cells to further elucidate mechanisms
underlying altered placental metabolic function in response to hyperglycemia.
The current study identified 197 differentially expressed genes (≥ ±1.3 FC) in
BeWo CT cells cultured under hyperglycemia for 72H. However, previous reports in
BeWo CT cells demonstrated more substantial variations in gene expression between
BeWo trophoblasts cultured under similar high and low glucose conditions [30]. The
differences between the current study and previous reports may be due in part to
differences in study design (pooling samples for arrays vs independent arrays for each
sample), cell media formulation (DMEM-F12 vs F12K) as well as length of
hyperglycemic exposure (48H vs 72H). Despite these differences in the number of
differentially expressed genes, our study did align with this previous transcriptomic
report, and demonstrated that elevated glucose levels impact the expression of genes
involved in metabolic processes [30]. Notably, HG-culture conditions in the current study
were associated with increased mRNA expression of ASCL1 in BeWo CT cells.
Additionally, we observed a simultaneous trend towards increased protein abundance of
ACSL1, although these trends did not reach statistical significance. Previous studies have
highlighted that ACSL1 is involved in lipid synthesis in various tissues and that
knockdown of ACSL1 is associated with reduced triglyceride and lipid droplet abundance
[64–67]. More importantly, cells transfected to overexpress ACSL1 have been found to
have increased triglyceride accumulation [67–69]. Thus, we speculate that ACSL1 may be
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involved in the trafficking of lipid species to lipid droplets and may underlie the glucoseinduced accumulation of triglyceride species that was observed in our BeWo CT cultures.
Our data additionally highlighted that isolated hyperglycemia in BeWo CT cells
was associated with an increased expression of HSD11B2, an enzyme involved in the
metabolism and inactivation of the glucocorticoid cortisol. In normal pregnancies,
cortisol is thought to be involved in mediating the physiological increase in maternal
insulin resistance that is necessary to support fetal growth [70,71], however, circulating
cortisol levels may be pathologically elevated in some GDM pregnancies [72].
Interestingly, placentae from GDM pregnancies have been found to have increased
expression of HSD11B2 leading to increased cortisol inactivation [73]. Since elevated
cortisol levels in fetal circulation have been associated with impaired brain development
processes [74], increased placental HSD11B2 expression in GDM pregnancies may act in
a protective manner to limit fetal glucocorticoid exposures. However, as cortisol also
activates the glucocorticoid receptor leading to modulated gene transcription [75,76].
Thus, alterations in placental cortisol metabolism may have downstream consequences on
placental function through altering gene expression. Overall, the results from the current
study demonstrated that hyperglycemia is an important regulator of placental HSD11B2
expression. However, it remains poorly understood whether these glucose-mediated
impacts to placental cortisol metabolism act in a protective or detrimental manner.

3.4.4

Metabolomic and lipidomic analysis of HG-cultured BeWo
CT cells
Multivariate analysis PCA analysis of BeWo trophoblast metabolome profiles

highlighted a divergence in metabolite signatures between HG and LG-cultured BeWo
CT cells suggesting that high glucose levels impact polar metabolite levels in the
placenta. In contrast, limited separation was observed between the lipidome profiles of
LG and HG-cultured BeWo CT in the unsupervised PCA analysis.
Subsequent pathway analysis of the metabolome data highlighted specific
intracellular accumulations of lactate (involved in the glycolysis/gluconeogenesis and
pyruvate metabolism pathways), malonate (involved in the fatty acid biosynthesis
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pathway), as well as riboflavin (involved in the riboflavin metabolism pathway) in the
HG-cultured BeWo CT cells.
The observed lactate accumulation likely suggests that glycolytic flux is in fact
increased in HG-cultured BeWo CT cells [77]. It is interesting to note that this study did
not observe increased basal or maximal glycolytic activity when assessed via the
Seahorse XF Glycolysis Stress Test. As the Glycolysis Stress Test utilizes extracellular
media acidification (resulting from the co-export of lactate and H+ from the cell) as a
proxy measurement of glycolytic activity, this functional assay may underestimate
glycolytic activity in the event of reduced lactate export as could potentially occur in a
“Cytosol-to-Mitochondrial Lactate Shuttle” metabolic pathway [77].
The observed increase in malonate levels may reflect an increase in de novo
lipogenesis via FASN in HG-cultured BeWo CT and may be another mechanism
underlying the increased TG levels observed in HG-cultured BeWo CT cells [78,79].
Interestingly, we also observed an increased accumulation of 16:0 carnitine levels in the
HG-cultured BeWo CT cells (+ 1.63 FC vs LG cultures) in our lipidomic analyses. As
FA species must be conjugated to carnitine to be transported into the mitochondrial
matrix for oxidation, the increased 16:0 carnitine levels may be reflective of increased FA
oxidation in HG-cultured BeWo CT cells [80]. However, as malonate has been
demonstrated to decrease FA oxidation rates, the increased accumulation of 16:0
carnitine could also indicate malonate-facilitated inhibition of β-oxidation in HG-cultured
BeWo CT cells [78]. Future studies and the use of radio-labelled metabolites may be
required to further characterize glycolytic activity, de novo lipogenesis, and β-oxidation
in high-glucose exposed BeWo trophoblasts.
The observed accumulation of riboflavin (the essential vitamin B2) in HGcultured BeWo CT cells either reflects an increased cellular uptake of riboflavin or an
inhibition of riboflavin metabolism into the cofactors flavin adenine dinucleotide (FAD)
and flavin mononucleotide (FMN) [81]. Reduced metabolism of riboflavin to its cofactor
intermediaries has previously been implicated in the development of mitochondrial
dysfunction [82]. However, riboflavin has also previously been suggested to act as an
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antioxidant [83] and has been demonstrated to be beneficial in reducing oxidative stress
in rodent models of DM [84,85]. Future investigations may be needed to assess the
impacts of riboflavin accumulation in HG-cultured trophoblasts and elucidate whether
accumulation of this vitamin is beneficial or harmful to the placenta.

3.4.5

Conclusion
The results of the current study highlighted that a 72-hour hyperglycemia

exposure independently impacts metabolic function and nutrient storage in BeWo
trophoblasts but does not mediate any global changes in functional readouts of
mitochondrial respiratory activity. Interestingly, HG-cultured BeWo trophoblasts
displayed markers of reduced glycogen storage capacity that potentially increases the
supply of free glucose for oxidation, as well as markers suggestive of a transition towards
altered mitochondrial dynamics, that overall may be indicative of early metabolic
adaptations, or of more concern, a transition towards mitochondrial failure. It is important
to note that while the 72-hour hyperglycemic exposure utilized in the current study is
relatively prolonged in the setting of in vitro cell culture experiments, this timeline is
acute in comparison to the 40-week duration of human pregnancy in vivo. Thus,
preventing even short periods of hyperglycemia may be important in the clinical
management of diabetic pregnancies to ensure appropriate placental function is sustained
throughout gestation, and in turn that the risk of the offspring developing later life noncommunicable metabolic diseases is limited.
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Impact BeWo Trophoblast Metabolism and Lipid
Processing: A Multi-OMICS Outlook

This chapter is a version of a manuscript under preparation for submission entitled
“Elevated Dietary Non-Esterified Fatty Acid Levels Impact BeWo Trophoblast
Metabolism and Lipid Processing: A Multi-OMICS Outlook”
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4.1 Introduction
Adverse intrauterine environments that arise in conditions of maternal obesity and
gestational diabetes mellitus (GDM) have been linked with an increased risk of
pregnancy complications [1–3]. Further, offspring from these at risk pregnancies have an
increased risk of developing non-communicable metabolic health disorders including
metabolic syndrome, obesity, and type 2 diabetes [4–8]. Alarmingly, these children have
been found to be impacted by these largely “adult-associated” metabolic diseases during
adolescence, highlighting the profound influence of the aberrant in utero programming
resulting from maternal obesity and GDM [9–11]. Investigating these poor health
outcomes is of great importance as the rates of obesity and gestational diabetes mellitus
(GDM) development during pregnancy have been increasing globally over the past
several decades [12,13]. It is currently estimated that one-third of pregnancies are
impacted by maternal obesity, and one-sixth of pregnancies are impacted by GDM,
however these rates may be greater in certain at-risk demographics [14–16]. These drastic
increase in the prevalence of maternal obesity and GDM and subsequent increased rates
of metabolic disease development in affected offspring will create further strains on
health care systems.
Aberrant placental metabolic function in diabetic and obese pregnancies may be
an important factor underlying the in-utero programming of metabolic diseases [17–19].
Specifically, impairments in mitochondrial respiratory (oxidative) function have been
identified in term villous trophoblast cells from obese and GDM pregnancies that impair
placental energy production and reduce ATP content [20–24]. Furthermore, maternal
obesity alters placental lipid processing at term highlighted by increased fatty acid
desaturation, lipid esterification, and ultimately increased placental triglyceride
abundance and steatosis [25–27]. Placental lysates from obese pregnancies have also
been found to have decreased abundance of short-chain acylcarnitine species (β-oxidation
intermediary metabolites) and reduced CPT1b expression that is indicative of reduced
placental β-oxidative activity and suggests placental steatosis in obese pregnancies may
be facilitated by reduced placental lipid oxidation [25,28,29]. Maternal GDM has also
been associated with increased placental steatosis at term that has likewise been attributed
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to reduced placental β-oxidative activity, further highlighting adverse maternal
environmental conditions negatively regulate important aspects of placental lipid
processing [24,30–32].
Recently, studies have highlighted the utility of “omics” based research
approaches to help further identify and understand the underlying biological mechanisms
that facilitate the development of placental disorders in at-risk pregnancies [33,34]. For
example, metabolomic and lipidomic analyses have expanded our understanding of
possible mechanisms underlying impaired placental lipid processing in obese and GDM
pregnancies. These readouts have described altered neutral and polar lipid profiles
highlighted by altered fatty acid (FA) compositions in placentae from obese and diabetic
pregnancies [35–39]. Pre-clinical mouse models of diet induced maternal pre-gestational
obesity have likewise described metabolomic and transcriptomic markers indicative of
altered placental lipid composition and metabolism, further highlighting the prevalence of
abnormal lipid processing in the obese placenta [40,41]. These alterations in placental
metabolic function and lipid handling likely leads to suboptimal transplacental nutrient
transport that impairs fetal growth, and development and ultimately resulting in in utero
programming of metabolic diseases [36,42].
Underlying the development of this aberrant placental function in obese and
GDM pregnancies is an increased fat supply to the placenta as a result of maternal
dyslipidemia [43,44]. Analysis of the fasting serum of women during the third trimester
of pregnancy has revealed that conditions of GDM and obesity elevate circulating levels
of non-esterified fatty acids (NEFA) species [45]. These analyses also demonstrated that
palmitate (C16:0; PA) and oleate (C18:1n9c; OA) are the most abundant NEFA species
in serum during pregnancy [45,47]. Since PA and OA are the most abundantly consumed
FA in the diets of Westernized populations, these fats themselves may be a link between
poor maternal diet and impaired placental function in obese and GDM pregnancies [48–
51]. Notably, maternal fat consumption has previously been demonstrated to be an
important regulator of placental lipid handling [26,46]. Thus, it is likely the increased
circulating NEFA levels in obese and GDM pregnancies directly impacts placental
metabolism. However, the extent to which PA and OA directly impact important
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placental lipid metabolic functions such as lipid esterification, FA desaturation, and betaoxidation remains poorly understood.
The purpose of the current project, therefore, was to examine the impacts of a
prolonged (72 hour) isolated dietary-FA exposure using an in vitro cell culture-based
system and BeWo trophoblast cells to elucidate the underlying mechanisms that regulate
placental nutrient processing and metabolism in response to elevated dietary fat supply.
Our first objective was to utilize targeted lipidomic readouts to examine FA and neutral
lipid profiles of BeWo cytotrophoblast (CT) and syncytiotrophoblast (SCT) cells, to gain
an initial understanding of how NEFA exposures impact placental lipid processing. These
analyses were additionally used to elucidate the impacts of NEFA exposures on placental
FA desaturation and elongation processing. It was postulated that exposure to elevated
levels of dietary NEFA would alter BeWo trophoblast lipid profiles, highlighted by
increased TG abundance, and increased FA elongation and desaturation.
The second objective of this project was to utilize transcriptomics, in conjunction
with untargeted metabolomics and lipidomics to characterize the underlying mechanisms
that regulate BeWo CT metabolism in response to elevated dietary NEFA supply. As
progenitor CT cells have previously been demonstrated to be the most metabolically
active cells of the placenta villous trophoblast layer as well as the primary site of nutrient
localization and storage in the placenta [24,52–54], the current study sought to examine
“omic” profiles only in the more metabolically active CT cells. We postulated that
dietary-FA treated BeWo CT cells would display altered transcriptomic, metabolomic
and lipidomic profiles indicative of altered lipid processing.
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4.2 Materials and methods:
4.2.1

Materials
All materials were purchased from Millipore Sigma (Oakville, Canada) unless

otherwise indicated.

4.2.2

Cell culture protocol
BeWo trophoblast cells (CCL-98) were purchased from the American Type

Culture Collection (ATCC; Cedarlane Labs, Burlington, Canada) and cultured in F12K
media (Gibco, ThermoFisher Scientific, Mississauga, Canada) as per ATCC guidelines.
Cell culture media was supplemented with 10% Fetal Bovine Serum (Gibco) and 1%
Penicillin-Streptomycin (Invitrogen, ThermoFisher Scientific, Mississauga, Canada) for
all experiments (complete F12K media). Cultures between passages 5-15 were utilized,
and all cells were maintained at 5% CO2/95% atmospheric air for all collections.
Cells were then cultured with exogenous NEFA species as previously reported in
Chapter 2 [52]. In brief, BeWo trophoblast cells were plated onto cell culture dishes at
the specific densities stated for each experiment and allowed to adhere to cell culture
plates overnight prior to NEFA treatments. At T0H, cells were treated with complete
F12K media further supplemented with either 100 µM PA, 100 µM OA, or 50 µM each
PA and OA (P/O). All FAs were conjugated 2:1 (molar ratio) to Bovine Serum Albumin
(BSA) for solubility in cell culture media. Complete F12K media supplemented with
BSA-alone (0.3%) was utilized as a control. Cell media was replenished every 24 hours,
and subsets of cells were additionally treated with 250 µM 8-Br-cAMP at T24H and
T48H to induce CT-to-SCT differentiation. All cultures were collected for analysis after
72H of NEFA exposure.
This duration of NEFA exposure was specifically utilized as it represented the
longest treatment period possible without being required to sub-culture the cells due to
increasing confluency. Additionally, the 100 µM concentrations of NEFAs utilized were
reflective of physiological fasting levels of PA and OA during the third trimester of
gestation [45], and more importantly in Chapter 2 were found to not impact BeWo
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trophoblast viability or differentiation capacity at 72-hours [52]. Thus, the data presented
in the current study highlight alterations in placental metabolic function independent
from lipotoxic effects.

4.2.3

Fatty acid and neutral lipid profile analysis
BeWo CT and SCT cells were plated at a density of 2x106 cells in 150 mm cell

culture dishes and cultured with exogenous NEFA species as described. At T72H cells
were collected via scraping and washed twice with PBS, and the resulting cell pellet was
flash frozen in liquid nitrogen and stored at -80℃ until analyzed.
Total cellular lipids were then collected from cell pellets via chloroform/methanol
extraction (Folch extraction method) as has previously been reported and adapted for use
with cell pellets [55–57]. In brief, cells were lysed in 2:1 chloroform:methanol with
0.01% butylated hydroxytoluene (BHT). Subsequently, 0.25% KCl was added, and
samples were heated at 70℃ for 5 mins to separate lipid and aqueous layers. Collected
lipids were then dried under a gentle stream of N2 gas, and resuspended in 2:1
chloroform:methanol (0.01% BHT) at 1 mg/mL concentrations and stored at -20℃ until
analysis.
To examine FA profiles, 100 µg of lipids were methylated to create FA methyl
esters (FAMEs), and subsequently separated and analyzed using gas chromatography
coupled flame ionization detection (GC-FID), as previously reported [56,57]. A 6890 N
gas chromatograph (Hewlett Packard, Palo Alto, CA, USA) with flame ionization
detector (Agilent Technologies, Santa Clara, CA, USA) and a J&W Scientific HighResolution Gas Chromatography Column (DB-23, Agilent Technologies; 30 m×250 μm
ID×0.25 μm film thickness) was utilized for the GC-FID. Helium was used as the carrier
gas. Separated FA species were then identified via comparison of retention times with
known standards (Supelco 37 Component FAME Mix). The peak area of each FA was
then quantified and expressed as a percent of total FAs detected.
Calculated FA profiles were then utilized to quantify the activities of FA
desaturase enzymes by calculating desaturation indices which reflect the ratio of enzyme
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product to substrate. Stearoyl-CoA Desaturase 1 (SCD1) activity was calculated as the
ratio of 16:1n7/16:0 as well as 18:1n9/18:0; Fatty Acid Desaturase 1 (FADS1) activity
was calculated as the ratio of 20:4n6/20:3n6; and Fatty Acid Desaturase 2 (FADS2)
activity was calculated as the ratio of 18:3n6/18:2n6 as previously reported [58–61].
Additionally, FA elongation indices of 20:1n9/18:1n9; 18:0/16:0 and 22:5n3/20:5n3 were
quantified to calculate the activity of FA elongase enzymes (reflective of enzyme product
to substrate ratio) as has previously been reported in placental lysates [62].
Finally, the profiles of neutral lipid species of NEFA treated BeWo trophoblasts
were analyzed via Thin Liquid Chromatography coupled Flame Ionization Detection
(TLC-FID) as previously described [63]. In brief, collected lipid samples were dried
under a gentle stream of N2 gas and resuspended in 100% chloroform. 1-4 µL of lipids
were then spotted onto TLC rods (Chromarod Type S5; Shell-USA, Spotsylvania, VA,
USA) and developed in a TLC chamber with benzene:chloroform:formic acid (70:30:0.5
v/v/v). Chromatography rods were then dried and analyzed using the Iatroscan MK-6
TLC-FID system (Shell-USA). Peaks were identified via comparison with known
standards, and neutral lipid peak area was quantified and expressed as a percentage of all
neutral lipid species identified.
Percent FA composition, percent neutral lipid composition and desaturation index
data was analyzed via Randomized Block Two-Way ANOVA (2WA) and Tukey’s
Multiple Comparisons Test. All statistical analysis was performed with GraphPad Prism
v9.2.0 software (GraphPad Software, San Diego, CA, USA).

4.2.4

Transcriptomic analysis of gene expression changes
BeWo CT cells were plated at a density of 3.5*105 cells/well in 60 mm cell

culture dishes and cultured with exogenous NEFAs as described above. At T72H the CT
cells were washed once with PBS and collected in 0.9 mL TRIzol reagent (Invitrogen)
and stored at -80℃. Samples were then sent to the Genome Québec Innovation Centre for
transcriptomic analysis using the Clariom S mRNA microarray (ThermoFisher Scientific,
Mississauga, Canada) as detailed in Chapter 3.
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Microarray data was subsequently analyzed using Transcriptome Analysis
Console v4.0 (ThermoFisher Scientific). Raw data was normalized using the Robust
Multiple-Array Averaging (RMA) method. Each NEFA treatment condition was then
compared to the BSA control group in binary, and samples collected from the same
passage were paired for analysis. Transcripts with ≥ ±1.3 fold-change (FC) vs BSA
control, and raw p-value < 0.05 were determined to be differentially expressed. Each set
of differentially expressed genes was then imported into the WEB-based Gene SeT
AnaLysis Toolkit (WebGestalt) for enrichment analysis of functional pathways using the
Wikipathways database. Functional pathways with FDR-corrected p-value < 0.05 were
considered to be significantly enriched.

4.2.5

RT-qPCR validation of differentially expressed genes
identified by mRNA microarray
Differentially expressed genes involved in lipid metabolic processes were

subsequently individually identified and selected for validation by RT-qPCR. RNA
extracted by Genome Québec for mRNA microarray analysis, as well as the RNA
extracted for analysis of BeWo syncytialization in Chapter 2 was utilized for RT-qPCR
validation. In brief, 2 µg of RNA was reverse transcribed using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems; ThermoFisher Scientific). RT-qPCR was
subsequently performed using sample cDNA and the CFX384 Real Time System (BioRad, Mississauga, Canada). Relative expression of genes of interest was then determined
using the ∆∆Ct method, with the geometric mean of PSMB6 and GAPDH utilized as a
reference. The expression of genes of interest were analyzed in each NEFA treatment in
binary versus BSA control samples via paired two-tailed T-test. The sequences of RTqPCR primers utilized for microarray validation are available in Table 4-1.
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Table 4-1 Primer sequences used for quantitative Real-Time PCR validation of
NEFA treatment microarrays, and their efficiencies.
Gene

Accession No.

GAPDH

NM_001357943.2

Annealing
Temperature
(°C)
60

PSMB6

NM_002798

60

ACACA

NM_198838.2

60

ACACB

NM_001093.4

60

ACADVL

NM_000018.4

60

ACSL5

NM_203379.2

60

AQP3

NM_004925.5

60

CREB3L3

NM_032607.3

60

PLIN2

NM_001122.4

60

SCD1

NM_005063.5

60

4.2.6

Primer Sequences

Efficiency

F – ATGGCATCAAGAAGGTGGTG
R – CATACCAGGAAAATGAGCTTG
F –CGGGAAGACCTGATGGCGGGA
R – TCCCGGAGCCTCCAATGGCAAA
F –GGAGGTGCAGATCTTAGCGG
R – CACAGTCCCAGCACTCACAT
F –ATTGCCAACAACGGGATTGC
R – GGGACGTAATGATCCGCCAT
F –CAGGTGTTCCCATACCCGTC
R – GGGATCGTTCACTTCCTCGAA
F –CACCCCAAAAGGCATTGGTG
R – AGGTCTTCTGGGCTAGGAGG
F –CATCTACACCCTGGCACAGA
R – ATTGGGGCCCGAAACAAAAAG
F –TTTTGGCCCCAACAAAACCG
R – GCAGCATCGTTGTGCAAAGT
F –ACCTCTCATGGGTAGAGTGGAA
R – CACCTTGGATGTTGGACAGG
F –TTCGTTGCCACTTTCTTGCG
R – AAGTTGATGTGCCAGCGGTA

102.0%
92.8%
95.2%
105.5%
98.5%
95.3%
98.3%
102.4%
100.9%
97.6%

Cell collections for untargeted metabolomic and lipidomic
profiling of BeWo CT cells.
BeWo trophoblasts were plated at a density of 2x106 cells/plate in 150 mm cell

culture dishes and cultured with exogenous NEFAs as described above. AT T72H cell
media was aspirated and cells were washed three times with cold PBS. Cellular
metabolism was quenched with methanol, and cells were dried under a gentle stream of
nitrogen and subsequently by lyophilization. Samples were then shipped to the
Metabolomics Innovation Centre (Edmonton, Canada) for untargeted metabolomic and
lipidomic profiling of NEFA treated BeWo CT cells as detailed in Chapter 3.

4.2.7

Untargeted metabolomic profiling
The collected metabolomic peak-pair data was then imported into IsoMS pro

v1.2.7 for data processing and statistical analysis. Metabolites with ≥ ±1.2 FC and raw pvalue < 0.05 in each NEFA treatment versus BSA control were determined to be
differentially abundant. Peak pairs of metabolites identified in tiers 1 and 2 that have an
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associated KEGG pathway ID number were then imported into MetaboAnalyst v5.0
software for pathway enrichment analysis (using the homo sapiens KEGG Library) to
determine biological impacts of differentially abundant metabolites. KEGG pathways
with raw p-value < 0.05 were determined to be significantly enriched.

4.2.8

Integration of BeWo cytotrophoblast transcriptomic and
metabolomic profiles
Peak Pair data of metabolites in tiers 1 and 2 that have an associated KEGG ID

number were imported into MetaboAnalyst v5.0, and metabolites with a ≥ ±1.2 FC and
raw p-value < 0.05 in each NEFA treatment were identified. These differentially
abundant metabolites associated with a KEGG ID number were subsequently integrated
with the list of Differentially Expressed Genes (DEGs) identified in the Clariom S
mRNA microarray using the Joint Pathway Analysis Tool in MetaboAnalyst v5.0 to
determine enriched pathways containing both DEGs and differentially abundant
metabolites. KEGG pathways with raw p-value < 0.05 were determined to be
significantly enriched.

4.2.9

Untargeted lipidomic profiling
Lipidomic profiling of NEFA-treated BeWo CT cells wads performed as detailed

in Chapter 3. Identified and normalized lipid feature intensities were then imported in
MetaboAnalyst v5.0 for statistical analysis. Lipid species in each NEFA treatment
condition with ≥ ±1.5 FC and raw p-value < 0.05 versus BSA control samples were
considered to be differentially abundant. The peak intensities of lipid species from each
lipid class from tiers 1 and 2 were subsequently summed to determine the total abundance
of each lipid class in the NEFA treatments. These summed data were imported into
MetaboAnalyst v5.0 and the total lipid class intensities of each NEFA condition were
compared in to the BSA control in binary using a Wilcoxon rank-sum test to determine
differentially abundant lipid classes in each NEFA treatment. Significance was
determined with a Bonferroni-correct p-value of p<0.0167.
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4.2.10

Supplementary data and materials

Microarray data are available on the National Center for Biotechnology
Information (NCBI) Gene Expression Omnibus (GEO) database (GSE197385).
Supplementary tables were uploaded to a publicly available data repository
(doi.org/10.5683/SP3/XMPKOK) and can be accessed via the Digital Object Identifier
(DOI) webpage address. Metabolomic and lipidomic peak-pair data are available in
Supplementary Tables 9 and 14, respectively.

4.3 Results
4.3.1

NEFA-treatments impact FA profiles of BeWo trophoblasts
A total of 10 saturated FAs (SFA) species, 6 monounsaturated FA (MUFA)

species, and 9 polyunsaturated FA (PUFA) species were detected in all BeWo trophoblast
samples from at least 4 out of 5 experimental replicates. Palmitic acid (16:0), stearic acid
(18:0), Oleic acid (18:1n9c) and arachidonic acid (20:4n6) were highlighted as the most
abundant FA species in BeWo trophoblast cultures (Table 4-2, n=4-5/group).
PA-treated BeWo cultures displayed increased relative abundances of total SFA
species, 16:0, 16:1n7, 22:2, and 20:5n3 as well as decreased relative abundances of total
MUFA species, 18:0, and 18:1n9c in both CT and SCT cultures compared to respective
differentiation state BSA-control (Table 4-2; p<0.05, n=4-5/group). PA-treated BeWo
CT cells further displayed increased relative abundance of 22:5n3, while PA-treated
BeWo SCT cells displayed reduced relative abundances of 18:1n7 and 18:2n6 versus
respective BSA-control cultures (Table 4-2; p<0.05, n=4-5/group).
Further, OA-treatment in BeWo CT and SCT trophoblasts was associated with an
increased relative abundance of total MUFA species, 18:1n9c, and 20:1n9 as well as a
reduced relative abundance of total SFA and PUFA species, 18:0, 24:0, 16:1n7, 18:1n7,
16:3n4, 18:2n6, 20:3n6, 20:4n6, and 22:5n3 versus respective differentiation state BSAcontrol cultures (Table 4-2; p<0.05, n=4-5/group). Additionally, OA-treated BeWo CT
cells displayed a significantly decreased relative abundance of 14:0, and 16:0 while OA-
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treated BeWo SCT cells displayed a significantly reduced relative abundance of 18:3n6
versus respective differentiation state BSA-control (Table 4-2; p<0.05, n=4-5/group).
P/O-treated BeWo CT and SCT cells were found to have an increased relative
abundance of total MUFA species, 20:1n9, and 20:2 as well as decreased relative
abundances of 18:0, 24:0, 18:1n7, 18:2n6, and 20:3n6 compared to BSA-control cultures
(Table 4-2; p<0.05). P/O-cultured BeWo CT cells further demonstrated an increased
relative abundance of 18:1n9c as well as decreased relative abundance of total SFA
species, 14:0, 16:1n7, and 16:3n4 versus BSA-control CT cultures (Table 4-2; p<0.05,
n=4-5/group). Additionally, P/O-treated BeWO SCT cells displayed a decreased relative
abundance of 18:3n6 compared to BSA-control SCT cultures (Table 4-2; p<0.05, n=45/group).
Syncytialization of BeWo cultures was associated with reduced relative
abundances of 20:1n9 and 20:2, as well as increased relative abundances of 18:2n6 and
20:4n6 compared to BeWo CT cells (Table 4-2; p<0.05, n=4-5/group).
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Table 4-2 FA profiles (% mol) of NEFA-treated BeWo trophoblast cells.
FA
Species

BSA Ctrl

PA

OA

P/O

BSA Ctrl

PA

OA

P/O

ΣSFA
8:0
10:0
14:0
15:0
16:0
18:0
20:0
22:0
23:0
24:0

39.64 ± 1.1 a
0.63 ± 0.23
0.40 ± 0.14
1.43 ± 0.35 a
0.54 ± 0.16
19.73 ± 0.81 a
14.98 ± 0.48 a
0.78 ± 0.06
0.68 ± 0.11
0.49 ± 0.14
1.02 ± 0.05 a

44.91 ± 1.63 b
0.32 ± 0.11
0.31 ± 0.09
0.85 ± 0.31 ab
0.51 ± 0.19
27.84 ± 2.12 b
12.79 ± 0.76 b
0.94 ± 0.09
0.80 ± 0.16
0.58 ± 0.11
1.08 ± 0.07 a

20.73 ± 1.04 c
0.40 ± 0.16
0.37 ± 0.11
0.52 ± 0.12 b
0.19 ± 0.03
8.27 ± 0.81 c
9.23 ± 0.41 c
0.79 ± 0.16
0.47 ± 0.10
0.52 ± 0.02
0.70 ± 0.06 b

33.28 ± 2.99 d
0.54 ± 0.10
0.37 ± 0.11
0.74 ± 0.25 b
0.34 ± 0.14
17.52 ± 2.87 a
12.04 ± 0.79 b
0.74 ± 0.07
0.53 ± 0.06
0.64 ± 0.05
0.79 ± 0.07 b

37.20 ± 0.92 a
0.49 ± 0.14
0.21 ± 0.07
1.03 ± 0.33
0.45 ± 0.10
16.32 ± 0.78 ab
16.20 ± 0.36 a
1.21 ± 0.17
0.76 ± 0.11 ab
0.23 ± 0.03
0.98 ± 0.05 a

44.67 ± 0.85 b
0.34 ± 0.12
0.24 ± 0.05
0.68 ± 0.24
0.59 ± 0.19
28.07 ± 1.37 c
12.46 ± 0.89 b
1.10 ± 0.24
0.91 ± 0.08 a
0.44 ± 0.12
0.89 ± 0.05 a

24.32 ± 3.18 c
0.45 ± 0.11
0.30 ± 0.07
0.40 ± 0.08
0.28 ± 0.02
12.17 ± 3.01 a
9.26 ± 0.41 c
0.73 ± 0.10
0.47 ± 0.07 b
0.27 ± 0.03
0.54 ± 0.02 b

34.25 ± 3.29 a
0.45 ± 0.06
0.21 ± 0.05
0.58 ± 0.18
0.48 ± 0.14
19.74 ± 2.80 b
10.98 ± 0.43 bc
0.92 ± 0.14
0.74 ± 0.08 ab
0.41 ± 0.09
0.63 ± 0.05 b

CT
vs
SCT
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

ΣMUFA
16:1n7
18:1n9c
18:1n9t
18:1n7
20:1n9
22:1n9

42.82 ± 1.14 a
3.12 ± 0.18 a
33.09 ± 1.32 a
0.23 ± 0.02
5.99 ± 0.26 a
0.49 ± 0.02 a
0.29 ± 0.13

36.29 ± 1.21 b
5.23 ± 0.67 b
24.76 ± 1.59 b
0.34 ± 0.08
5.69 ± 0.23 a
0.45 ± 0.02 a
0.21 ± 0.08

68.11 ± 1.26 c
0.80 ± 0.12 c
63.73 ± 1.47 c
0.38 ± 0.07
2.91 ± 0.17 b
1.46 ± 0.08 b
0.19 ± 0.01

49.99 ± 4.19 d
1.87 ± 0.42 c
43.84 ± 4.64 d
0.23 ± 0.04
3.78 ± 0.31 c
0.92 ± 0.14 c
0.20 ± 0.03

42.91 ± 1.15 a
2.86 ± 0.33 a
32.65 ± 1.29 a
0.28 ± 0.03
6.86 ± 0.23 a
0.48 ± 0.04 a
0.16 ± 0.03

34.91 ± 0.43 b
6.20 ± 0.46 b
23.08 ± 0.54 b
0.46 ± 0.23
4.89 ± 0.20 b
0.37 ± 0.02 a
0.24 ± 0.09

63.40 ± 4.28 c
1.43 ± 0.41 c
62.64 ± 0.68 c
0.33 ± 0.07
3.03 ± 0.16 c
0.99 ± 0.10 b
0.18 ± 0.02

49.35 ± 4.35 d
2.42 ± 0.39 ab
38.52 ± 0.83 ab
0.41 ± 0.19
3.39 ± 0.18 c
0.77 ± 0.17 c
0.20 ± 0.06

NS
NS
NS
NS
NS
*
NS

ΣPUFA
16:3n4
18:2n6
18:3n6
20:2
20:3n6
20:4n6
20:4n3
20:5n3
22:5n3

16.30 ± 0.94 ab
0.34 ± 0.04 ab
2.52 ± 1.21 ab
0.230 ± 0.005
1.48 ± 0.12 ab
1.45 ± 0.07 ab
8.68 ± 0.39 ab
0.15 ± 0.06
0.54 ± 0.14 ac
0.43 ± 0.05 a

17.47 ± 0.82 a
0.23 ± 0.02 ab
1.36 ± 0.24 a
0.234 ± 0.029
3.03 ± 0.24 b
1.43 ± 0.08 a
9.18 ± 0.50 a
0.19 ± 0.10
0.95 ± 0.14 b
0.52 ± 0.03 b

9.18 ± 0.44 c
0.16 ± 0.02 b
0.61 ± 0.04 b
0.194 ± 0.006
1.69 ± 0.11 a
0.72 ± 0.05 b
5.08 ± 0.25 b
0.07 ± 0.01
0.16 ± 0.02 a
0.31 ± 0.01 c

15.02 ± 1.79 b
0.22 ± 0.03 b
0.82 ± 0.08 b
0.226 ± 0.022
3.23 ± 0.48 b
1.09 ± 0.12 c
8.07 ± 0.94 a
0.15 ± 0.04
0.64 ± 0.15 bc
0.39 ± 0.04 ac

18.89 ± 0.78 a
0.37 ± 0.04 a
3.24 ± 0.98 a
0.324 ± 0.016 a
0.97 ± 0.15 a
1.66 ± 0.06 a
11.12 ± 0.28 a
0.14 ± 0.03
0.39 ± 0.05 a
0.53 ± 0.01 a

18.96 ± 0.42 a
10.68 ± 1.24 b
0.30 ± 0.05 a
0.19 ± 0.02 b
1.45 ± 0.04 b
0.94 ± 0.04 c
0.265 ± 0.024 ab 0.201 ± 0.009 c
2.00 ± 0.18 b
1.23 ± 0.27 a
1.46 ± 0.05 a
0.76 ± 0.08 b
11.34 ± 0.38 a
6.52 ± 0.78 b
0.28 ± 0.11
0.08 ± 0.02
0.92 ± 0.13 b
0.27 ± 0.06 a
0.61 ± 0.02 a
0.33 ± 0.02 b

14.84 ± 1.27 b
0.28 ± 0.03 ab
1.11 ± 0.07 c
0.235 ± 0.011 bc
1.83 ± 0.23 b
1.03 ± 0.08 c
8.82 ± 0.85 c
0.21 ± 0.09
0.63 ± 0.11 ab
0.41 ± 0.04 b

NS
NS
*
NS
*
NS
*
NS
NS
NS

CT

SCT

Data are mean ± SEM (n=4-5/group). Different lower-case letters denote statistical difference in FA abundance between NEFA
treatments within a differentiation state. * denotes a differentiation state dependent difference in FA abundance between BeWo CT
and SCT cells; NS indicates no statistical significance between differentiation states.
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4.3.2

The impact of NEFA treatments on desaturation and
elongation indices in BeWo trophoblasts
FA profile data was utilized to quantify the activity of FA desaturase and elongase

enzymes via calculation of the ratios of enzyme products to substrates
(desaturation/elongation index). OA and P/O-treated BeWo SCT and SCT cells displayed
a reduced SCD1 index compared to respective BSA-control cultures when assessed by
the 16:1n7/16:0 index (Figure 4-1 A; p<0.05, n=5/group). However, when the SCD1
index was assessed by the ratio of 18:1n9c/18:0, OA and P/O-treated BeWo CT and SCT
cells were found to have increased SCD1 activity compared to respective BSA-control
cultures (Figure 4-1 B; p<0.05, n=5/group). Furthermore, OA-treated BeWo CT cells
displayed an increased FADS2 index (Figure 4-1 C; p<0.05, n=5/group) while OAtreated SCT cells displayed increased FADS2 and FADS1 indices compared to BSAcontrol cultures (Figure 4-1 C,D; p<0.05, n=5/group). P/O-treated BeWo CT and SCT
also displayed increased FADS1 and FADS2 indices compared to BSA-controls (Figure
4-1 C,D; p<0.05, n=5/group). Finally, PA-treated BeWo SCT cells displayed an
increased FADS2 index compared to BSA-control SCT cells (Figure 4-1 C; p<0.05,
n=5/group). BeWo syncytialization was additionally linked with an increased SCD1
(when assessed as 16:1n7/16:0), and FADS1 index as well as with a decreased FADS2
index (Figure 4-1 A,C,D; p<0.05, n=5/group).
OA-treatment was additionally increased elongation of 18:1n9, 16:0, and 20:5n3
in BeWo CT cells, while P/O-treated BeWo CT were only observed to have increased
18:1n9 elongation (Figure 4-2 A-C). PA-treatment in BeWo SCT cells, however, was
linked with reduced 16:0, and 20:5n3 elongation (Figure 4-2 B,C). BeWo SCT also
displayed an overall reduced elongation of 18:1n9 compared to BeWo CT cells (Figure
4-2 A).
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Figure 4-1 FA desaturase enzyme activity indices in NEFA-treated BeWo CT and
SCT cells.
The abundance of desaturase enzyme substrate and product FAs were quantified via Gas
Chromatography-coupled Flame Ionization Detection, and the activity of each desaturase
enzyme was quantified via desaturation index, reflecting the ratio of enzyme product to
substrate. The Stearoyl-CoA Desaturase-1 (SCD1) index was quantified via the ratios (A)
16:1n7/16:0 ratio and (B) 18:1n9/18:0; (C) the Fatty Acid Desaturase 1 index was
quantified via the ratio of 18:3n6/18:2n6; and (D) the Fatty Acid Desaturase 2 index was
quantified via the ratio of 20:4n6/20:3n6 (N=5/group; different upper-case letters denote
statistical significance between NEFA treatments within each BeWo differentiation state,
and different lower-case represents statistical significance between differentiation states;
Two-Way Randomized Block ANOVA, Tukey’s multiple comparisons Test).
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Figure 4-2 FA elongase enzyme activity Indices in NEFA-treated BeWo CT and
SCT cells.
The abundance of products and substrates of FA elongase enzymes were quantified via gas
chromatography coupled flame ionization detection. Subsequently the ratios of (A)
20:1n9/18:1n9, (B) 18:0/16:0, and (C) 22:5n3/20:5n3 (elongation indices) were quantified
to determine elongase enzyme activities (N=5/group; different upper-case letters denote
statistical significance between NEFA treatments within each BeWo differentiation state,
and different lower-case represents statistical significance between differentiation states;
Two-Way Randomized Block ANOVA, Tukey’s multiple comparisons Test).
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4.3.3

OA-treatment alters neutral lipid profiles of BeWo
trophoblasts
TLC-FID analysis of extracted lipids from BeWo cultures identified five neutral

lipid species in all samples. Specifically, these analyses identified cholesterol ester, free
FAs, triglycerides, free cholesterol, and diacylglycerols in the neutral lipid fractions of
BeWo trophoblast cells. OA-treated BeWo CT and SCT displayed increased relative
triglyceride abundances as well as decreased relative free cholesterol abundances relative
to respective differentiation state BSA-control cultures (Table 4-3; 2WA: NEFA
treatment p < 0.05, n=5/group).
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Table 4-3 Neutral lipid profiles of NEFA-treated BeWo trophoblast cells.
Neutral Lipid
Species
Cholesterol Esters
Free FAs
Triglycerides
Free Cholesterol
Diacylglycerols

CT
BSA Ctrl
10.07 ± 2.66
10.46 ± 3.67
15.99 ± 5.14 a
61.80 ± 6.21 a
1.68 ± 0.32

PA
25.46 ± 9.52
11.91 ± 5.12
17.12 ± 2.63 a
43.6 ± 5.91 bc
1.91 ± 0.77

OA
11.29 ± 2.28
8.90 ± 3.36
39.47 ± 2.59 b
37.84 ± 1.32 b
2.51 ± 0.35

SCT
P/O
15.44 ± 4.39
10.05 ± 4.04
18.35 ± 2.88 a
53.79 ± 3.88 ac
2.37 ± 0.42

BSA Ctrl
9.03 ± 1.69
11.33 ± 3.69
14.34 ± 1.97 a
62.88 ± 3.19 a
2.43 ± 0.89

PA
17.56 ± 6.19
9.93 ± 2.81
14.74 ± 1.51 a
56.39 ± 5.57 ab
1.38 ± 0.24

OA
12.19 ± 4.33
7.81 ± 2.89
30.86 ± 4.95 b
46.40 ± 4.62 b
2.75 ± 0.07

P/O
19.18 ± 7.54
8.72 ± 2.55
17.96 ± 1.19 a
52.24 ± 6.66 ab
1.90 ± 0.26

Data are percent of neutral lipid fraction (mean ± SEM; n=5/group). Different lower-case letters denote statistical differences
between NEFA-treatments within each differentiation state.
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4.3.4

Transcriptomic profiles of BeWo cytotrophoblasts are
impacted by NEFA treatment.
PA-treated BeWo CT cultures displayed 340 differentially expressed genes

(DEGs) (140 up-regulated, and 200 down-regulated); OA-treated CT cultures displayed
208 DEGs (88 up-regulated, and 120 down-regulated); and P/O-treated BeWo CT
cultures displayed 221 DEGs (96 up-regulated, and 125 down-regulated) when compared
to BSA-control CT cultures (≥ ± 1.3 FC vs BSA control CT cultures; raw-p < 0.05,
n=5/group). A 3D Principal Component Analysis (PCA) plot was constructed to visualize
the degree of separation in transcriptome profiles between the NEFA-treated BeWo CT
cells (Figure 4-3). Volcano plots were additionally constructed to visualize differentially
expressed transcripts in each NEFA-treatment versus the BSA control samples (Figure 44 A-C). A summary of the DEGs identified in each NEFA-treatment condition is
available in Supplementary Table 7 (doi.org/10.5683/SP3/XMPKOK).
The DEG sets from each NEFA condition were then imported into WebGestalt to
examine enrichment of functional pathways in the Wikipathways database. No
significantly enriched functional pathways were highlighted in the DEG sets for PA and
OA-treated BeWo CT cells (Figure 4-5 A,B; FDR-corrected p>0.05). The Fatty Acid
Biosynthesis Pathway (DEG involved were ACACB (+1.32 FC), ACSL5 (+1.77 FC),
ACSL6 (-1.34 FC), and SCD (-1.24 FC)) was found to be significantly enriched in the
P/O-cultured cells (Figure 4-5 C; FDR-corrected p < 0.05).

199

Figure 4-3 Principal Component Analysis (PCA) plot highlighting separation in
transcriptome profiles between NEFA-treated BeWo CT cells.
An unsupervised PCA plot was constructed to visualize the degree of separation in
transcriptomic profiles between PA-treated (purple dots), OA-treated (red dots), P/Otreated (green dots), and BSA-control (blue dots) BeWo CT cells.
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Figure 4-4 Volcano plot visualization of differentially expressed genes in BeWo CT
cells cultured with 100 µM NEFAs for 72 hours.
The transcriptome profiles of NEFA-treated BeWo cytotrophoblast cells was determined
via Clariom S mRNA microarray, and differentially expressed genes were determined with
± 1.3 fold-change and raw p < 0.05 cut-offs. Volcano plots were constructed to visualize
differentially expressed genes in (A) PA-treated cells; (B) OA-treated cells; and (C) P/Otreated cells compared to BSA-alone treated cells (n=5/group). The x-axis indicates foldchange vs BSA control, and the y-axis indicates p-value (-log10). Red dots represent upregulated genes, green dots represent down-regulated genes while the black dots represent
non-statistically significant transcripts.
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Figure 4-5 Functional pathways enriched by NEFA-treatments in BeWo CT cells.
The WEB-based Gene SeT AnaLysis Toolkit (Webgestalt) was utilized to examine
functional pathway enrichment in (A) PA-treated; (B) OA-treated; and (C) P/O-treated
BeWo CT cultures. Each plot highlights the top 10 (by FDR-corrected p-value) functional
pathways enriched in the differentially expressed gene sets. Black bars represent
significantly enriched functional pathways (FDR-corrected p < 0.05), and grey bars
highlight non-significantly enriched functional pathways. The Fatty Acid Biosynthesis
pathway was identified as significantly enriched in P/O-treated BeWo CT cells.

202

4.3.5

RT-qPCR Validation of Differentially Expressed Genes
A Venn-diagram was additionally then constructed to visualize the DEGs that

were unique to each NEFA-treatment, as well as those common in two or all of the
NEFA-treatment conditions (Figure 4-6A). Twenty-three differentially expressed
transcripts were found to be common between PA and OA-treated CT cells; 32 DEGs
were common between PA and P/O treatments; and 9 genes were found to be
differentially expressed in both OA and PO-treated cells (Figure 4-6A). A further 9
genes were found to be differentially expressed in all NEFA-treated BeWo CT cells
(Figure 4-6 A). A summary list of unique and common DEGs is available in
Supplementary Table 8 (doi.org/10.5683/SP3/XMPKOK).
In PA-treated BeWo CT cells, RT-qPCR analysis confirmed differential expression of
ACACB (+1.57 FC microarray; +1.34 FC RT-qPCR); ACADVL (+1.32 FC microarray;
+1.47 FC RT-qPCR); ACSL5 (+1.77 FC microarray; +2.57 FC RT-qPCR); CREB3L3
(+2.31 FC microarray; +5.29 FC RT-qPCR); PLIN2 (+1.35 FC microarray; +1.83 FC
RT-qPCR) (Figure 4-6 B, p<0.05, n=9). It is important to note that SCD mRNA
abundance although statistically significant (p < 0.05) in the microarray panel did not
meet the ±1.3 FC cut-off to be considered differentially expressed in PA-treated CT cells
(-1.16 FC). However, subsequent RT-qPCR analysis highlighted a significant decrease in
SCD mRNA abundance in PA-treated BeWo CT cells (-1.24 FC; Figure 4-6 B, p<0.05,
n=9). The microarray panel also highlighted a significant downregulation in a transcript
best identified as ACACA, however RT-qPCR analysis demonstrated no significant
alterations in ACACA mRNA abundance (Figure 4-6 B, p=0.057, n=9). Finally, AQP3
was highlighted as differentially expressed in the microarray panel, however there was no
significant difference in AQP3 mRNA abundance when assessed by RT-qPCR (Figure 46 B, p=0.4287, n=9).
In OA-treated BeWo CT cells, RT-qPCR analysis confirmed the differential
expression of: ACSL5 (+1.87 FC microarray; +2.60 FC RT-qPCR); CREB3L3 (+2.48 FC
microarray; +7.38 FC RT-qPCR); PLIN2 (+1.46 FC microarray; +1.90 FC RT-qPCR);
and SCD (-1.41 FC microarray; -1.98 FC RT-qPCR) (Figure 4-6 C, p<0.05, n=9). The
microarray panel also highlighted a significant increase in ACADVL mRNA abundance
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although this transcript did not meet the ±1.3 FC cut-off to be considered differentially
expressed. However, the RT-qPCR analysis highlighted a significant increase in
ACADVL mRNA abundance in OA-treated BeWo CT cells (+1.43 FC; Figure 4-6 C,
p<0.05, n=9).
In P/O-treated BeWo CT cells, RT-qPCR analysis confirmed the differential
expression of ACACB (+1.32 FC microarray; +1.12 FC RT-qPCR); ACSL5 (+1.77 FC
microarray; +2.50 FC RT-qPCR); CREB3L3 (+2.13 FC microarray; +6.23 FC RTqPCR); PLIN2 (+1.30 FC microarray; +1.79 FC RT-qPCR); and SCD (-1.34 FC
microarray; -1.52 FC RT-qPCR) (Figure 4-6 D; p<0.05, n=9/group). The RT-qPCR
analysis additionally highlighted a significant increase in the expression of ACADVL
(+1.48 FC) and a decrease in the expression of ACACA (-1.32 FC) (Figure 4-6 D,
p<0.05, n=9/group). Interestingly, the expression of both ACADVL (+1.22 FC, p=0.0609)
and ACACA (-1.11 FC, p=0.0862) were trending towards significance in the microarray
panel.
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Figure 4-6 Venn-diagram representation of differentially expressed genes between
NEFA-treated BeWo CT cells and RT-qPCR validation of differentially expressed
genes.
(A) A Venn-diagram was constructed to visualize the number of differentially expressed
transcripts that are unique to each NEFA-treatment or common to multiple NEFAtreatments. Differential expression of genes involved in lipid metabolic processes were
validated in (B) PA, (C) OA, and (D) P/O-treated BeWo CT cells via RT-qPCR. RT-qPCR
data were analyzed via paired two-tailed t-test (n=9/group), and the data expressed as foldchange vs BSA-control cultures (mean±SEM). *indicates ≥ ±1.3 FC vs BSA-control,
p<0.05 for microarray data; and p<0.05 for RT-qPCR data. #indicates <1.3 FC vs BSAcontrol, p<0.05 for microarray data.
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4.3.6

Metabolomic profiles of BeWo Cytotrophoblast in response
to NEFA treatment
On average, 6569 ± 50 (± SD) metabolite features were identified in each NEFA-

treated BeWo CT samples. A summary of the identified metabolite features and peak-pair
data in NEFA-treated BeWo CT cells is available in Supplementary Table 9
(doi.org/10.5683/SP3/XMPKOK). Of these features, 179 metabolites were identified with
high confidence in tier 1 and a further 602 metabolites were identified with high
confidence in tier 2. In PA-treated cultures, 2 metabolites in tier 1, 7 metabolites in tier 2,
and 97 metabolites in tier 3 were found to be differentially abundant when compared to
BSA-control samples (≥ ±1.2 FC vs BSA control CT cultures, raw-p<0.05, n=5/group).
Furthermore, 5 metabolites identified in tier 1, 12 metabolites from tier 2, and 78
metabolites in tier 3 were found to be differentially abundant in OA-treated CT cells
when compared to BSA-control samples (≥ ±1.2 FC vs BSA control CT cultures, rawp<0.05, n=5/group). Finally, 7 metabolites identified in tier 1; 7 metabolites identified in
tier 2; and 92 metabolites identified in tier 3 were found to be differentially abundant in
P/O-treated BeWo CT cultures when compared to BSA-control samples (≥ ±1.2 FC vs
BSA control CT cultures, raw-p<0.05, n=5/group). A summary of the differentially
abundant metabolites (from all tiers) in each NEFA treatment versus the BSA control is
available in Supplementary Tables 10–12 (doi.org/10.5683/SP3/XMPKOK).
An unsupervised principal component analysis (PCA) 2D plot as well as
supervised partial-least squares discriminant analysis (PLS-DA) 2D plot was constructed
to visualize the degree of difference between metabolite profiles in all NEFA-treatment
groups (Figure 4-7). Volcano plots were constructed to visualize the differentially
abundant metabolite species in each NEFA-treatment group versus BSA-control samples
(Figure 4-8 A-C). Additionally, a Venn-diagram was constructed to highlight the number
of unique and shared differentially abundant metabolites in the NEFA treatments which
highlighted that most differentially abundant metabolites were unique to one NEFA
treatment (Figure 4-9). Only 3 high confidence identified metabolites from tiers 1 and 2
were found to be differentially abundant in at least 2 of the NEFA treatments.
Specifically, the abundance of Kahweol was found to be significantly increased (+1.69
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FC in OA; +1.64 FC in P/O), and the abundance of N-acetylethanolamine was found to
be significantly decreased in both the OA and P/O treatments (-1.66 FC in OA; -1.46 FC
in P/O), while the abundance of 3-hydroxymethylglutaric acid was found to be
significantly decreased in both the PA and P/O treatments (-2.89 FC in PA; -2.00 FC in
P/O). A summary of the unique and shared differentially abundant metabolites in the
NEFA-treated BeWo CT cells is available in Supplementary Table 13
(doi.org/10.5683/SP3/XMPKOK).
Analysis of KEGG pathway enrichment of the metabolite sets from tiers 1 and 2
was subsequently performed using MetaboAnalyst software. Scatterplots were created to
visualize the KEGG pathway nodes highlighted by each metabolite (Figure 4-10). No
significantly KEGG pathways were identified as significantly enriched in the metabolite
sets from PA and P/O-treated BeWo CT cells (Figure 4-10 A,C). The KEGG pathways
for i) Ether lipid metabolism (highlighted by increased sn-glycerol-3phosphoethanolamine (+3.44 FC) levels), ii) Amino sugar and nucleotide sugar
metabolism (highlighted by reduced 6-deoxy-L-galactose (-1.17 FC) levels); iii) Fructose
and mannose metabolism (highlighted by reduced 6-deoxy-L-galactose (-1.17 FC)
levels); and iv) Taurine and hypotaurine metabolism (highlighted by a trend towards
reduced abundance of 5-L-Glutamyl taurine (-1.82 FC; p=0.062) and 3-sulfino-L-alanine
(-1.47 FC; p=0.054)) were determined to be significantly enriched in the OA-treated CT
metabolite set (Figure 4-10 B).
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Figure 4-7 Multivariate visualization of the degree of separation between metabolite
profiles in NEFA-treated BeWo CT cells.
(A) Unsupervised principal component analysis (PCA) and (B) supervised partial least
squares discriminant analysis (PLS-DA) plots were utilized to visualize the degree of
difference in metabolite profiles between PA, OA, P/O and BSA-control cultures.
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Figure 4-8 Volcano plot visualization of the differentially abundant metabolites in
NEFA-treated BeWo CT cultures.
Volcano plots were constructed to visualize differentially abundant metabolites in (A) PAtreated; (B) OA-treated; and (C) P/O-treated BeWo CT cultures vs BSA-control cultures.
Statistically significant differentially expressed metabolites were determined as ≥ ±1.2
fold-change vs BSA-control and raw p <0.05 (n=5/group). The x-axis represents log2(foldchange) vs BSA-control and the y-axis represents p-value (-log10). Red dots represent
individual metabolites with significantly increased abundance while the blue dots represent
metabolites with significantly reduced abundance.
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Figure 4-9 Venn Diagram highlighting the number of shared and unique
differentially abundant metabolites in NEFA treated BeWo CT cells.
A Venn-diagram was constructed to visualize the number of differentially abundant
metabolites species that were unique to each NEFA-treatment or common to multiple
NEFA-treatments.
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Figure 4-10 Pathway analysis of metabolite profiles of NEFA-treated BeWo CT
cells.
Metabolite peak pairs identified in tier 1 and tier 2 were imported into MetaboAnalyst v5.0
for analysis of enriched KEGG pathways. Pathways with raw-p<0.05 were considered
significantly enriched and scatterplots were created for (A) PA-treated; (B) OA-treated;
and (C) P/O-treated cultures to visualize identified KEGG pathways. The x-axis represents
pathway impact and y-axis represents pathway enrichment p-value (-log10). The KEGG
pathways for i) Ether lipid metabolism; ii) Amino sugar and nucleotide sugar metabolism;
iii) Fructose and mannose metabolism; and iv) Taurine and hypotaurine metabolism were
highlighted to be significantly enriched in the OA-treated BeWo CT cultures.
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4.3.7

BeWo Cytotrophoblast transcriptome and metabolome
integration
Integration of the transcriptomic and metabolomic datasets revealed no

significantly enriched pathways in the KEGG database containing both differential genes
and differential metabolites in the PA and P/O-treated BeWo CT cells. However, the
integration analysis highlighted significantly enriched pathways only containing
differentially expressed genes in the PA and P/O treatments. Specifically, there was a
significant enrichment in the i) Inositol Phosphate Metabolism and ii)
Phosphatidylinositol Signaling System KEGG pathways (both highlighted by
downregulation of IMPA1 (-1.34 FC) and PIP5K1B (-1.37 FC) as well as upregulation of
PLCE1 (+1.50 FC) and INPP5D (+1.447 FC)) in the PA-treated BeWo CT cells, as well
as a significant enrichment in the i) Fatty Acid Biosynthesis KEGG Pathway (highlighted
by upregulation of ACACB (+1.32 FC) and ACSL5 (+1.77 FC) and downregulation of
ACSL6 (-1.34 FC)) in the P/O-treated BeWo CT cells (Figure 4-11 A,C; raw-p<0.05).
Integration analysis of the OA-treated BeWo CT cell transcriptome and
metabolome profiles highlight significantly enriched pathways containing both
differential genes and metabolites. Specifically, the i) Ether Lipid Metabolism pathway
(highlighted by increased accumulation of sn-glycero-3-phosphoethanolamine (+3.44 FC)
in conjunction with upregulation of GDPD1 (+1.34 FC) and downregulation of
PLA2G12A (-1.35 FC) and ii) Purine Metabolism pathway (highlighted by increased
levels of adenosine (+3.30 FC), inosine (+2.45 FC), and guanosine (+1.69 FC), in
conjunction with upregulation of PRPS1 (+1.31 FC), and ADK (+1.31 FC), as well as
downregulation of GMPR (-1.76 FC) were found to be significantly enriched in OAtreated BeWo CT cells (Figure 4-11 B).
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Figure 4-11 Joint Pathway Analysis of Transcriptome and Metabolome Profiles of
NEFA-treated BeWo CT cells.
Differentially expressed gene and differentially abundant metabolites (from identification
tiers 1 and 2) datasets were analyzed via the Joint Pathway Analysis module in
MetaboAnalyst Software. Pathways with raw-p<0.05 were considered significantly
enriched, and scatterplots were constructed to visualize identified pathways. The x-axis
represents pathway impact and y-axis represents pathway enrichment p-value (-log10). (A)
The i) inositol phosphate metabolism and ii) phosphatidylinositol signaling system KEGG
pathways were highlighted as significantly enriched in PA-treated BeWo CT cells. (B) The
i) ether lipid metabolism and ii) purine metabolism KEGG pathways were highlighted as
significantly enriched in the OA-treated BeWo CT cells. (C) The i) fatty acid biosynthesis
KEGG pathway was highlighted as significantly enriched in P/O-treated BeWo CT cells.
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4.3.8

The impact of NEFA-treatment of BeWo cytotrophoblast
lipidome profiles
An average of 9199 ± 295 (± SD) lipid species were identified in each sample. Of

these features, 950 were positively identified in tier 1, 161 were positively identified in
tier 2, and a further 6808 features were putatively identified in tier 3. A summary of the
identified features and peak-pair data for NEFA-treated BeWo CT cells and quality
control (QC) samples is available in Supplementary Table 14
(doi.org/10.5683/SP3/XMPKOK). An unsupervised principal component analysis (PCA)
2D plot as well as supervised partial-least squares discriminant analysis (PLS-DA) 2D
plot was constructed to visualize the degree of difference between lipidome profiles in all
NEFA-treatment groups and highlighted a separation in lipid profiles between the
different NEF treatments (Figure 4-12 A,B).
Non-parametric volcano plots were then constructed to visualize differentially
abundant lipid species in each NEFA-treatment compared to BSA-control samples
(Figure 4-13; ≥ ±1.5 FC vs BSA control; raw-p<0.05, n=5/group). In PA-treated
samples, 679 lipid species were found to have significantly reduced abundance, while
676 lipid species were found to have significantly increased abundance (Figure 4-13 A).
In OA-treated samples, 834 lipid species were found to have significantly reduced
abundance, while 799 lipid species were found to have significantly increased abundance
(Figure 4-13 B). In P/O-treated samples, 640 lipid species were found to have
significantly reduced abundance, while 639 lipid species were found to have significantly
increased abundance (Figure 4-13 C). A summary of the differentially abundant lipid
species is available in Supplementary Table 15 (doi.org/10.5683/SP3/XMPKOK).
Analysis of the totaled peak intensities of lipids from each independent class
revealed 8 differentially abundant lipid classes in PA-treated BeWo CT cells; 6
differentially abundant lipid classes in OA-treated BeWo CT cell; and 7 differentially
abundant lipid classes in P/O-treated BeWo CT cells (Figure 4-14 A-C; raw-p<0.0167,
n=5/group). A Venn-diagram was subsequently constructed to visualize the number of
shared and unique differentially abundant lipid classes in each NEFA treatment (Figure
4-15). Specifically, the abundance of lipids in the CER, PE, and PI classes were only
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significantly increased in PA-treated BeWo CT cells. The lipids in the BMP class were
only significantly decreased in OA-treated BeWo CT cells. No significantly altered lipid
classes were unique to the P/O treatment group. The Car, LPG and TG lipid classes were
found to be significantly elevated in all NEFA treatment groups relative to BSA control.
The DG class was significantly increased, and ST lipid class was significantly decreased
in both the PA and P/O treatments. Finally, the HexCer and SM lipid classes were found
to be significantly elevated in both the OA and P/O treated BeWo CT cells.
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Figure 4-12 Visualization of the degree of separation between lipidome profiles in
NEFA-treated BeWo CT cells.
(A) Unsupervised principal component analysis (PCA) and (B) supervised partial least
squares discriminant analysis (PLS-DA) plots were utilized to visualize the degree of
difference in lipidome profiles between PA, OA, P/O and BSA-control cultures.
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Figure 4-13 Volcano Plot visualization of differentially abundant lipid species in
NEFA-treated BeWo CT cells.
Differentially abundant metabolites in (A) PA-treated; (B) OA-treated; and (C) P/O-treated
BeWo CT cells were determined with ≥ ±1.5 fold-change vs LG, raw p-value < 0.05 cutoffs and visualized via non-parametric volcano plot (n=5/group). The x-axis represents
log2(fold-change), and the y-axis represents p-value (-log10). Lipid species with
significantly increased abundance vs BSA-control cultures are represented by red dots and
lipid species with significantly decreased abundance are represented by blue dots.
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Figure 4-14 Differentially Abundant Lipid Classes in NEFA-treated BeWo CT cells.
Differentially abundant lipid species identified in tiers 1 and 2 were sorted by lipid subclass and total peak intensity of lipid class was determined. The abundances of lipid class
in each NEFA treatment were compared to the BSA-control samples in binary via
Wilcoxon-rank sum test. Boxplot were constructed to highlight lipid classes with
differential abundance versus BSA-control in (A) PA-treated, (B) OA-treated, and (C) P/Otreated BeWo CT cells (raw-p<0.0167, n=5/group). Lipid class abbreviations: BMP
(Bis[monoacylglycero]phosphates); Car (Fatty acyl carnitines); Cer (Ceramides); DG
(Diacylglycerols); HexCer (Glucosylceramides); LPG (Lysophosphatidylglycerol); PE
(Diacylglycerophosphoethanolamines); PI (Phosphatidylinositols); SM (Ceramide-1phosphates); ST (Cholesterol and Derivatives); TG (Triacylglycerols).
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Figure 4-15 Venn Diagram highlighting the number of shared and unique
differentially abundant lipid classes in NEFA treated BeWo CT cells.
A Venn-diagram was constructed to provide visualization of the differentially abundant
lipid classes that were unique to each NEFA-treatment or common to multiple NEFAtreatments in the box-plot analyses in Figure 4-14.
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4.4 Discussion:
PA and OA are the most abundant circulating NEFA species in the serum of
pregnant women, and the concentrations of these NEFA are increased under conditions of
maternal GDM and obesity [45]. As maternal diet has been demonstrated to be an
important regulator of placental metabolic function [26,46], and dietary fat consumption
data has highlighted that PA and OA are the most abundantly consumed dietary fats [48–
51], these fats themselves may be important in regulating placental function in obese and
GDM pregnancies. The current study is the first, to our knowledge, to utilize a multiomics research approach to characterize the independent and combined impacts of the
dietary NEFA species PA and OA on the lipid metabolic processing of BeWo villous
trophoblast cells.
The first objective of the current study was to utilize targeted lipidomic analyses
via GC-FID and TLC-FID to characterize cellular FA and neutral profiles, as well as FA
desaturation and elongation indices to better understand lipid processing in BeWo CT and
SCT cells cultured with dietary NEFA species. The current study subsequently aimed to
utilize a multi-omics research approach (combining transcriptomic data, with untargeted
metabolomic and lipidomic data) to elucidate the underlying biochemical impacts of
increased NEFA supply on the metabolic function of BeWo CT cells, given that previous
studies have highlighted the dominant metabolic profile of these progenitor placental
trophoblast cells [24,52–54]. Overall, our results highlighted that the dietary NEFAs PA
and OA have different metabolic fates in placental trophoblast cells, as well as
demonstrated that these FAs are processed differentially when exposed to trophoblasts
independently (PA and OA treatments) and in combination (P/O treatments). Our multiomic analyses demonstrated that PA exposure (either alone or in combination with
oleate) is associated with an oxidative fuel switch indicative of increased β-oxidation.
Further, these analyses highlighted underling metabolic changes that suggested OA
exposure exerts anti-inflammatory and anti-oxidant effects in placental trophoblasts.
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4.4.1

Impacts of dietary NEFA on BeWo FA and Neutral Lipid
Profiles
The current study utilized GC-FID as a preliminary readout of the impacts of

increased dietary NEFA supply on BeWo trophoblasts via analysis of cellular FA
profiles. It is important to note that altered FA compositions have been described in
placentae from obese and GDM pregnancies [35–37], as well as in the development of
placental dysfunctions including preeclampsia [64]. Thus, specific dietary NEFA-induced
alterations to FA profiles may be reflective of a transition towards aberrant placental
function. The current study highlighted that a 72-hour PA exposure was associated with
increased SFA levels in both CT and SCT cultures, with specific elevations in the C16:0
content in these cells. OA exposure however, resulted in a profound increase in cellular
MUFA species, and strikingly C18:1n9 accounted for almost two-thirds of all FA content
in both OA-treated CT and SCT cells. In contrast, the P/O treatments only moderately
impacted BeWo SFA and PUFA compositions, and no specific alterations in C16:0
composition were observed in both the P/O-treated CT and SCT cells. However, the P/Otreated cells displayed altered MUFA and profiles and increased C18:1n9 levels similar
to the trends in the OA- treatments although with lower magnitude of change.
Interestingly, previous data from rodent models have highlighted that placental MUFA
but not SFA content correlates with maternal plasma FA levels [65], similar to the
findings in P/O-treated BeWo cells reported here. Overall, these data highlighted that
altering the supply of dietary NEFA to placental trophoblasts independently impacts
trophoblast cell FA composition and suggests that increased circulating NEFA levels
contribute to alterations to placental lipid compositions.
The collected FA profile data also allowed for investigation into elongation and
desaturation metabolic processing of dietary FA through the calculation of FA elongase
and desaturase indices, as has previously been demonstrated [58–62]. Of particular
interest to the current study was FA desaturation mediated by Stearoyl-CoA Desaturase 1
(SCD1), which is responsible for the production of palmitoleate (C16:1n7) and OA
(C18:1n9) from PA (C16:0) and stearate (C18:0), respectively. Previously, obesity has
been found to impact placental FA desaturation via SCD1, although current reports have
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been somewhat inconsistent. Specifically, obese placentae have been found to display
increased placental abundance of SCD1 mRNA suggesting increased FA desaturation
[25]. However, a subsequent report described an overall decrease in SCD1 activity in
obese placentae and highlighted no alterations in SCD protein abundance, suggesting that
FA desaturation may be regulated by post-translational modifications [66]. In the current
study, we observed decreased SCD1 activity (assessed as POA/PA ratio) in OA and P/Otreated BeWo CT and SCT cells, that suggested previously observed reductions in SCD1
activity in term obese placentae may be facilitated in part by increased placental OA or
MUFA supply [66]. Interestingly, all NEFA-treated BeWo CT cells displayed reduced
expression of SCD1, that could indicate elevated NEFA levels modulate SCD1-mediated
FA desaturation in placental trophoblasts by altering enzyme transcription. Despite an
overall reduction in SCD1 mRNA expression, we observed increased SCD1 activity in
PA-treated BeWo CT and SCT cells. As palmitoleate has previously been linked with
increased oxygen consumption and β-oxidation activity in adipocytes [67,68], we
speculate that increased PA desaturation to POA in PA-treated BeWo CT cells may
underlie the increased mitochondrial respiratory activity that we have previously
observed in these cells [52].
Further, our results demonstrated that OA-exposure whether alone or in
combination with PA resulted in increased Fatty Acid Desaturase 2 (FADS2) production
of γ-Linoleic Acid (GLA; C18:2n6), as well as increased elongation of OA to Gondoic
Acid (C20:1n9). Increased levels of these specific FA species have previously been
associated with anti-inflammatory outcomes [69,70]. As OA has been demonstrated to
attenuate the lipotoxic effects of increased PA levels in trophoblast cells [71,72], we
speculate that OA partially exert its protective effects on trophoblast cells via the
increased production of anti-inflammatory lipid intermediaries. Overall, our data
demonstrated that modulating dietary FA composition impacts placental FA elongation
and desaturation, and in turn leads to altered production of various FA species which
themselves may be able to directly impact placental metabolic processes.
Using TLC-FID, the current study also demonstrated that the proportion of TG in
the neutral lipid fractions of BeWo CT and SCT cells was elevated only in cells exposed
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to with OA independently, likely reflecting that OA is highly lipogenic in trophoblasts.
These results were consistent with previous reports in cultured placental explants and
isolated trophoblasts [71,73] and NEFA-treated BeWo [74,75] cells that have
demonstrated that imported OA is highly localized to TG lipid fractions. This may
indicate that increased supply of OA to the placenta is an important regulator of the
increased TG synthesis that has previously been reported in obese and GDM placentae
[24,25,27,30]. Interestingly, the combination P/O-treated BeWo CT and SCT cells were
not observed to have altered neutral lipid and TG compositions when assessed by TLCFID. These data aligned with reports from isolated primary human trophoblasts,
demonstrating reduced lipid droplet formation with a combined OA and PA exposure
versus OA-alone exposures [71]. Subsequent analysis of lipid class abundance using
untargeted LC-MS/MS also highlighted increased levels of PI, and PE lipid species in
PA-treated BeWo CT cells. These results were also consistent with readouts in primary
placental samples that have highlighted PA is highly localized to trophoblast
phospholipid fractions [66]. Overall, this suggests that saturated and monounsaturated
dietary NEFA have different metabolic fates in placental trophoblasts as well as that the
metabolic fates of these FA species are altered when present in combination with other
dietary FAs.
The FA and neutral lipid profile data, however, highlighted limited alterations in
trophoblast lipid composition following syncytialization and, specifically, only four
differentially abundant FA species were found in BeWo SCT cells. In contrast, previous
work in cultured PHT cells demonstrated profound reductions in the levels of many FA
species in placental villous trophoblast cells following syncytialization [76]. The
differences between the current study and previous reports are likely due to differences in
the reporting of FA profile data and may highlight a limitation in the current study. While
previous reports highlighted protein normalized FA quantity, the current study
highlighted FA profiles as a percentage of total FA abundance. Thus, the current study
was not able to report whether BeWo trophoblast cells demonstrate similar reductions in
the absolute quantities of different FA species as was highlighted with PHT cultures.
Future works using quantitative readouts of FA abundances are therefore needed to
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establish if BeWo trophoblasts exhibit similar differences in lipid metabolism between
differentiated and progenitor states.

4.4.2

A multi-omics analysis of NEFA-treated BeWo CT metabolic
function
Overall, the multi-omic analyses in the current study revealed that exposure to

different dietary NEFA species extensively altered BeWo CT cellular transcriptome and
lipidome profiles but led to limited alterations in cellular metabolome profiles. The
mRNA microarray transcriptomic analyses highlighted 340 DEG in PA-treated BeWo CT
cells; 308 DEGs in OA-treated BeWo CT cells; as well as 221 DEGs in P/O-treated
BeWo CT cells. Gene-set over-representation analysis, however, only found one
significantly enriched functional pathway in the transcriptomic datasets with the Fatty
Acid Biosynthesis Pathway enriched in P/O-treated BeWo CT cells. Despite limited
enrichment in functional pathways, the transcriptomic analysis demonstrated differential
expression of key genes involved in lipid metabolic pathways in all NEFA treatment
groups, suggesting that placental trophoblasts modulate lipid processing functions in
direct response to an increased supply of PA and OA.
Specifically, we highlighted an increase in the mRNA abundance of cAMP
responsive element-binding protein 3-like 3 (CREB3L3) in all NEFA treatment groups.
CREB3L3 is a transcription factor that has previously been demonstrated to regulate lipid
metabolism via modulating the expression of genes involved in FA oxidation [77–79].
Interestingly, CREB3L3 has also been implicated in the pathophysiology of inflammation
and Endoplasmic Reticulum (ER) stress [78–80]. This could indicate that CREB3L3
controls lipid processing functions in trophoblasts, as well as underlies the development
of inflammation and ER stress that has previously been observed in some PA-treated
placental trophoblasts [71,72,81]. The microarray analysis in the current study revealed
that BeWo CT cells exposed to elevate PA levels for 72 hours do not have elevated
expression of genes related to inflammation (such as TNFα, IL6, and IL-32), and ER
stress (such as BCL2, DDIT3, and XBP1) that have previously been highlighted in PAtreated primary trophoblasts [71,81]. These differential responses may arise from
variations in PA dose utilized (100 µM in the current study compared to 200-500 µM in
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primary trophoblasts [71,81]). We speculate that the increased CREB3L3 expression
highlighted in the current study may reflect an early timepoint in transition towards ER
stress and inflammation in PA-exposed BeWo trophoblasts.
The microarray readouts also highlighted an upregulation of Acyl-CoA
Synthetase Long Chain Family Member 5 (ACSL5) in NEFA-treated BeWo CT cells.
Acyl-CoA synthetase (ACSL) enzymes have been highlighted to be directly involved in
FA uptake and are responsible for conjugating FA species to Coenzyme A, an important
first step in lipid metabolism that helps prevent FA efflux [66,82,83]. Interestingly,
ACSL5 expression has also been found to be induced in PUFA-exposed BeWo
trophoblasts, leading to an overall increase in FA uptake [84]. The data from the current
study therefore suggests that ACSL5 is also involved in the processing of PA and OA in
BeWo trophoblasts, and its increased expression likely facilitates increased cellular
uptake of FA species.
Additionally, our microarray data also described an upregulation of perilipin 2
(PLIN2) expression in BeWo trophoblasts exposed to dietary NEFAs. Previously, PLIN2
has been shown to be required for lipid droplet synthesis in trophoblasts [85]. More
importantly, placental expression of PLIN2 has been demonstrated to be elevated in
GDM pregnancies [86], and its expression has been found to be correlated with maternal
pre-pregnancy Body-Mass-Index (BMI) [27]. Thus, the current study suggests that
increased supply of dietary NEFAs to the placenta in obese and GDM pregnancies
directly facilitates an increased expression of PLIN2. In turn, this dietary NEFAmediated modulation of PLIN2 expression may promote TG accumulation in lipid
droplets, and subsequently placental steatosis in obese and GDM pregnancies.
Subsequently, the current study utilized an integrative approach with the multiomic readouts to further describe the impacts of dietary NEFA exposure on BeWo CT
metabolic function. Specifically, the transcriptome and metabolome datasets were
integrated via the Joint Pathway Analysis module of MetaboAnalyst. This analysis
highlighted a significant enrichment in the Purine Metabolism pathway in OA-treated
BeWo CT cells that was associated with increased cellular accumulations of adenosine
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(+3.30 FC), inosine (+2.45 FC), and guanosine (+1.69 FC) that may be suggestive of
reduced purine breakdown. As increased degradation of purines is involved in placental
responses to increased inflammation [87], the increased purine accumulation in OAtreated trophoblasts in the current study may further highlight anti-inflammatory
processes in dietary OA-treated trophoblasts. Alternatively, the increased purine
abundances, in conjunction with the upregulation of phosphoribosyl pyrophosphate
synthetase 1 (PRPS1) observed in the microarray panel, could reflect increased purine
synthesis via the Pentose Phosphate Pathway (PPP) [88]. As the PPP increases generation
of NADPH, a metabolite with antioxidant effects [89,90], these data may highlight that
OA also acts to reduce oxidative stress in placental trophoblasts.
Combining readouts from the transcriptomic, metabolomic and lipidomic datasets
also highlighted a potential shift in oxidative substrate selection in BeWo trophoblasts
cultured with PA (both alone and in conjunction with OA) towards increased FA
oxidation (β-oxidation). Examination of differentially abundant metabolites in PA and
P/O-treated BeWo CT revealed a significant reduction in intracellular levels of 3hydroxymethylglutaric acid (-2.89 FC in PA-treated CT cells; -2.00 FC in P/O-treated CT
cells), a byproduct of leucine degradation [91]. We speculate that this may indicate a
reduced breakdown of branched-chain amino acid species into byproducts that can enter
into The Tricarboxylic Acid Cycle (TCA Cycle) in BeWo trophoblasts cultured under
increased PA levels. Additionally, we observed increased C16:0 carnitine (+13.92 FC in
PA-treated CT cells; +3.79 FC in P/O-treated CT cells) levels in BeWo trophoblasts
treated with PA. As FA species must first be conjugated to carnitine before being
translocated to the mitochondrial matrix for oxidation [92], the increased acylcarnitine
levels in the cells may reflect a metabolic shift towards using PA as an oxidative fuel.
Moreover, PA and P/O-treated BeWo CT cells were found to have elevated
expression of genes involved in β-oxidative metabolism. Specifically, we observed
increased expression of Very-Long Chain Acyl-CoA Dehydrogenase (ACADVL), the
enzyme responsible for the catalyzing the preliminary step in β-oxidation metabolism,
and an increased expression of Acetyl-CoA Carboxylase Beta (ACACB), an enzyme
thought to control β-oxidative activity by catalyzing the carboxylation of acetyl-CoA to
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malonyl-CoA. Notably, elevated beta-oxidative activity has previously been linked with
increased generation of Reactive Oxygen Species (ROS) [93,94], that ultimately
promotes oxidative mitochondrial damage [95,96]. Therefore, the PA-mediated increase
in β-oxidative activity in BeWo trophoblasts could be indicative of an early transition
towards placental mitochondrial dysfunction.
Interestingly, malonic acid, an end-point metabolic byproduct of beta-oxidation
that is synthesized by ACACB, was only found to be increased in P/O-cultured BeWo CT
cells (+1.85 FC), but not PA-cultured cells. As malonate has been found to limit βoxidation activity by inhibiting acylcarnitine transport into the mitochondrial matrix [97],
these data may highlight that BeWo trophoblasts exposed to PA in combination with OA,
but not PA-alone, are able to prevent excessive β-oxidation activity. Malonate-mediated
inhibition of β-oxidation in the P/O-cultured BeWo CT cells may act to suppress
excessive mitochondrial ROS protection and could therefore protect against
mitochondrial damage. We additionally speculate that these data may highlight a shift
towards incomplete beta-oxidation in BeWo trophoblasts cultured with PA alone, as these
cells (but not P/O-treated CT cells) also displayed increased intracellular levels of the
shortened-chain C14:0 carnitine (+3.99 FC). Increased production of short-chain
acylcarnitine species has previously been liked with pro-inflammatory processes [98],
and thus these data may further highlight a transition towards inflammation in PAexposed trophoblasts. However, the insights of the current study into incomplete betaoxidation are minimized due to the limited identifications of short chain acylcarnitine
species in our untargeted lipidomic readouts. Future studies may need to utilize targeted
metabolomic approaches or utilize radio-labelled FA species to better identify the
production of short-chain acylcarnitine species and incomplete β-oxidation in PA-treated
BeWo trophoblasts.

4.4.3

Conclusion
Overall, the results of the current study highlighted the continued utility of the

BeWo preparation as a pre-clinical placental model, and that the dietary FAs PA and OA
are important regulators of placental trophoblast lipid metabolism. Moreover, it is shown
that excessive availability of these fats is associated with changes in FA desaturation,
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elongation, esterification, and oxidation processes in placental trophoblast cells. These
results further support the concept that increased levels of certain dietary fats in maternal
circulation are involved in facilitating the aberrant placental function that underlies the
development of metabolic health complications in offspring exposed to obesity and
GDM. In turn these data suggest that monitoring circulating FA levels in obese and GDM
pregnancies, and subsequently implementing dietary interventions through modulating
dietary fat content and composition continues to be needed in the clinical management of
these at-risk pregnancies. Implementation of healthy diet and lifestyle choices in these
“at-risk” pregnancies could act to preserve appropriate placental metabolic function
throughout gestation and in turn reduce risk of future metabolic health complication in
the offspring.

230

4.5 References
[1]

W. Zhuang, J. Lv, Q. Liang, W. Chen, S. Zhang, X. Sun, Adverse effects of
gestational diabetes-related risk factors on pregnancy outcomes and intervention
measures, Exp. Ther. Med. (2020). doi:10.3892/etm.2020.9050.

[2]

Z. Yang, H. Phung, L. Freebairn, R. Sexton, A. Raulli, P. Kelly, Contribution of
maternal overweight and obesity to the occurrence of adverse pregnancy
outcomes, Aust. New Zeal. J. Obstet. Gynaecol. 59 (2019) 367–374.
doi:10.1111/ajo.12866.

[3]

Y. Yogev, G.H.A. Visser, Obesity, gestational diabetes and pregnancy outcome,
Semin. Fetal Neonatal Med. 14 (2009) 77–84. doi:10.1016/j.siny.2008.09.002.

[4]

J.A. Armitage, L. Poston, P.D. Taylor, Developmental origins of obesity and the
metabolic syndrome: the role of maternal obesity., Front. Horm. Res. 36 (2008)
73–84. doi:10.1159/000115355.

[5]

J. Manderson, B. Mullan, C. Patterson, D. Hadden, A. Traub, D. McCance,
Cardiovascular and metabolic abnormalities in the offspring of diabetic pregnancy,
Diabetologia. 45 (2002) 991–996. doi:10.1007/s00125-002-0865-y.

[6]

P. Agarwal, T.S. Morriseau, S.M. Kereliuk, C.A. Doucette, B.A. Wicklow, V.W.
Dolinsky, Maternal obesity, diabetes during pregnancy and epigenetic mechanisms
that influence the developmental origins of cardiometabolic disease in the
offspring, Crit. Rev. Clin. Lab. Sci. 55 (2018) 71–101.
doi:10.1080/10408363.2017.1422109.

[7]

P.M. Catalano, The impact of gestational diabetes and maternal obesity on the
mother and her offspring, J. Dev. Orig. Health Dis. 1 (2010) 208–215.
doi:10.1017/S2040174410000115.

[8]

N. Shrestha, H.C. Ezechukwu, O.J. Holland, D.H. Hryciw, Developmental
programming of peripheral diseases in offspring exposed to maternal obesity
during pregnancy, Am. J. Physiol. Integr. Comp. Physiol. 319 (2020) R507–R516.
doi:10.1152/ajpregu.00214.2020.

[9]

R.C. Whitaker, Predicting Preschooler Obesity at Birth: The Role of Maternal
Obesity in Early Pregnancy, Pediatrics. 114 (2004) e29–e36.
doi:10.1542/peds.114.1.e29.

[10]

C.M. Boney, A. Verma, R. Tucker, B.R. Vohr, Metabolic syndrome in childhood:
association with birth weight, maternal obesity, and gestational diabetes mellitus.,
Pediatrics. 115 (2005) e290-6. doi:10.1542/peds.2004-1808.

[11]

M. Vääräsmäki, A. Pouta, P. Elliot, P. Tapanainen, U. Sovio, A. Ruokonen, A.-L.
Hartikainen, M. McCarthy, M.-R. Järvelin, Adolescent Manifestations of
Metabolic Syndrome Among Children Born to Women With Gestational Diabetes
in a General-Population Birth Cohort, Am. J. Epidemiol. 169 (2009) 1209–1215.
doi:10.1093/aje/kwp020.

[12]

A. Ferrara, Increasing Prevalence of Gestational Diabetes Mellitus: A public health
perspective, Diabetes Care. 30 (2007) S141–S146. doi:10.2337/dc07-s206.

231

[13]

S.Y. Kim, P.M. Dietz, L. England, B. Morrow, W.M. Callaghan, Trends in Prepregnancy Obesity in Nine States, 1993–2003*, Obesity. 15 (2007) 986–993.
doi:10.1038/oby.2007.621.

[14]

G. Li, T. Wei, W. Ni, A. Zhang, J. Zhang, Y. Xing, Q. Xing, Incidence and Risk
Factors of Gestational Diabetes Mellitus: A Prospective Cohort Study in Qingdao,
China, Front. Endocrinol. (Lausanne). 11 (2020). doi:10.3389/fendo.2020.00636.

[15]

M. Hod, A. Kapur, D.A. Sacks, E. Hadar, M. Agarwal, G.C. Di Renzo, L.C.
Roura, H.D. McIntyre, J.L. Morris, H. Divakar, The International Federation of
Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A
pragmatic guide for diagnosis, management, and care #, Int. J. Gynecol. Obstet.
131 (2015) S173–S211. doi:10.1016/S0020-7292(15)30033-3.

[16]

A.K. Driscoll, E.C.W. Gregory, Increases in Prepregnancy Obesity: United States,
2016-2019., NCHS Data Brief. (2020) 1–8.
http://www.ncbi.nlm.nih.gov/pubmed/33270551.

[17]

K.R. Howell, T.L. Powell, Effects of maternal obesity on placental function and
fetal development, Reproduction. 153 (2017) R97–R108. doi:10.1530/REP-160495.

[18]

J.F. Hebert, L. Myatt, Placental mitochondrial dysfunction with metabolic
diseases: Therapeutic approaches, Biochim. Biophys. Acta - Mol. Basis Dis. 1867
(2021) 165967. doi:10.1016/j.bbadis.2020.165967.

[19]

A.C. Kelly, T.L. Powell, T. Jansson, Placental function in maternal obesity, Clin.
Sci. 134 (2020) 961–984. doi:10.1042/CS20190266.

[20]

R. Hastie, M. Lappas, The effect of pre-existing maternal obesity and diabetes on
placental mitochondrial content and electron transport chain activity., Placenta. 35
(2014) 673–83. doi:10.1016/j.placenta.2014.06.368.

[21]

C. Mandò, G.M. Anelli, C. Novielli, P. Panina-Bordignon, M. Massari, M.I.
Mazzocco, I. Cetin, Impact of Obesity and Hyperglycemia on Placental
Mitochondria, Oxid. Med. Cell. Longev. 2018 (2018) 1–10.
doi:10.1155/2018/2378189.

[22]

A. Maloyan, J. Mele, S. Muralimanoharan, L. Myatt, Placental metabolic
flexibility is affected by maternal obesity, Placenta. 45 (2016) 69.
doi:10.1016/j.placenta.2016.06.031.

[23]

J. Mele, S. Muralimanoharan, A. Maloyan, L. Myatt, Impaired mitochondrial
function in human placenta with increased maternal adiposity., Am. J. Physiol.
Endocrinol. Metab. 307 (2014) E419-25. doi:10.1152/ajpendo.00025.2014.

[24]

A.M. Valent, H. Choi, K.S. Kolahi, K.L. Thornburg, Hyperglycemia and
gestational diabetes suppress placental glycolysis and mitochondrial function and
alter lipid processing, FASEB J. 35 (2021). doi:10.1096/fj.202000326RR.

[25]

V. Calabuig-Navarro, M. Haghiac, J. Minium, P. Glazebrook, G.C. Ranasinghe, C.
Hoppel, S. Hauguel de-Mouzon, P. Catalano, P. O’Tierney-Ginn, Effect of
Maternal Obesity on Placental Lipid Metabolism, Endocrinology. 158 (2017)

232

2543–2555. doi:10.1210/en.2017-00152.
[26]

V. Calabuig-Navarro, M. Puchowicz, P. Glazebrook, M. Haghiac, J. Minium, P.
Catalano, S. Hauguel deMouzon, P. O’Tierney-Ginn, Effect of ω-3
supplementation on placental lipid metabolism in overweight and obese women.,
Am. J. Clin. Nutr. 103 (2016) 1064–72. doi:10.3945/ajcn.115.124651.

[27]

B. Hirschmugl, G. Desoye, P. Catalano, I. Klymiuk, H. Scharnagl, S. Payr, E.
Kitzinger, C. Schliefsteiner, U. Lang, C. Wadsack, S. Hauguel-de Mouzon,
Maternal obesity modulates intracellular lipid turnover in the human term placenta,
Int. J. Obes. 41 (2017) 317–323. doi:10.1038/ijo.2016.188.

[28]

M. Bucher, K.R.C. Montaniel, L. Myatt, S. Weintraub, H. Tavori, A. Maloyan,
Dyslipidemia, insulin resistance, and impairment of placental metabolism in the
offspring of obese mothers, J. Dev. Orig. Health Dis. 12 (2021) 738–747.
doi:10.1017/S2040174420001026.

[29]

T.L. Powell, K. Barner, L. Madi, M. Armstrong, J. Manke, C. Uhlson, T. Jansson,
V. Ferchaud-Roucher, Sex-specific responses in placental fatty acid oxidation,
esterification and transfer capacity to maternal obesity, Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 1866 (2021) 158861. doi:10.1016/j.bbalip.2020.158861.

[30]

C.H. Hulme, A. Nicolaou, S.A. Murphy, A.E.P. Heazell, J.E. Myers, M.
Westwood, The effect of high glucose on lipid metabolism in the human placenta,
Sci. Rep. 9 (2019) 14114. doi:10.1038/s41598-019-50626-x.

[31]

F. Visiedo, F. Bugatto, R. Quintero-Prado, I. Cózar-Castellano, J.L. Bartha, G.
Perdomo, Glucose and Fatty Acid Metabolism in Placental Explants From
Pregnancies Complicated With Gestational Diabetes Mellitus, Reprod. Sci. 22
(2015) 798–801. doi:10.1177/1933719114561558.

[32]

F. Visiedo, F. Bugatto, V. Sánchez, I. Cózar-Castellano, J.L. Bartha, G. Perdomo,
High glucose levels reduce fatty acid oxidation and increase triglyceride
accumulation in human placenta, Am. J. Physiol. Metab. 305 (2013) E205–E212.
doi:10.1152/ajpendo.00032.2013.

[33]

M.A. Ortega, M.A. Saez, F. Sainz, O. Fraile-Martínez, S. García-Gallego, L.
Pekarek, C. Bravo, S. Coca, M.Á.- Mon, J. Buján, N. García-Honduvilla, Á.
Asúnsolo, Lipidomic profiling of chorionic villi in the placentas of women with
chronic venous disease, Int. J. Med. Sci. 17 (2020) 2790–2798.
doi:10.7150/ijms.49236.

[34]

S. Mohammad, J. Bhattacharjee, T. Vasanthan, C.S. Harris, S.A. Bainbridge, K.B.
Adamo, Metabolomics to understand placental biology: Where are we now?,
Tissue Cell. 73 (2021) 101663. doi:10.1016/j.tice.2021.101663.

[35]

C. Fattuoni, C. Mandò, F. Palmas, G.M. Anelli, C. Novielli, E. Parejo Laudicina,
V.M. Savasi, L. Barberini, A. Dessì, R. Pintus, V. Fanos, A. Noto, I. Cetin,
Preliminary metabolomics analysis of placenta in maternal obesity, Placenta. 61
(2018) 89–95. doi:10.1016/j.placenta.2017.11.014.

[36]

M.T. Segura, H. Demmelmair, S. Krauss-Etschmann, P. Nathan, S. Dehmel, M.C.
Padilla, R. Rueda, B. Koletzko, C. Campoy, Maternal BMI and gestational

233

diabetes alter placental lipid transporters and fatty acid composition, Placenta. 57
(2017) 144–151. doi:10.1016/j.placenta.2017.07.001.
[37]

Y. Yang, Z. Pan, F. Guo, H. Wang, W. Long, H. Wang, B. Yu, Placental metabolic
profiling in gestational diabetes mellitus: An important role of fatty acids, J. Clin.
Lab. Anal. (2021). doi:10.1002/jcla.24096.

[38]

S. Furse, D.S. Fernandez-Twinn, B. Jenkins, C.L. Meek, H.E.L. Williams, G.C.S.
Smith, D.S. Charnock-Jones, S.E. Ozanne, A. Koulman, A high-throughput
platform for detailed lipidomic analysis of a range of mouse and human tissues,
Anal. Bioanal. Chem. 412 (2020) 2851–2862. doi:10.1007/s00216-020-02511-0.

[39]

O. Uhl, H. Demmelmair, M.T. Segura, J. Florido, R. Rueda, C. Campoy, B.
Koletzko, Effects of obesity and gestational diabetes mellitus on placental
phospholipids, Diabetes Res. Clin. Pract. 109 (2015) 364–371.
doi:10.1016/j.diabres.2015.05.032.

[40]

K.L. Bidne, A.L. Rister, A.R. McCain, B.D. Hitt, E.D. Dodds, J.R. Wood,
Maternal obesity alters placental lysophosphatidylcholines, lipid storage, and the
expression of genes associated with lipid metabolism, Biol. Reprod. 104 (2021)
197–210. doi:10.1093/biolre/ioaa191.

[41]

T.J. Stuart, K. O’Neill, D. Condon, I. Sasson, P. Sen, Y. Xia, R.A. Simmons, Dietinduced obesity alters the maternal metabolome and early placenta transcriptome
and decreases placenta vascularity in the mouse†, Biol. Reprod. 98 (2018) 795–
809. doi:10.1093/biolre/ioy010.

[42]

F. Delhaes, S.A. Giza, T. Koreman, G. Eastabrook, C.A. McKenzie, S. Bedell,
T.R.H. Regnault, B. de Vrijer, Altered maternal and placental lipid metabolism
and fetal fat development in obesity: Current knowledge and advances in noninvasive assessment, Placenta. 69 (2018) 118–124.
doi:10.1016/j.placenta.2018.05.011.

[43]

A. Herrera Martínez, Hyperlipidemia during gestational diabetes and its relation
with maternal and offspring complications, Nutr. Hosp. (2018).
doi:10.20960/nh.1539.

[44]

C.M. Scifres, J.M. Catov, H.N. Simhan, The impact of maternal obesity and
gestational weight gain on early and mid-pregnancy lipid profiles, Obesity. 22
(2014) 932–938. doi:10.1002/oby.20576.

[45]

X. Chen, T.O. Scholl, M. Leskiw, J. Savaille, T.P. Stein, Differences in maternal
circulating fatty acid composition and dietary fat intake in women with gestational
diabetes mellitus or mild gestational hyperglycemia, Diabetes Care. 33 (2010)
2049–2054. doi:10.2337/dc10-0693.

[46]

F.L. Alvarado, V. Calabuig-Navarro, M. Haghiac, M. Puchowicz, P.-J.S. Tsai, P.
O’Tierney-Ginn, Maternal obesity is not associated with placental lipid
accumulation in women with high omega-3 fatty acid levels, Placenta. 69 (2018)
96–101. doi:10.1016/j.placenta.2018.07.016.

[47]

P.M. Villa, H. Laivuori, E. Kajantie, R. Kaaja, Free fatty acid profiles in
preeclampsia, Prostaglandins, Leukot. Essent. Fat. Acids. 81 (2009) 17–21.

234

doi:10.1016/j.plefa.2009.05.002.
[48]

J. Denomme, K.D. Stark, B.J. Holub, Directly quantitated dietary (n-3) fatty acid
intakes of pregnant Canadian women are lower than current dietary
recommendations., J. Nutr. 135 (2005) 206–11. doi:135/2/206 [pii].

[49]

C. Savard, S. Lemieux, S. Weisnagel, B. Fontaine-Bisson, C. Gagnon, J.
Robitaille, A.-S. Morisset, Trimester-Specific Dietary Intakes in a Sample of
French-Canadian Pregnant Women in Comparison with National Nutritional
Guidelines, Nutrients. 10 (2018) 768. doi:10.3390/nu10060768.

[50]

D. Iggman, U. Risérus, Role of different dietary saturated fatty acids for
cardiometabolic risk, Clin. Lipidol. 6 (2011) 209–223. doi:10.2217/clp.11.7.

[51]

C.L. Kien, J.Y. Bunn, R. Stevens, J. Bain, O. Ikayeva, K. Crain, T.R. Koves, D.M.
Muoio, Dietary intake of palmitate and oleate has broad impact on systemic and
tissue lipid profiles in humans, Am. J. Clin. Nutr. 99 (2014) 436–445.
doi:10.3945/ajcn.113.070557.

[52]

Z.J.W. Easton, F. Delhaes, K. Mathers, L. Zhao, C.M.G. Vanderboor, T.R.H.
Regnault, Syncytialization and prolonged exposure to palmitate impacts BeWo
respiration, Reproduction. 161 (2021) 73–88. doi:10.1530/REP-19-0433.

[53]

K. Kolahi, A. Valent, K.L. Thornburg, Cytotrophoblast, Not Syncytiotrophoblast,
Dominates Glycolysis and Oxidative Phosphorylation in Human Term Placenta.,
Sci. Rep. (2017) 1–12. doi:10.1038/srep42941.

[54]

K. Kolahi, S. Louey, O. Varlamov, K. Thornburg, Real-time tracking of BODIPYC12 long-chain fatty acid in human term placenta reveals unique lipid dynamics in
cytotrophoblast cells, PLoS One. 11 (2016) 1–23.
doi:10.1371/journal.pone.0153522.

[55]

J. Folch, M. Lees, G.H.S. Stanley, A SIMPLE METHOD FOR THE ISOLATION
AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES, J. Biol.
Chem. 226 (1957) 497–509. doi:10.1016/S0021-9258(18)64849-5.

[56]

J.M. Klaiman, E.R. Price, C.G. Guglielmo, Fatty acid composition of pectoralis
muscle membrane, intramuscular fat stores and adipose tissue of migrant and
wintering white-throated sparrows ( Zonotrichia albicollis ), J. Exp. Biol. 212
(2009) 3865–3872. doi:10.1242/jeb.034967.

[57]

O. Sarr, K.E. Mathers, L. Zhao, K. Dunlop, J. Chiu, C.G. Guglielmo, Y. Bureau,
A. Cheung, S. Raha, T.-Y. Lee, T.R.H. Regnault, Western diet consumption
through early life induces microvesicular hepatic steatosis in association with an
altered metabolome in low birth weight Guinea pigs, J. Nutr. Biochem. 67 (2019)
219–233. doi:10.1016/j.jnutbio.2019.02.009.

[58]

D.M. Merino, H. Johnston, S. Clarke, K. Roke, D. Nielsen, A. Badawi, A. ElSohemy, D.W.L. Ma, D.M. Mutch, Polymorphisms in FADS1 and FADS2 alter
desaturase activity in young Caucasian and Asian adults, Mol. Genet. Metab. 103
(2011) 171–178. doi:10.1016/j.ymgme.2011.02.012.

[59]

V. Chajès, V. Joulin, F. Clavel-Chapelon, The fatty acid desaturation index of

235

blood lipids, as a biomarker of hepatic stearoyl-CoA desaturase expression, is a
predictive factor of breast cancer risk, Curr. Opin. Lipidol. 22 (2011) 6–10.
doi:10.1097/MOL.0b013e3283404552.
[60]

S.M. Jeyakumar, P. Lopamudra, S. Padmini, N. Balakrishna, N. V Giridharan, A.
Vajreswari, Fatty acid desaturation index correlates with body mass and adiposity
indices of obesity in Wistar NIN obese mutant rat strains WNIN/Ob and
WNIN/GR-Ob, Nutr. Metab. (Lond). 6 (2009) 27. doi:10.1186/1743-7075-6-27.

[61]

Y.N. Massih, A.G. Hall, J. Suh, J.C. King, Zinc Supplements Taken with Food
Increase Essential Fatty Acid Desaturation Indices in Adult Men Compared with
Zinc Taken in the Fasted State, J. Nutr. 151 (2021) 2583–2589.
doi:10.1093/jn/nxab149.

[62]

A. Gómez-Vilarrubla, B. Mas-Parés, M. Díaz, S. Xargay-Torrent, G. CarrerasBadosa, M. Jové, M. Martin-Gari, A. Bonmatí-Santané, F. de Zegher, L. Ibañez,
A. López-Bermejo, J. Bassols, Fatty acids in the placenta of appropiate- versus
small-for-gestational-age infants at term birth, Placenta. 109 (2021) 4–10.
doi:10.1016/j.placenta.2021.04.009.

[63]

K.P. Dunlop, Skeletal Muscle Lipid Metabolism and Markers of Insulin Resistance
in Young Male Low Birth Weight Offspring in Combination With a Postnatal
Western Diet, Electron. Thesis Diss. Respository. 2946 (2015).

[64]

S.H.J. Brown, S.R. Eather, D.J. Freeman, B.J. Meyer, T.W. Mitchell, A Lipidomic
Analysis of Placenta in Preeclampsia: Evidence for Lipid Storage, PLoS One. 11
(2016) e0163972. doi:10.1371/journal.pone.0163972.

[65]

E. Amusquivar, E. Herrera, Influence of Changes in Dietary Fatty Acids during
Pregnancy on Placental and Fetal Fatty Acid Profile in the Rat, Neonatology. 83
(2003) 136–145. doi:10.1159/000067963.

[66]

V. Ferchaud‐Roucher, K. Barner, T. Jansson, T.L. Powell, Maternal obesity results
in decreased syncytiotrophoblast synthesis of palmitoleic acid, a fatty acid with
anti‐inflammatory and insulin‐sensitizing properties, FASEB J. 33 (2019) 6643–
6654. doi:10.1096/fj.201802444R.

[67]

M.M. Cruz, J.J. Simão, R.D.C.C. de Sá, T.S.M. Farias, V.S. da Silva, F. Abdala,
V.J. Antraco, L. Armelin-Correa, M.I.C. Alonso-Vale, Palmitoleic Acid Decreases
Non-alcoholic Hepatic Steatosis and Increases Lipogenesis and Fatty Acid
Oxidation in Adipose Tissue From Obese Mice, Front. Endocrinol. (Lausanne). 11
(2020). doi:10.3389/fendo.2020.537061.

[68]

M.M. Cruz, A.B. Lopes, A.R. Crisma, R.C.C. de Sá, W.M.T. Kuwabara, R. Curi,
P.B.M. de Andrade, M.I.C. Alonso-Vale, Palmitoleic acid (16:1n7) increases
oxygen consumption, fatty acid oxidation and ATP content in white adipocytes,
Lipids Health Dis. 17 (2018) 55. doi:10.1186/s12944-018-0710-z.

[69]

J. Muralidharan, C. Papandreou, A. Sala-Vila, N. Rosique-Esteban, M. Fitó, R.
Estruch, M. Angel Martínez-González, D. Corella, E. Ros, C. Razquín, O.
Castañer, J. Salas-Salvadó, M. Bulló, Fatty Acids Composition of Blood Cell
Membranes and Peripheral Inflammation in the PREDIMED Study: A Cross-

236

Sectional Analysis, Nutrients. 11 (2019) 576. doi:10.3390/nu11030576.
[70]

R. Kapoor, Y.-S. Huang, Gamma Linolenic Acid: An Antiinflammatory Omega-6
Fatty Acid, Curr. Pharm. Biotechnol. 7 (2006) 531–534.
doi:10.2174/138920106779116874.

[71]

B.N. Colvin, M.S. Longtine, B. Chen, M.L. Costa, D.M. Nelson, Oleate attenuates
palmitate-induced endoplasmic reticulum stress and apoptosis in placental
trophoblasts, Reproduction. 153 (2017) 369–380. doi:10.1530/REP-16-0576.

[72]

S.K. Natarajan, T. Bruett, P.G. Muthuraj, P.K. Sahoo, J. Power, J.L. Mott, C.
Hanson, A. Anderson-Berry, Saturated free fatty acids induce placental trophoblast
lipoapoptosis, PLoS One. 16 (2021) e0249907. doi:10.1371/journal.pone.0249907.

[73]

O.C. Watkins, M.O. Islam, P. Selvam, R.A. Pillai, A. Cazenave-Gassiot, A.K.
Bendt, N. Karnani, K.M. Godfrey, R.M. Lewis, M.R. Wenk, S.-Y. Chan,
Metabolism of 13C-Labeled Fatty Acids in Term Human Placental Explants by
Liquid Chromatography–Mass Spectrometry, Endocrinology. 160 (2019) 1394–
1408. doi:10.1210/en.2018-01020.

[74]

F.M. Campbell, A.M. Clohessy, M.J. Gordon, K.R. Page, A.K. Dutta-Roy, Uptake
of long chain fatty acids by human placental choriocarcinoma (BeWo) cells: role
of plasma membrane fatty acid-binding protein., J. Lipid Res. 38 (1997) 2558–68.
http://www.ncbi.nlm.nih.gov/pubmed/9458279.

[75]

K.A.R. Tobin, G.M. Johnsen, A.C. Staff, A.K. Duttaroy, Long-chain
Polyunsaturated Fatty Acid Transport across Human Placental Choriocarcinoma
(BeWo) Cells, Placenta. 30 (2009) 41–47. doi:10.1016/j.placenta.2008.10.007.

[76]

V. Ferchaud-Roucher, M.C. Rudolph, T. Jansson, T.L. Powell, Fatty acid and lipid
profiles in primary human trophoblast over 90 h in culture, Prostaglandins, Leukot.
Essent. Fat. Acids. 121 (2017) 14–20. doi:10.1016/j.plefa.2017.06.001.

[77]

Y. Nakagawa, A. Satoh, H. Tezuka, S. Han, K. Takei, H. Iwasaki, S. Yatoh, N.
Yahagi, H. Suzuki, Y. Iwasaki, H. Sone, T. Matsuzaka, N. Yamada, H. Shimano,
CREB3L3 controls fatty acid oxidation and ketogenesis in synergy with PPARα,
Sci. Rep. 6 (2016) 39182. doi:10.1038/srep39182.

[78]

H. Wade, K. Pan, Q. Su, CREBH: A Complex Array of Regulatory Mechanisms in
Nutritional Signaling, Metabolic Inflammation, and Metabolic Disease, Mol. Nutr.
Food Res. 65 (2021) 2000771. doi:10.1002/mnfr.202000771.

[79]

L. Sampieri, P. Di Giusto, C. Alvarez, CREB3 Transcription Factors: ER-Golgi
Stress Transducers as Hubs for Cellular Homeostasis, Front. Cell Dev. Biol. 7
(2019). doi:10.3389/fcell.2019.00123.

[80]

K. Zhang, X. Shen, J. Wu, K. Sakaki, T. Saunders, D.T. Rutkowski, S.H. Back,
R.J. Kaufman, Endoplasmic Reticulum Stress Activates Cleavage of CREBH to
Induce a Systemic Inflammatory Response, Cell. 124 (2006) 587–599.
doi:10.1016/j.cell.2005.11.040.

[81]

J. Saben, Y. Zhong, H. Gomez-Acevedo, K.M. Thakali, S.J. Borengasser, A.
Andres, K. Shankar, Early growth response protein-1 mediates lipotoxicity-

237

associated placental inflammation: role in maternal obesity, Am. J. Physiol. Metab.
305 (2013) E1–E14. doi:10.1152/ajpendo.00076.2013.
[82]

D.G. Mashek, M.A. McKenzie, C.G. Van Horn, R.A. Coleman, Rat Long Chain
Acyl-CoA Synthetase 5 Increases Fatty Acid Uptake and Partitioning to Cellular
Triacylglycerol in McArdle-RH7777 Cells, J. Biol. Chem. 281 (2006) 945–950.
doi:10.1074/jbc.M507646200.

[83]

A.K. Dutta-Roy, Cellular uptake of long-chain fatty acids: role of membraneassociated fatty-acid-binding/transport proteins, Cell. Mol. Life Sci. 57 (2000)
1360–1372. doi:10.1007/PL00000621.

[84]

G.M. Johnsen, M.S. Weedon-Fekjær, K.A.R. Tobin, A.C. Staff, A.K. Duttaroy,
Long-chain Polyunsaturated Fatty Acids Stimulate Cellular Fatty Acid Uptake in
Human Placental Choriocarcinoma (BeWo) Cells, Placenta. 30 (2009) 1037–1044.
doi:10.1016/j.placenta.2009.10.004.

[85]

I. Bildirici, W.T. Schaiff, B. Chen, M. Morizane, S.-Y. Oh, M. O’Brien, C.
Sonnenberg-Hirche, T. Chu, Y. Barak, D.M. Nelson, Y. Sadovsky, PLIN2 Is
Essential for Trophoblastic Lipid Droplet Accumulation and Cell Survival During
Hypoxia, Endocrinology. 159 (2018) 3937–3949. doi:10.1210/en.2018-00752.

[86]

L. Stirm, M. Kovářová, S. Perschbacher, R. Michlmaier, L. Fritsche, D. SiegelAxel, E. Schleicher, A. Peter, J. Pauluschke-Fröhlich, S. Brucker, H. Abele, D.
Wallwiener, H. Preissl, C. Wadsack, H.-U. Häring, A. Fritsche, R. Ensenauer, G.
Desoye, H. Staiger, BMI-Independent Effects of Gestational Diabetes on Human
Placenta, J. Clin. Endocrinol. Metab. 103 (2018) 3299–3309. doi:10.1210/jc.201800397.

[87]

Y.-C. Lien, Z. Zhang, G. Barila, A. Green-Brown, M.A. Elovitz, R.A. Simmons,
Intrauterine Inflammation Alters the Transcriptome and Metabolome in Placenta,
Front. Physiol. 11 (2020). doi:10.3389/fphys.2020.592689.

[88]

A. Stincone, A. Prigione, T. Cramer, M.M.C. Wamelink, K. Campbell, E. Cheung,
V. Olin‐Sandoval, N. Grüning, A. Krüger, M. Tauqeer Alam, M.A. Keller, M.
Breitenbach, K.M. Brindle, J.D. Rabinowitz, M. Ralser, The return of metabolism:
biochemistry and physiology of the pentose phosphate pathway, Biol. Rev. 90
(2015) 927–963. doi:10.1111/brv.12140.

[89]

C. Riganti, E. Gazzano, M. Polimeni, E. Aldieri, D. Ghigo, The pentose phosphate
pathway: An antioxidant defense and a crossroad in tumor cell fate, Free Radic.
Biol. Med. 53 (2012) 421–436. doi:10.1016/j.freeradbiomed.2012.05.006.

[90]

C.M. Grant, Metabolic reconfiguration is a regulated response to oxidative stress,
J. Biol. 7 (2008) 1. doi:10.1186/jbiol63.

[91]

Y. Duan, F. Li, Y. Li, Y. Tang, X. Kong, Z. Feng, T.G. Anthony, M. Watford, Y.
Hou, G. Wu, Y. Yin, The role of leucine and its metabolites in protein and energy
metabolism, Amino Acids. 48 (2016) 41–51. doi:10.1007/s00726-015-2067-1.

[92]

N. Longo, M. Frigeni, M. Pasquali, Carnitine transport and fatty acid oxidation,
Biochim. Biophys. Acta - Mol. Cell Res. 1863 (2016) 2422–2435.
doi:10.1016/j.bbamcr.2016.01.023.

238

[93]

R.H. Lambertucci, S.M. Hirabara, L. dos R. Silveira, A.C. Levada‐Pires, R. Curi,
T.C. Pithon‐Curi, Palmitate increases superoxide production through
mitochondrial electron transport chain and NADPH oxidase activity in skeletal
muscle cells, J. Cell. Physiol. 216 (2008) 796–804. doi:10.1002/jcp.21463.

[94]

M.G. Rosca, E.J. Vazquez, Q. Chen, J. Kerner, T.S. Kern, C.L. Hoppel, Oxidation
of Fatty Acids Is the Source of Increased Mitochondrial Reactive Oxygen Species
Production in Kidney Cortical Tubules in Early Diabetes, Diabetes. 61 (2012)
2074–2083. doi:10.2337/db11-1437.

[95]

M. Zhao, Y. Wang, L. Li, S. Liu, C. Wang, Y. Yuan, G. Yang, Y. Chen, J. Cheng,
Y. Lu, J. Liu, Mitochondrial ROS promote mitochondrial dysfunction and
inflammation in ischemic acute kidney injury by disrupting TFAM-mediated
mtDNA maintenance, Theranostics. 11 (2021) 1845–1863.
doi:10.7150/thno.50905.

[96]

H. Rizwan, S. Pal, S. Sabnam, A. Pal, High glucose augments ROS generation
regulates mitochondrial dysfunction and apoptosis via stress signalling cascades in
keratinocytes, Life Sci. 241 (2020) 117148. doi:10.1016/j.lfs.2019.117148.

[97]

A. Honda, K. Yamashita, T. Ikegami, T. Hara, T. Miyazaki, T. Hirayama, M.
Numazawa, Y. Matsuzaki, Highly sensitive quantification of serum malonate, a
possible marker for de novo lipogenesis, by LC-ESI-MS/MS, J. Lipid Res. 50
(2009) 2124–2130. doi:10.1194/jlr.D800054-JLR200.

[98]

J.M. Rutkowsky, T.A. Knotts, K.D. Ono-Moore, C.S. McCoin, S. Huang, D.
Schneider, S. Singh, S.H. Adams, D.H. Hwang, Acylcarnitines activate
proinflammatory signaling pathways., Am. J. Physiol. Endocrinol. Metab. 306
(2014) E1378-87. doi:10.1152/ajpendo.00656.2013.

239

Chapter 5

5

General Discussion and Conclusions
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5.1 Overview of thesis and major findings
Recent advances in the Developmental Origins of Health and Disease (DOHaD)
field have highlighted that obese and diabetic pregnancies are associated with abnormal
maternal intrauterine environments high in circulating nutrients that lead to pathological
in utero programming of fetal development [1–3]. Aberrant maternal environments such
as these increase the risk of offspring developing non-communicable cardiometabolic
health complications early in their lives [1–3]. Impairments in placental metabolic and
mitochondrial function, induced by overabundant circulating nutrient levels, are thought
to specifically underlie the development of non-communicable diseases in the offspring
of these “at-risk” pregnancies [4–6]. However, the direct impacts of increased nutrient
levels on placental metabolic functions are poorly understood, and the underlying
mechanisms that regulate placental metabolic function in response to nutrient
overabundance have not yet been characterized. Thus, through the work in this thesis, we
sought to further elucidate the direct impacts of nutrient overabundance on placental
metabolic function, mitochondrial respiration, and nutrient processing using an in vitro
cell culture model.
The governing hypothesis of this thesis was: increased nutrient abundance will
impact placental metabolic function specifically highlighted by altered nutrient storage,
impaired mitochondrial respiratory activity, as well as an altered transcriptomic,
metabolomic, and lipidomic profile representative of dysfunctional metabolism.
This hypothesis was explored using BeWo cytotrophoblast (CT) and
syncytiotrophoblast (SCT) cells to model the two primary cell types of the placental
chorionic villi that are involved in materno-fetal nutrient exchange. BeWo CT and SCT
cells were exposed to increased levels of the dietary non-esterified fatty acids (NEFA)
palmitate (PA) and oleate (OA) to model hyperlipidemia in obese and gestational diabetic
(GDM) pregnancies caused by a poor maternal diet. Further, BeWo trophoblast cells
were exposed to increased levels of glucose to model hyperglycemia in diabetic
pregnancies. The main findings that support this hypothesis are:

241

(1) Increased levels of saturated NEFAs and glucose were associated with altered
metabolic function that was suggestive of a transition towards mitochondrial
dysfunction in BeWo trophoblast cells.
(2) Independent exposure to elevated levels of monounsaturated NEFAs and glucose
was linked to increased nutrient storage in BeWo placental trophoblasts
(3) Increased nutrient abundance modulated transcriptomic, metabolomic, and
lipidomic profiles in BeWo trophoblast cells that were indicative of altered
placental nutrient processing and metabolic function

5.2 Summary of Findings
5.2.1

Chapter 2: Syncytialization and prolonged exposure to
palmitate impacts BeWo respiration
In chapter 2, we investigated BeWo trophoblast cell metabolic function following

a prolonged exposure to PA, a saturated dietary NEFA; OA, a monounsaturated dietary
NEFA; as well as a combination of PA and OA (P/O). As these NEFA are the most
abundant in maternal circulation, and are elevated with obesity, we postulated that they
may be directly involved in facilitating impaired placental metabolic function in
pregnancies complicated by maternal pre-pregnancy obesity [7–9]. Additionally, as these
NEFA are the most abundantly consumed in westernized diets, their elevated levels in
obese pregnancies have been considered reflective of increased maternal consumption of
these fats and highlight a link between poor maternal diet and impaired placental function
[10–12]. The overall hypothesis of this specific investigation was that a prolonged
exposure to the dietary NEFAs PA and OA both independently and in combination would
impair mitochondrial function in BeWo CT and SCT cells.
In these experiments, we established a 72-hour cell culture protocol in which the
impacts of these NEFA could be observed in both progenitor BeWo cytotrophoblast (CT)
cells and differentiated BeWo syncytiotrophoblast (SCT) cells. Under normal culture
conditions BeWo trophoblasts display low spontaneous cell fusion and a CT phenotype,
however treating BeWo cells with 8-Br-cAMP (250 µM) enables fusion and
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differentiation to a SCT phenotype. Following a 24-hour pre-treatment with the NEFA
species, subsets of BeWo trophoblasts were cultured with 8-Br-cAMP to facilitate CT-toSCT differentiation over the final 48 hours of the culture period. This specific
differentiation protocol was utilized as it is analogous to human placenta syncytialization
whereby underling progenitor CT cells divide and propagate under exposure to maternal
nutrients, before undergoing terminal differentiation under those same nutrient
conditions. Prior to our investigations of metabolic and mitochondrial function in NEFAtreated BeWo trophoblast cells, we first examined cell viability and differentiation
capacity of these cells to ensure differences in metabolic activity were not the result of
lipotoxicity. We determined that 100 µM doses of NEFA were the most appropriate for
these investigations as they did not impact BeWo viability or differentiation capacity. It is
important to note that the 100 µM doses of PA and OA utilized in this study aligned with
fasting serum levels of these dietary fats during the third trimester [7], demonstrating a
physiological relevance of these NEFA treatments.
We next utilized functional readouts of mitochondrial activity using the Seahorse
Extracellular Flux Analyzer and the Mito Stress Test to examine BeWo mitochondrial
function following NEFA exposure in live cells. Through the use of this functional
activity assay, we demonstrated that BeWo CT cells exposed to PA, either alone or in
combination with OA (P/O-treatment) have increased basal and maximal mitochondrial
respiratory activity. Our subsequent functional analysis of individual metabolic enzymes
and electron transport chain (ETC) complexes, however, highlighted no impacts to the
underlying metabolic machinery in BeWo CT cells cultured with PA. Previously,
increased mitochondrial respiratory activity has been associated with increased
generation of Reactive Oxygen Species (ROS) that induce oxidative damage in
mitochondria leading to an overall mitochondrial dysfunction [13,14]. In these
investigations, we did not observe evidence of increased oxidative stress in NEFAexposed BeWo trophoblasts at 72-hours of NEFA exposure when examined by endpoint
immunoblots for 4-Hydroxynonenol (4-HNE, a marker of lipid peroxidation) and total
nitrotyrosine residues (a marker of nitrative stress). Thus, we speculated that the observed
increase in mitochondrial activity without a simultaneous increase in cellular oxidative
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stress indicated that the PA-exposed BeWo CT cells were in an early stage of a
progression towards mitochondrial dysfunction.
The investigations in Chapter 2 also highlighted a suppressed metabolic activity
in differentiated BeWo SCT cultures, independent of NEFA exposure. Specifically, our
Seahorse Mito Stress Test analyses revealed reduced basal and maximal mitochondrial
respiratory activity, as well as a reduced spare respiratory capacity in BeWo SCT cells.
Reductions in mitochondrial respiratory activity have previously been described in
syncytialized primary human trophoblast (PHT) cultures, demonstrating that BeWo
trophoblast mitochondrial function is similar to that of primary placental cells following
differentiation [15–17]. Subsequent investigations into underlying metabolic enzyme
activities demonstrated that reduced ETC complex 2 activity and reduced total Pyruvate
Dehydrogenase (PDH) activity (concomitant with reduced total PDH protein abundance)
underlies the observed reduction in mitochondrial respiration in differentiated BeWo SCT
cultures. Overall, these data provided novel insight into the mechanisms that may
underlie the reduced mitochondrial function that has been observed in differentiated
placental syncytiotrophoblasts. However, future studies are still needed to confirm if the
specific mechanisms associated with reduced mitochondrial function of syncytialized
BeWo trophoblasts also regulated mitochondrial respiratory activity in differentiated
PHT cultures.

5.2.2

Chapter 3: The impact of hyperglycemia upon BeWo
trophoblast cell metabolic function: A multi-omics and
functional metabolic analysis
In Chapter 3 we shifted our focus from dietary NEFAs to glucose to evaluate the

impacts of diabetic hyperglycemia on placental metabolic and mitochondrial function. In
addition to examining functional readouts of mitochondrial function and metabolic
enzyme activity as was done in Chapter 2, this study also utilized a multi-omics research
approach combining transcriptome, metabolome, and lipidome readouts to characterize
the underlying impacts of hyperglycemic (HG) culture conditions on BeWo trophoblast
metabolism. Overall, it was postulated that HG-culture conditions would be associated
with increased nutrient storage and impaired mitochondrial respiratory function in BeWo
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CT and SCT cells, in association with altered transcriptome, metabolome, and lipidome
signatures in BeWo CT cells indicative of altered metabolic function.
To examine the impacts of high glucose culture conditions on BeWo trophoblast
metabolism, we employed the prolonged 72-hour cell culture protocol that was developed
in Chapter 2. In these analyses, F12K growth media supplemented to 25 mM total
glucose was utilized for the HG treatments. It is important to note that this dose has
previously been used with BeWo trophoblast cells and ex vivo placental explants and has
been demonstrated to alter BeWo transcriptomic and metabolomic profiles in a manner
suggestive of altered metabolic function after 48 hours in culture [18,19]. Our
preliminary validation experiments revealed that BeWo trophoblasts were over 90%
viable following 72-hours of hyperglycemia exposure, which aligned with previous
reports of BeWo trophoblast and PHT viability after 48-hours of high glucose exposure
[18,20]. Furthermore, our analysis of syncytialization capacity highlighted that increased
glucose levels did not impact the syncytialization ability of BeWo trophoblasts. Overall,
these validation experiments demonstrated that BeWo trophoblasts are highly stable
following a 72-hour exposure to 25 mM of glucose.
The Seahorse Extracellular Flux Analyzer assays and individual metabolic
enzyme activity assays used in this study were the first experiments, to our knowledge, to
examine functional readouts of metabolic and mitochondrial activity of BeWo placental
trophoblasts cultured under independent hyperglycemia. Additionally, while previous
studies investigating the impacts of high glucose on BeWo trophoblasts have focused on
progenitor CT cells [18,21,22], our analyses also discussed metabolic activity of
differentiated BeWo SCT cells. Thus, the results in this chapter increased our general
understanding of how hyperglycemia impacts different placental villous trophoblast cell
lineages. Overall, we highlighted that HG-exposure was not associated with alterations in
global functional readouts of mitochondrial and metabolic enzyme activity in BeWo CT
and SCT cells. Subsequent investigation into underlying mitochondrial fission/fusion
dynamics in these cells suggested that key aspects of placental mitochondrial physiology
could be impacted by HG exposures. Future studies utilizing high-resolution microscopy
imaging techniques that better characterize mitochondrial morphology and cristae
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structure, could allow for the impacts of hyperglycemia on mitochondrial fission/fusion
dynamics to be explored in more detail.
In this chapter we also investigated the impacts of high glucose conditions on
placental nutrient storage and its regulation. Overall, we highlighted that HG-cultured
BeWo CT cells displayed increased glycogen and triglyceride (TG) content, and that HGcultured BeWo SCT cells displayed increased glycogen abundance compared to
respective LG controls. These data also highlighted that progenitor BeWo CT cells have a
greater capacity for generating new nutrient stores than differentiated SCT cells. As a
similar differentiation-state suppression in nutrient storage capacity has been highlighted
in primary trophoblast cells [23–26], these data further highlighted similarities between
BeWo cells and primary placental material following syncytialization. Surprisingly, our
investigations into the underlying regulation of nutrient storage found a reduced total
glycogen synthase abundance and increased inhibitory pSer641 phosphorylation of
glycogen synthase in HG-cultured BeWo trophoblast cells. These data suggested that
following 72 hours of high glucose exposure, BeWo trophoblasts have a diminished
capacity to continue to store excess glucose as glycogen. This may reflect the presence of
a negative feedback loop mediated by the increased cellular glycogen content itself [27],
that acts to limit excessive glycogen accumulation in BeWo trophoblasts. We speculated
that if hyperglycemic conditions were continued beyond our 72-hour timepoint, this
reduced glycogen storage capacity will increase free glucose available for oxidation and
in turn lead to increased ROS generation and oxidative mitochondrial damage. This
speculation is supported by previous cell culture systems utilizing kidney glomerular
cells and human umbilical cord endothelial cells which have demonstrated that
prolonging glucose exposure is associated with an eventual development of impaired
mitochondrial respiratory function [28,29].
We therefore suspect that we have established a cell culture system that captures
an early timepoint in a progression of BeWo trophoblasts towards ultimate mitochondrial
failure in response to high glucose. As previously stated, we speculated the 72-hour
exposure to excess PA in Chapter 2 also likely reflected an early timepoint in a
progression towards ultimate mitochondrial dysfunction. Therefore, the data from
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Chapter 2 and Chapter 3 together suggest that increased nutrient supply primes placental
trophoblasts for mitochondrial dysfunction, and that saturated NEFAs and glucose
overabundance both negatively regulate placental metabolism.
Notably, the functional investigations of mitochondrial and metabolic activity
completed in this chapter were found to align with the readouts in Chapter 2 in that
syncytialized BeWo trophoblast cells display suppressed mitochondrial activity. In this
study, differentiated BeWo SCT cells specifically displayed reduced mitochondrial
respiratory spare capacity, and reduced mitochondrial coupling efficiency, concomitant
with reduced activity of ETC complex II, and reduced protein abundance of ETC
complex IV. Readouts of mitochondrial fission/fusion dynamics in this chapter provided
further insight into the mechanisms underlying reduced mitochondrial function in SCT
cells. Specifically, we observed reduced total protein abundance of optic atrophy type 1
(OPA1, a marker of mitochondrial fusion) in conjunction with increased total protein
abundance of DRP1 in BeWo SCT cells indicative of increased mitochondrial fission. As
increased mitochondrial fission has also been described in differentiating PHTs [15,30],
these data provided further evidence of similarities between BeWo trophoblasts and
primary placental cells following differentiation. A schematic illustrating the
syncytialization-induced changes in BeWo trophoblast nutrient processing and metabolic
function is available in Figure 5-1.
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Figure 5-1 Summary illustration of the impacts of 8-Br-cAMP exposure on BeWo
trophoblast cells.
Treating BeWo trophoblast cells with 8-Br-cAMP (250 µM) increased mRNA expression
of CGB and OVOL1 concomitant with reduced abundance of ZO1 tight junctions; these
changes are indicative of placental trophoblast syncytialization. These BeWo SCT cells
were found to have decreased nutrient store (glycogen) abundance, which was linked to
increased inhibitory phosphorylation (pSer641) of glycogen synthase. BeWo SCT cells were
additionally found to have decreased basal and maximal mitochondrial respiratory activity
that was associated with reduced PDH activity, decreased ETC complex II activity and
reduced ETC complex IV protein abundance. Further underlying these alterations in
functional aspects of mitochondrial respiration was an increased protein abundance of
DRP1 in conjunction with decreased protein abundance of OPA1 that may lead to
mitochondrial fission in these cells.
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Recently, studies utilizing placental villous trophoblast models have highlighted that
“omics” based investigations are useful to gain an in-depth understanding of the
underlying mechanisms governing placental development and function [31–33].
Therefore, to further characterize the impacts of hyperglycemia on BeWo trophoblast
metabolism in this study, we utilized a multi-omic research approach combining
transcriptomics, metabolomics and lipidomics. In these analyses, we specifically
examined progenitor BeWo CT cells due to the higher basal metabolic activity that we,
and others [15,16], have observed in this cell type. With multivariate principal
component analyses (PCA) we highlighted divergences in transcriptomic and
metabolomic profiles between HG and low glucose (LG)-cultured BeWo CT cells, but a
limited separation in lipidome profiles between LG and HG-cultured BeWo CT cells. Our
subsequent investigations into the “omic” profiles of HG-culture BeWo CT cells revealed
biomarkers that provided insight into the underlying regulation of mitochondrial function
and nutrient storage in hyperglycemia exposed BeWo trophoblasts.
First, we demonstrated increased mRNA expression of ACSL1 (+1.36 fold-change
(FC)) in HG-cultured BeWo CT cells. The protein encoded by this gene is involved in
lipid trafficking and may facilitate the increased TG synthesis in these cells [34–36].
Additional readouts from the metabolomic analyses showed increased accumulation of
malonate (+3.74 FC) in HG-cultured BeWo CT cells. These data may highlight that de
novo lipogenesis is also involved in the production of TG species in HG-exposed BeWo
trophoblasts. However, malonate has also been demonstrated to inhibit β-oxidative
activity [37]. As HG-cultured BeWo also displayed increased (+1.63 FC) 16:0
acylcarnitine levels (a β-oxidation intermediary), these data could also indicate that FA
oxidation is reduced in placental trophoblasts in response to high glucose, and this change
may further enhance placental steatosis.
Interestingly, we also observed an increased accumulation of lactate (+2.72 FC) in
HG-cultured BeWo CT cells that was suggestive of increased glycolytic activity in these
cells. These findings are notable as our analyses using the Seahorse XF Glycolysis Stress
Test did not detect differences in glycolysis function between LG and HG-cultured BeWo
trophoblasts. These data could indicate that the Seahorse XF Glycolysis Stress Test
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readouts are less sensitive than the metabolomic readouts and that the Seahorse functional
assay does not accurately quantify BeWo trophoblast glycolytic activity. Any future
study examining more prolonged glucose exposures in BeWo trophoblasts will need to
consider these experimental limitations, especially considering BeWo cells appear to
downregulate glycogen storage in hyperglycemic conditions and these changes could lead
to initially increased rates of glycolysis.
Finally, our metabolomic analysis highlighted increased accumulation of
riboflavin (+3.68 FC) in HG-cultured BeWo trophoblasts that may either be reflective of
increased riboflavin uptake, or reduced riboflavin metabolism. As riboflavin metabolites
(flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD)) are important cofactors needed for appropriate mitochondrial respiratory activity, the observed riboflavin
accumulation may indicate that BeWo trophoblast mitochondria are not functioning
appropriately following exposure to high glucose conditions [38,39].
Overall, the multi-omic research approach utilized in Chapter 3 provided greater
insight into the underlying mechanisms that regulate placental trophoblast metabolism in
response to high glucose exposures, and further highlighted nutrient (TG) storage, and
mitochondrial function are important areas of trophoblast metabolism that are impacted
by glucose. A schematic summarizing the changes we observed in BeWo trophoblast
cells exposed to hyperglycemia for 72 hours is available in Figure 5-2.
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Figure 5-2 Summary illustration of the impacts of hyperglycemia (25 mM) on BeWo
trophoblast cells.
BeWo trophoblasts cultured under hyperglycemic (HG) conditions for 72 hours were found
to have increased nutrient stores. Specifically, HG-cultured BeWo CT (but not SCT) cells
were found to have increased triglyceride abundance that may be related to increased fatty
acid trafficking to lipid droplets by ACSL1 and/or increased de novo lipogenesis. Further,
both BeWo CT and SCT cells displayed increased glycogen content. Investigations into
underlying regulation of glycogen synthesis revealed reduced protein abundance of
glycogen synthase and increased inhibitory phosphorylation (pSer641) of glycogen synthase
in the HG-cultured BeWo trophoblasts. These changes could increase free glucose
available for glycolysis and subsequent mitochondrial oxidation and may ultimately result
in increased ROS generation and mitochondrial oxidative damage. HG-cultured BeWo CT
cells were also found to have increased accumulation of riboflavin which may further
indicate the development of mitochondrial dysfunction. The increased malonate and C16:0
acylcarnitine levels observed in HG-cultured BeWo CT cells suggested reduced fatty acid
β-oxidation and may be reflective of an oxidative fuel switch induced by increased glucose
levels.
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Ultimately the alterations in placental nutrient storage (particularly the diminished
glycogen storage capacity potentially leading to increased free glucose) and transition
towards mitochondrial dysfunction that we observed in high glucose treated BeWo
trophoblasts may impact transplacental nutrient transport. Our data could highlight that
the increased prevalence of macrosomia in diabetic pregnancies [40] is in part facilitated
by hyperglycemia-mediated modifications in placental nutrient processing that promotes
an increased transfer of glucose from mother to the developing fetus [41]. Therefore,
ensuring proper and consistent glycemic control that limits periods of maternal
hyperglycemia is likely of paramount importance in the clinical management of diabetic
pregnancies. As we have demonstrated that even a short-term (72-hour) high glucose
exposure can negatively impact placental nutrient processing, preventing any placental
hyperglycemic exposures may be necessary to limit fetal overgrowth and in turn limit the
prevalence of DOHaD-related metabolic health complications in the exposed offspring.

5.2.3

Chapter 4: Elevated Dietary Non-Esterified Fatty Acid Levels
Impact BeWo Trophoblast Metabolism and Lipid Processing:
A Multi-OMICS Outlook
In Chapter 3 we highlighted that utilizing a multi-omics research approach

provided in-depth insight into the underlying mechanisms that regulate BeWo trophoblast
metabolic function in response to elevated glucose. In Chapter 4, we turned our attention
back to the dietary NEFA species PA and OA and sought to utilize these integrative
“omics” approaches to better characterize the impacts of dietary NEFA species on
placental metabolic function. In these analyses we utilized transcriptomic, metabolomic,
and lipidomic readouts as were performed with hyperglycemia exposed BeWo CT cells
in Chapter 3. In this chapter, we additionally utilized targeted Gas Chromatography (GC)
and targeted Thin Layer Chromatograph (TLC) to specifically characterize cellular fatty
acid (FA) and neutral lipid profiles in both BeWo CT cells and SCT cells. We postulated
that exposure to elevated levels of dietary NEFA would alter BeWo trophoblast lipid
profiles, highlighted by increased TG abundance, and increased FA elongation and
desaturation. It was additionally postulated that that dietary-FA treated BeWo CT cells
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would display altered transcriptomic, metabolomic and lipidomic profiles indicative of
altered lipid processing.
Our targeted analyses of FA and neutral lipid profiles highlighted that PA and OA
are differentially processed by BeWo trophoblast cells. Of particular interest, our TLC
analyses demonstrated that BeWo CT and SCT cells have increased TG content when
cultured with OA alone. These data suggested that OA is highly lipogenic in BeWo
trophoblasts, and interestingly, similar trends have been reported in OA-cultured PHT
cells [42]. However, co-culture of BeWo trophoblasts with both PA and OA (P/O
treatment) was not associated with elevated TG abundance. Overall, these data
demonstrated that both NEFA concentration and composition are important in regulating
placental trophoblast lipid processing.
The utilization of targeted FA analyses in this chapter also allowed for
investigations into FA desaturation and elongation processing in NEFA-exposed BeWo
trophoblasts. These FA metabolic pathways were specifically examined by calculating
elongase and desaturase indices (enzyme product to substrate ratios) that are reflective of
enzyme activity. These analyses specifically revealed that OA-treated BeWo CT
displayed increased production of gondoic acid (20:1n9; via OA elongation) and γlinolenic acid (18:3n6; via desaturation of linoleic acid). As these FA species have been
associated with anti-inflammatory outcomes [43,44], the data could suggest that OA
reduces inflammatory signaling in placental trophoblasts.
Integrating the transcriptomic and metabolomic datasets in this chapter provided
further evidence that OA exposure is associated with anti-inflammatory outcomes in
BeWo trophoblast cells. Specifically, we observed a significant enrichment in the Purine
metabolism KEGG pathway in OA-treated BeWo CT cells that was associated with
accumulations of the purine metabolites adenosine (+3.30 FC), inosine (+2.45 FC), and
guanosine (+1.69 FC) compared to BSA-control cultures. As purine breakdown has been
previously observed in placental responses to inflammation [45], these data may highlight
that OA-exposure exerts anti-inflammatory benefits by preventing purine degradation.
However, an alternate explanation may be that BeWo trophoblasts have increased purine
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synthesis via the Pentose Phosphate Pathway (PPP) when exposed to elevated OA levels.
As the PPP generates NADPH, a molecule with antioxidant effects, these data could also
indicate that OA exerts antioxidant effects in BeWo trophoblasts [46,47]. Overall, these
data alluded that altered FA elongation and desaturation, as well as altered purine
metabolism may specifically underlie the previously observed anti-apoptotic effects of
OA on placental trophoblasts [42,48]. A schematic summarizing the alterations observed
in OA-cultured BeWo trophoblasts in chapters 2 and 4 is available in Figure 5-3.
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Figure 5-3 Summary illustration of the impact of OA-exposure (100 µM) on BeWo
trophoblast cells.
BeWo trophoblasts cultured with OA for 72 hours were found to have altered lipid
processing highlighted by increased triglyceride abundance and altered fatty acid
metabolism via desaturase and elongase enzymes. This altered desaturation and elongation
processing was highlighted by increased production of gondoic acid (C20:1n9) and γlinolenic acid (C18:3n6), that may be associated with anti-inflammatory outcomes.
Additionally, OA-cultured BeWo CT cell displayed increased purine (adenosine, inosine,
and guanosine) accumulations that may be reflective of decreased purine breakdown or
increased purine synthesis via the Pentose Phosphate Pathway. As purine breakdown has
been implicated in placental responses to inflammatory stimuli, the observed purine
accumulation may further highlight anti-inflammatory signaling in OA-cultured BeWo
trophoblasts. Further, as the Pentose Phosphate Pathway generates NADPH, a molecule
with antioxidant properties, purine accumulation could indicate that OA acts as an
antioxidant in BeWo trophoblasts leading to decreased oxidative stress.
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Combining the transcriptome, metabolome, and lipidome readouts in Chapter 4
additionally suggested that PA treatments, both independently and in combination with
OA (P/O treatments) increased β-oxidative activity in BeWo CT cells. Specifically, we
observed upregulated expression of the β-oxidation genes ACADVL and ACACB in PA
and P/O-treated BeWo CT cells. Additionally, PA and P/O-cultured BeWo CT cells
displayed elevated levels of C16:0 acylcarnitine, a β-oxidation intermediary that
facilitates the transport of PA into the mitochondrial matrix for oxidation. Notably, BeWo
CT cells cultured with PA-alone (But not the P/O mixture) also displayed increased
C14:0 acylcarnitine levels that may be reflective of incomplete β-oxidation processes. In
contrast, P/O-cultured BeWo CT cells displayed elevated malonate levels that may be
reflective of complete β-oxidation.
Further, these data may indicate that the increased basal and maximal
mitochondrial respiratory activities observed in PA and P/O-treated BeWo CT cells in
Chapter 2 were the result of increased β-oxidation activity. Additionally, as increased βoxidation has in itself been linked with increased ROS generation, mitochondrial
oxidative stress, and mitochondrial dysfunction [49–51], the data in Chapter 4 further
suggests that our 72-hour PA exposure (both alone and in combination with OA)
represents an early timepoint in a progression towards mitochondrial impairments.
However, as the data in Chapter 4 also highlighted that OA may exert anti-inflammatory
effects and act as an antioxidant in BeWo trophoblasts, future investigations may need to
better elucidate if the combination P/O-exposure ultimately results in mitochondrial
dysfunction, or if the additional OA exposure in this treatment group helps preserve
appropriate mitochondrial function. Schematics summarizing the impacts of PA and P/O
exposure on BeWo trophoblasts are available in Figure 5-4, and Figure 5-5.
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Figure 5-4 Summary illustration of the impacts of PA-exposure (100 µM) on BeWo
trophoblast cells.
BeWo CT cells cultured with PA for 72 hours were found to have increased basal and
maximal mitochondrial respiratory activity. These changes in mitochondrial function were
associated with markers suggestive of an oxidative fuel switch that favoured increased βoxidation. Specifically, reduced 3-hydroxymethylglutaric acid levels and reduced PDH
activity in PA-cultured BeWo CT cells suggested reduced oxidation of amino acid fuels
and carbohydrate fuels. Further, the observed accumulation of C16:0 acylcarnitine in
conjunction with increased mRNA expression of β-oxidation enzymes (ACADVL and
ACACB) was indicative of increased fatty acid oxidation for ATP production. Interestingly,
PA-cultured BeWo CT cells also displayed an increased accumulation of C14:0
acylcarnitine, that could be indicative of incomplete β-oxidation, a marker of a
dysfunctional mitochondria. Overall, we speculated that the increased mitochondrial
respiratory activity and β-oxidation in PA-culture BeWo CT cells would lead to increased
ROS generation, and ultimately oxidative mitochondrial damage.
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Figure 5-5 Summary illustration of the impacts of P/O-exposure (50 µM each PA
and OA) on BeWo trophoblast cells.
BeWo CT cells cultured with a combination of PA and OA were, like PA-alone
cultured BeWo CT cells, found to have increased basal and maximal mitochondrial
respiratory activity. Increased C16:0 acylcarnitine levels, and increased expression of βoxidation enzymes (ACADVL and ACACB) in these cells suggested that the observed
increased mitochondrial respiration was resultant from increased fatty acid oxidation. We
speculated that these increases in mitochondrial respiration and β-oxidation would
ultimately lead to increased ROS generation and oxidative mitochondrial damage.
However, P/O-cultured BeWo CT cells also displayed increased malonate levels that may
indicate complete β-oxidation, as well as a functional negative feedback system that acts
to reduce excessive fatty acid oxidation. These changes in conjunction with increased OA
levels may act to reduce excessive ROS generation in P/O combination cultured BeWo CT
cells and may help to preserve appropriate mitochondrial function despite exposure to lipid
overabundance.
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We speculate that mitochondrial impairments in placental trophoblasts that develop in
response to elevated levels of dietary saturated FA could lead to subsequent increases in
transplacental transport of lipid species [52], as well as placental lipid storage. Therefore,
the data in Chapter 2 and Chapter 4 could indicate that the increased prevalence of
placental steatosis [19,53] and fetal macrosomia [40,54,55] that has been observed in
obese and GDM pregnancies is directly facilitated by increased saturated FA delivery to
the placenta. Reducing placental saturated NEFA exposure, perhaps through maternal
dietary interventions (e.g. adherence to a Mediterranean-style [56] or pacific-style [57]
style high in omega-3 FA species), may be of increasing importance in the clinical
management of obese and GDM pregnancies to help preserve appropriate placental
nutrient processing and in turn facilitate healthy fetal development.

5.3 Considerations for clinical diagnosis of placental
dysfunction
The data presented in this thesis overall suggested that a 72-hour exposure to elevated
levels of both dietary NEFAs and glucose was associated with a transition towards
mitochondrial dysfunction in placental villous trophoblast cells. These mitochondrial
impairments are specifically important as in both conditions of nutrient overabundance
they could impact placental nutrient processing leading to increased nutrient delivery to
the fetus. Increased transplacental nutrient transport would promote increased fetal
growth and macrosomia, and in turn, in utero programming associated with later-life
development of DOHaD-related non-communicable cardio-metabolic health
complications [58,59]. However, in order to properly implement and personalize clinical
interventions that prevent, or potentially reverse these placental mitochondrial
impairments, clinical diagnostic tests must be developed in order to accurately assess in
real time during gestation if the placenta is on a trajectory towards failure. Ideally, these
diagnostic tests would assess biomarker abundance in easily accessible biofluids (i.e.
urine and blood samples) that can be collected during routine prenatal care appointments.
Interestingly, the data in this thesis highlighted that while increased saturated
NEFAs and glucose supply were both associated with altered BeWo metabolic function
suggestive of a transition towards ultimate mitochondrial failure, these nutrients have
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vastly different underlying impacts to placental metabolism. In our multi-omic analyses,
we utilized multivariate PCA analyses to examine the degree of separation in
metabolome, lipidome and transcriptome profiles in BeWo CT cells cultured with
different NEFA species and hyperglycemia. Specifically, the glucose treatments in
Chapter 3 were associated with divergent transcriptome and metabolome profiles, but
limited differences in cellular lipidome profiles. In contrast, the omic analyses in Chapter
4 revealed that BeWo CT transcriptome and lipidome profiles, but not polar metabolome
profiles were divergent following exposure to elevated dietary NEFA levels. Thus, the
biomarkers that are associated with an early phenotype of mitochondrial dysfunction in
placenta trophoblasts are likely different in cells exposed to high NEFA levels and
hyperglycemia. Future studies that seek to utilize the biomarkers reported in our studies
in preliminary clinical tests to diagnose failing placenta mitochondria in cases of maternal
obesity, GDM and pre-existing type 1 diabetes will need to consider these differences to
enable an accurate point of care assessment of placental function.
The altered abundances of acylcarnitine species (e.g. C16:0 and C14:0
acylcarnitines) in PA and P/O-cultured BeWo trophoblast cells could indicate that
acylcarnitine analysis can be utilized to diagnose aberrant placental mitochondrial
function in response to excessive saturated fats. Interestingly, diagnostic tests measuring
circulating acylcarnitine species (reflective of abnormal placental lipid oxidation) in
maternal serum and plasma have already been utilized in the early detection of placenta
disorders such as pre-eclampsia, although they are not yet suitable for implementation in
reproductive clinical settings [60,61]. Therefore, it may be possible to adapt these
previously established protocols to integrate new biomarkers and better develop
diagnostic tests that assess placental mitochondrial function and the transition towards
mitochondrial failure in high fat environments such as obesity. Acylcarnitine analysis has
been utilized to detect the metabolic perturbations associated with cardiovascular disease
[62,63], further highlighting the future potential clinical utility of these readouts.
In contrast, utilizing different metabolomic strategies that emphasize the detection
of small, polar metabolites will likely need to be developed to detect early onset placental
mitochondrial dysfunction in response to a hyperglycemic environment. Notably, such
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metabolomic analyses have previously been utilized to detect placental dysfunctions in
pregnancies complicated with intrauterine growth restriction [64], and pre-eclampsia
[65], although these tests have, like acylcarnitine analysis, not been approved for use in
clinical settings.

5.4 Limitations and Future Considerations
The current thesis demonstrated that both dietary NEFAs and glucose are
important independent regulators of BeWo trophoblast cell metabolic function. However,
as some pregnancies complicated with GDM are associated with concurrent elevations in
both dietary fat and glucose levels [66,67], the combined impacts of these nutrient
exposures still need to be explored. A logical extension of the work in the current thesis
would be to combine the NEFA and glucose exposures, potentially by supplementing the
P/O NEFA media with 25 mM glucose. These specific investigations will allow greater
insight into whether the combined nutrient exposures result in a synergistic “double-hit”
that ultimately worsens or accelerates the development of metabolic and mitochondrial
impairments in placental trophoblast cells.
A major limitation of the work presented in the current thesis is that a single
timepoint (72 hours) was utilized for all assessments of BeWo trophoblast metabolic
function. As we speculated our glucose and PA-treated BeWo trophoblasts are
progressing towards mitochondrial dysfunction after 72-hours of nutrient exposure, more
chronic exposures may better highlight the development of nutrient-induced placental
mitochondrial impairments. However, BeWo trophoblast cells quickly grow to form a
confluent monolayer, and interestingly do not display contact inhibition, ultimately
leading to the creation of a confluent multi-layer of cells [68–70]. The 72-hour protocol
was specifically utilized in these investigations as it represented the longest possible cell
culture exposure prior to the cells becoming confluent and forming a multi-layered
culture system. The avoidance of a multi-layered cell culture system was important in the
investigations in this thesis to ensure accurate measurements of metabolic activity in the
Seahorse XF assays performed in chapters 2 and 3 [71]. One possible method of
extending the nutrient exposures while avoiding the production of confluent multi-layers
would be through sub-culturing the cells prior to confluence and redistributing them onto
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new cell culture dishes. However, this would require additional manipulation of the cell
culture system that could lead to increased cellular stress, and potentially lead to the
unwanted selection of nutrient-resistant cell populations. Future studies may look to
prolong these treatment durations to characterize markers associated with endpoint
mitochondrial failure in BeWo trophoblasts, although care must be taken to avoid
selecting NEFA and glucose resistant cell populations during sub-culturing procedures.
Further, the data in this thesis are limited as all cell culture experiments were
performed in 5% CO2/95% atmospheric air, corresponding to a growth environment with
approximately 20% oxygen. Additional analysis of BeWo trophoblast mitochondrial and
metabolic activity may need to be performed at physiological placental oxygenation
levels (approximately 8% during the third trimester) [72,73] to better model in vivo
placental conditions, and further characterize placental responses to nutrient
overabundance.
Additionally, these studies are limited as only a single placental cell line model
was utilized to assess metabolic function in response to nutrient overabundance. In
addition to BeWo trophoblast cells, previous studies have highlighted that the JAR, and
JEG-3 placental cell lines are useful in in vitro analyses of placental villous trophoblast
function [74–77]. Future investigations using these other placental cell systems may be
needed to elucidate if the underlying mechanisms governing trophoblast responses to
nutrient overabundance are common to all human trophoblast cell line lineages, or if the
responses discussed in the current thesis are unique to BeWo trophoblast cells. However,
as JEG-3 cells have previously been found to have lower glucose transport capabilities
than BeWo cells, JAR cells and PHTs [76], this particular cell line may not be useful in
examining placental responses to hyperglycemia. Further, as only BeWo trophoblast
cells, and not JAR or JEG-3 trophoblast cells, have been found to form large multinucleated syncytia [75], these other placental cell line systems may be limited in their
evaluation of differentiation-state dependent differences in metabolic function between
placental CT and SCT cells.
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While these placental cell line models are useful to investigate the independent
impacts of nutrient overabundance on trophoblast metabolic function, the cancerous
origins of these cells may ultimately impact their underlying physiology [78]. Thus,
future investigations may be needed to elucidate if elevated nutrient supply also directly
regulates metabolic and mitochondrial function in ex vivo primary placental cells to
strengthen the data obtained in this thesis. Additionally, the JEG-3, JAR and BeWo
placental cell lines are all genetically male [79,80]. As recent studies have highlighted
placental responses to an adverse intrauterine environment are sex-dependent [81–84],
these placental cell line studies are limited in that they cannot discuss how fetal sex
influences placental metabolic function in a nutrient-rich environment. Interestingly,
male placentae have also been found to display fewer adaptations in response to the
nutrient stresses of obese and diabetic pregnancies [82,83]. This sex-dependent influence
and the male sex of BeWo trophoblasts may highlight a high stability of the BeWo
transcriptome and could be an underlying explanation of why only 3 transcripts (SGK1,
CREB3L3, and MAMDC2) displayed a > ± 2-fold change in NEFA-treated BeWo cells,
and also why no transcripts displayed > 2-fold-change in HG-cultured BeWo CT cells.
Future investigations utilizing primary placental material may be needed to better
understand how fetal sex influences the regulation of placental metabolism and gene
expression following a nutrient overload challenge.
One method of examining these responses in primary placental material is
through the isolation and culture of term CT cells (PHTs) from healthy control
pregnancies using well validated methodologies [85,86]. However, PHT cultures have
been demonstrated to display spontaneous fusion and display a SCT phenotype as soon as
48 hours in culture [87,88]. Thus, these studies may themselves be limited in examining
differentiation-state dependent differences in the responses of CT and SCT cells to
elevated nutrient content. Additionally, this spontaneous fusion capacity also highlights
that more prolonged and chronic NEFA, and glucose exposures cannot be examined in
primary human CT cultures, and thus these models may not have the capability to
examine endpoint CT mitochondrial failure.
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An additional method of examining responses to elevated nutrient levels in
primary placental material is through the use of ex vivo explants, as has previously been
described [89,90]. Explant-based analysis may have increased physiological relevance
compared to other in vitro and ex vivo placental models due to the co-culture of many
different placental cell types including trophoblast cells, fetal mesenchymal cells, and
placental immune cells in their proper three-dimensional physiological orientations [89].
These explant-based studies may help elucidate how “cross-talk” between different
placental cells impacts overall placental metabolic function. Additionally, as placental
explants have the ability to be cultured for up 12 days, these systems may be beneficial in
elucidating the impacts of more chronic nutrient exposures on placental trophoblasts
[89,91]. A potential shortfall of these explant studies, however, is that it may be difficult
to determine how the different placental cell types individually contribute to the overall
observed metabolic phenotypes. However, the use of single cell “omics” techniques, such
as single cell RNA sequencing (scRNAseq), in these studies may allow for the
identification and characterization of unique placental cell types, as has been performed
in other tissue models [92,93].
Finally, while the results in the current study have demonstrated that nutrient
overabundance modulates placental trophoblast metabolism and nutrient processing
functions, the ultimate impact that these changes have on transplacental nutrient transport
remains poorly understood. The work in this thesis could additionally be extended to
elucidate these outcomes by utilizing BeWo transwell culture systems that better model
placental barrier functions, as has previously been described [94–96]. In these systems,
BeWo trophoblasts can be cultured on semi-permeable membranes on an inner cell
culture chamber. Subsequently, the transport of nutrients through the BeWo cell layer and
into an outer cell culture chamber can be examined, most likely via metabolomic analyses
of the conditioned media in the outer chamber. Additionally, some previously established
transwell systems have utilized co-culture of BeWo trophoblasts and human umbilical
vein endothelial cells (HUVEC cells) on opposite sides of the semi-permeable transwell
membranes [96]. These co-culture systems have the ability to examine how different
placental cell types work together to modulate transplacental nutrient transport. More
recently, “placenta-on-a-chip” systems have also been developed to better model in vivo
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placental barrier functions [97,98]. In these systems, much like transwell systems, BeWo
cells can be cultured on semi-permeable membrane in co-culture with other placental
cells like HUVECs, and nutrient transfer across the cellular barrier can be quantified.
However, unlike transwell cultures, placenta-on-a-chip system utilize a dynamic flow of
cell culture media that also models in vivo blood flow, and trophoblast responses to fluid
shear stresses [99,100]. Overall, the use of these placental barrier cell culture systems in
future investigations could provide better insight into how nutrient overabundance
impacts transplacental nutrient transport.

5.5

Conclusion

The work in this thesis evaluated the impacts of independent dietary NEFA and
glucose exposure on BeWo placental trophoblast nutrient processing and mitochondrial
function. These investigations have expanded our understanding of how dietary nutrients
regulate placental metabolism. We highlighted that a 72-hour exposure to elevated
dietary nutrient levels impacted nutrient storage and was associated with altered
transcriptome, metabolome and lipidome profiles in BeWo trophoblast cells.
Additionally, we observed markers indicative of a transition towards overall oxidative
mitochondrial failure in BeWo trophoblast cells exposed to both elevated saturated
NEFA and glucose levels. Furthermore, we demonstrated a differentiation-state
dependent suppression of mitochondrial activity and nutrient storage in BeWo SCT cells.
Overall, the data in this thesis suggests that an increased delivery of nutrients to the
placenta in pregnancies complicated by nutrient overabundance (often clinically
displayed in obese and diabetic pregnancies) may facilitate the development of placental
impairments that increase the risk of non-communicable metabolic diseases development
in the exposed offspring. These data continue to support the idea that modulating
maternal nutrient levels through healthy lifestyle choice, dietary interventions, and
glycemic management strategies is important in the clinical management of these “highrisk” pregnancies to ensure appropriate placental function is maintained throughout
gestation.
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